var title_f9_43_9904="Types of splicing mutations";
var content_f9_43_9904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Types of splicing mutations and correction with antisense morpholino oligonucleotides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 667px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Type I refers to the classical splicing mutation that causes the deletion of an entire exon during pre-mRNA splicing. B) Type II splicing mutations occur in the mid-intron and result in the insertion of a pseudoexon at the cDNA level. C) Type III mutations lie within the coding region, resulting in the partial deletion of an exon. D) Type IV mutations lie within the intron and lead to partial deletion of an exon. E) Type V mutations disturb the lariat branch point and result in deletion of an exon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hu H, Gatti R. New approaches to treatment of primary immunodeficiencirs fixing mutations with chemicals. Curr Opin Allergy Clin Immunol 2008; 8:540. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9904=[""].join("\n");
var outline_f9_43_9904=null;
var title_f9_43_9905="Patient information: Skin tags (acrochordon) (The Basics)";
var content_f9_43_9905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83336\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/27/12721\">",
"         Skin tag on the thigh",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Skin tags (acrochordon) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/skin-tags-acrochordon-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H91450033\">",
"      <span class=\"h1\">",
"       What are skin tags?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Skin tags are small growths of normal skin (",
"      <a class=\"graphic graphic_picture graphicRef83130 \" href=\"UTD.htm?12/27/12721\">",
"       picture 1",
"      </a>",
"      ). Skin tags often grow on a short stalk or stem. They tend to form in places where the skin rubs together, such as the armpit, the neck, under the breasts, or in the groin. The medical term for skin tags is &ldquo;acrochordon.&rdquo;",
"     </p>",
"     <p>",
"      Skin tags are harmless and many people have them. The chances of getting skin tags increase as you get older. People who are overweight have a greater chance of getting skin tags. Some pregnant women develop skin tags during the middle of their pregnancy, but the skin tags often shrink or go away after the baby is born. Skin tags also seem to run in some families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91450048\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should see your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You are not sure that what you have is a skin tag.",
"       </li>",
"       <li>",
"        The skin tag is irritated and painful.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91450063\">",
"      <span class=\"h1\">",
"       Is there a test for skin tags?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have a skin tag by doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91450078\">",
"      <span class=\"h1\">",
"       How are skin tags treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is usually no reason to treat skin tags. Your doctor can remove the tag if it is painful or if you don&rsquo;t like the way it looks. There are different ways that your doctor might remove the skin tag. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Freezing the tag with a special fluid that gets very cold (called liquid nitrogen)",
"       </li>",
"       <li>",
"        Cutting the tag off with surgical scissors",
"       </li>",
"       <li>",
"        Burning the tag off with a special tool",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Skin tags can bleed when they come off, so never try to cut or pull off a skin tag on your own.",
"     </p>",
"     <p>",
"      If you have a skin tag taken off, it is not unusual to form a new skin tag in the same area.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/43/9905?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83336 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9905=[""].join("\n");
var outline_f9_43_9905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91450033\">",
"      What are skin tags?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91450048\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91450063\">",
"      Is there a test for skin tags?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91450078\">",
"      How are skin tags treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/27/12721\">",
"      Skin tag on the thigh",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_43_9906="Calculator: Stroke Risk in Male Patients 55-84 Years Old (Framingham data)";
var content_f9_43_9906=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"StrokeRiskFramingham_M_form\" name=\"StrokeRiskFramingham_M_form\" onkeydown=\"clrResults();\" onkeyup=\"StrokeRiskFramingham_M_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Stroke Risk in Male Patients 55-84 Years Old (Framingham data)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         RiskFactorDiff = (Age * 0.0505) + (SysBP * 0.014) + HTNMed + DM + Cig + CVD + AFib + LVH - 5.677",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         RiskDuringPeriod = 100 * (1 - RiskPeriodFactor",
"         <sup>",
"          e",
"          <sup>",
"           (RiskFactorDiff)",
"          </sup>",
"         </sup>",
"         )",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"StrokeRiskFramingham_M_fx(); minMaxCheck();\" onchange=\"StrokeRiskFramingham_M_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:105px;\">",
"             <option value=\"0.0833333333333333|0|mo\">",
"              mo",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|yr\">",
"              yr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Sys BP",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Sys_BP_param\" onblur=\"StrokeRiskFramingham_M_fx(); minMaxCheck();\" onchange=\"StrokeRiskFramingham_M_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Sys_BP_unit\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:105px;\">",
"             <option value=\"0.00750063755419211|0|Pascal\">",
"              Pascal",
"             </option>",
"             <option value=\"760.002100178515|0|atm\">",
"              atm",
"             </option>",
"             <option value=\"750.063755419211|0|bar\">",
"              bar",
"             </option>",
"             <option value=\"0.735561538478802|0|cmH2O\">",
"              cmH2O",
"             </option>",
"             <option value=\"10|0|cmHg\">",
"              cmHg",
"             </option>",
"             <option value=\"22.4199156928339|0|ftH2O\">",
"              ftH2O",
"             </option>",
"             <option value=\"0.735561538478802|0|gm/sqcm\">",
"              gm/sqcm",
"             </option>",
"             <option value=\"1.86832630773616|0|inH2O\">",
"              inH2O",
"             </option>",
"             <option value=\"25.4000840071406|0|inHg\">",
"              inHg",
"             </option>",
"             <option value=\"7.50063755419211|0|kPa\">",
"              kPa",
"             </option>",
"             <option value=\"0.750063755419211|0|mbar\">",
"              mbar",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mmHg\">",
"              mmHg",
"             </option>",
"             <option value=\"51.7150957831416|0|psi\">",
"              psi",
"             </option>",
"             <option value=\"1|0|torr\">",
"              torr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             On BP medication",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"HTN_Med_pulldown\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.3263\">",
"              Yes (0.3263)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Diabetes present",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"DM_pulldown\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.3384\">",
"              Yes (0.3384)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Cigarette smoker",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"Cig_pulldown\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.5147\">",
"              Yes (0.5147)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Cardiovascular dx",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"CVD_pulldown\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.5195\">",
"              Yes (0.5195)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Atrial fibrillation",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"AFib_pulldown\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.6061\">",
"              Yes (0.6061)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             LV hypertrophy",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"LVH_pulldown\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.8415\">",
"              Yes (0.8415)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Risk period",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"Risk_Period_Factor_pulldown\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:170px;\">",
"             <option value=\"0.9948\">",
"              1 year (0.9948)",
"             </option>",
"             <option value=\"0.9889\">",
"              2 years (0.9889)",
"             </option>",
"             <option value=\"0.9826\">",
"              3 years (0.9826)",
"             </option>",
"             <option value=\"0.9740\">",
"              4 years (0.9740)",
"             </option>",
"             <option value=\"0.9642\">",
"              5 years (0.9642)",
"             </option>",
"             <option value=\"0.9551\">",
"              6 years (0.9551)",
"             </option>",
"             <option value=\"0.9422\">",
"              7 years (0.9422)",
"             </option>",
"             <option value=\"0.9270\">",
"              8 years (0.9270)",
"             </option>",
"             <option value=\"0.9144\">",
"              9 years (0.9144)",
"             </option>",
"             <option selected=\"selected\" value=\"0.9044\">",
"              10 years (0.9044)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Risk Factor Diff",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Risk_Factor_Diff_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Risk During Period",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Risk_During_Period_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"Risk_During_Period_unit\" onchange=\"StrokeRiskFramingham_M_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|%\">",
"               %",
"              </option>",
"              <option value=\"100|0|fraction\">",
"               fraction",
"              </option>",
"              <option value=\"100|0|ratio\">",
"               ratio",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"StrokeRiskFramingham_M_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      This risk assessment tool is based on the Cox regression model of proportional hazards.",
"     </li>",
"     <li>",
"      It may be applied to men between the ages of 55 and 84 who have had no prior history of stroke.",
"     </li>",
"     <li>",
"      Cardiovascular disease includes coronary disease, heart failure, or claudication.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study.",
"       <i>",
"        Stroke",
"       </i>",
"       . 1991 Mar;22(3):312-8.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9906=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function StrokeRiskFramingham_M_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.StrokeRiskFramingham_M_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Sys_BP_param.value.indexOf(',') >= 0){ Sys_BP_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Sys_BP_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Sys_BP_unit.options[Sys_BP_unit.selectedIndex].value.split('|');",
"Sys_BP = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"HTN_Med = parseFloat(HTN_Med_pulldown.options[HTN_Med_pulldown.selectedIndex].value);",
"DM = parseFloat(DM_pulldown.options[DM_pulldown.selectedIndex].value);",
"Cig = parseFloat(Cig_pulldown.options[Cig_pulldown.selectedIndex].value);",
"CVD = parseFloat(CVD_pulldown.options[CVD_pulldown.selectedIndex].value);",
"AFib = parseFloat(AFib_pulldown.options[AFib_pulldown.selectedIndex].value);",
"LVH = parseFloat(LVH_pulldown.options[LVH_pulldown.selectedIndex].value);",
"Risk_Period_Factor = parseFloat(Risk_Period_Factor_pulldown.options[Risk_Period_Factor_pulldown.selectedIndex].value);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Risk_Factor_Diff =  (Age * 0.0505) + (Sys_BP * 0.014) + HTN_Med + DM + Cig + CVD + AFib + LVH - 5.677;",
"",
"if (doCalc) Risk_Factor_Diff_param.value = fixDP(Risk_Factor_Diff, dp);",
"",
"",
"",
"Risk_During_Period =  100 * (1 - power(Risk_Period_Factor, eTo(Risk_Factor_Diff)));",
"",
"unit_parts = Risk_During_Period_unit.options[Risk_During_Period_unit.selectedIndex].value.split('|');",
"if (doCalc) Risk_During_Period_param.value = fixDP((Risk_During_Period - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.StrokeRiskFramingham_M_form){",
"",
"if (Age_param.value && Age < 55) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 55 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 84) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 84 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.StrokeRiskFramingham_M_form){",
"",
"Risk_Factor_Diff_param.value = '';",
"Risk_During_Period_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f9_43_9906=null;
var title_f9_43_9907="Brain MRI age 13 years juvenile Alexander disease";
var content_f9_43_9907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Brain MRI, T2-weighted images, of a 13 year old with juvenile Alexander disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Sagittal: symmetric lesions in the medulla oblongata at the level of the vestibular nuclei and the corticospinal tract. (B) Axial: symmetric intramedullary lesions extending from the craniocervical level down to the middle of the cervical spine. (C) Axial: normal cerebral white matter and basal ganglia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Probst EN, Hagel C, Weisz V, et al. Atypical focal MRI lesions in a case of juvenile Alexander's disease. Ann Neurol 2003; 53:118. Copyright &copy;2003 John Wiley and Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9907=[""].join("\n");
var outline_f9_43_9907=null;
var title_f9_43_9908="Cefotetan: Pediatric drug information";
var content_f9_43_9908=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefotetan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"    see \"Cefotetan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/50/8996?source=see_link\">",
"    see \"Cefotetan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Second Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"      see \"Cefotetan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Safety and efficacy in children have not been established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 40-80 mg/kg/day divided every 12 hours; maximum dose: 6 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative prophylaxis: 40 mg/kg 30-60 minutes prior to procedure;",
"     <b>",
"      Note:",
"     </b>",
"     May add gentamicin 2 mg/kg for cases of ruptured viscus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: 2-4 g/day divided every 12 hours; maximum dose: 6 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urinary tract infections: 1-2 g/day divided every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative prophylaxis: 1-2 g 30-60 minutes prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pelvic inflammatory disease: 2 g every 12 hours continued for 24-48 hours after significant clinical improvement is demonstrated",
"     <b>",
"      plus",
"     </b>",
"     doxycycline 100 mg I.V. or orally every 12 hours for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 48 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 10 g [products contain sodium 80 mg (3.5 mEq)/g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. intermittent: Infuse over 20-60 minutes at a concentration of 10-40 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F147628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, bivalirudin, dexmedetomidine, diltiazem, docetaxel, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), insulin (regular), linezolid, melphalan, meperidine, morphine, paclitaxel, palonesetron, propofol, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Droperidol, pemetrexed, promethazine, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Doxapram, promethazine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thawed solutions of the commercially available frozen cefotetan injections are stable for 48 hours at room temperature or 21 days when refrigerated; do not refreeze; incompatible with aminoglycosides, heparin, and tetracycline",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible lower respiratory tract, skin and skin structure, bone and joint, urinary tract, sepsis, gynecologic, and intra-abdominal infections; active against anaerobes including",
"     <i>",
"      Bacteroides",
"     </i>",
"     species of GI tract, gram-negative enteric bacilli including",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     , and",
"     <i>",
"      Proteus",
"     </i>",
"     ; active against many strains of",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ; inactive against",
"     <i>",
"      Enterobacter",
"     </i>",
"     sp.; less active against staphylococci and streptococci than first generation cephalosporins; preoperative prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CefoTEtan may be confused with ceFAZolin, cefOXitin, cefTAZidime, Ceftin&reg;, cefTRIAXone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F147627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, anaphylaxis, bleeding, BUN increased, creatinine increased, eosinophilia, fever, hemolytic anemia, leukopenia, nausea, nephrotoxicity, phlebitis, prolonged PT, pruritus, pseudomembranous colitis, rash, thrombocytopenia, thrombocytosis, urticaria, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, cholestasis, colitis, hemolytic anemia, hemorrhage, pancytopenia, renal dysfunction, seizure, Stevens-Johnson syndrome, superinfection, toxic epidermal necrolysis, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefotetan, cephalosporins, any component, or patients who have experienced a cephalosporin-associated hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with renal impairment; use with caution in patients with history of colitis or penicillin hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in superinfection; do not use in patients with immediate-type hypersensitivity reactions to penicillin. May cause pseudomembranous colitis or secondary antibiotic-associated colitis. Severe cases of immune mediated hemolytic anemia have been reported with cefotetan administration. Risk of developing cefotetan-induced hemolytic anemia is 3-fold higher relative to other cephalosporins. Monitor hematologic parameters; blood transfusion may be needed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CefoTEtan may enhance the adverse/toxic effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6347590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Cefotetan crosses the placenta and produces therapeutic concentrations in the amniotic fluid and cord serum. Cefotetan is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, prothrombin time, renal function tests; number and type of stools/day for diarrhea; signs and symptoms of hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis resulting in cell wall death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Completely absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into tissues and fluids including gallbladder, kidney, skin, tonsils, uterus, sputum, prostatic and peritoneal fluids; poor penetration into CSF; crosses the placenta; small amounts appear in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 76% to 91%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 3.5 hours, prolonged in patients with impaired renal function (up to 10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 1.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 49% to 81% excreted as unchanged drug in urine, 20% of dose is excreted in bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: &lt;10% removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/50/8996?source=see_link\">",
"      see \"Cefotetan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol during and for at least 72 hours after the last cefotetan dose.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g: 3.5 mEq; chemical structure contains a methyltetrazolethiol side chain which may be responsible for the disulfiram-like reaction with alcohol and increased risk of bleeding",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Martin C, Thomachot L, and Albanese J, &ldquo;Clinical Pharmacokinetics of Cefotetan,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 26(4):248-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/43/9908/abstract-text/8013159/pubmed\" id=\"8013159\" target=\"_blank\">",
"        8013159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13130 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9908=[""].join("\n");
var outline_f9_43_9908=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046003\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045995\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147571\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147555\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046006\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147628\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045999\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046005\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147630\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147627\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046009\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045994\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045993\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298991\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147564\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147567\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6347590\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046002\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045992\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046008\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046001\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046010\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13130\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13130|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=related_link\">",
"      Cefotetan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/50/8996?source=related_link\">",
"      Cefotetan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_43_9909="Examination of the precordial pulsation";
var content_f9_43_9909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Examination of the precordial pulsation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9909/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9909/contributors\">",
"     Kanu Chatterjee, MB, FRCP, FCCP, FACC, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9909/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9909/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9909/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9909/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/43/9909/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection and palpation of precordial cardiovascular pulsations is best performed with patients supine and with a modest elevation of the head and chest (not over 45&ordm;). The examiner should observe by looking down at the chest and from the side.",
"   </p>",
"   <p>",
"    Other aspects of the cardiovascular examination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"     \"Examination of the arterial pulse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INSPECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A slight abrupt inward pulsation normally can be seen over the left ventricular apex at the fifth intercostal space in the left parasternal area, particularly in children and thin chested subjects. A hyperdynamic left ventricular impulse associated with severe aortic or mitral regurgitation is frequently visible and can cause occasional shaking of the entire precordium. In patients with severe dilated congestive cardiomyopathy, a double impulse may be visible over the apical region, usually due to a sustained left ventricular impulse and a prominent early diastolic filling impulse.",
"   </p>",
"   <p>",
"    Cardiac pulsations that are visible lateral to the left midclavicular line usually suggest cardiac enlargement. Leftward cardiac displacement due to left pulmonary fibrosis, right-sided tension pneumothorax, massive pleural effusion, absent left pericardium, and thoracic deformity may also cause visible pulsation beyond the midclavicular line.",
"   </p>",
"   <p>",
"    Systolic outward parasternal and left ventricular outward movements are better appreciated by palpation than by inspection. Such movements are often associated with aneurysms of the apex or anterolateral wall of the left ventricle and frequently indicates reduced left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    Epigastric and subxiphoid pulsations are usually abnormal and are related to right ventricular hypertrophy and dilation or to abdominal aortic aneurysm. However, in patients with emphysema, subxiphoid pulsations may not always indicate right ventricular hypertrophy. An abdominal aortic pulsation is frequently visible over the epigastrium in children and in persons with a scaphoid abdomen.",
"   </p>",
"   <p>",
"    Pulsation over the right second intercostal space or right sternoclavicular joint may indicate aneurysm of the ascending aorta. Aneurysm of the aortic arch is occasionally associated with suprasternal pulsation. The most common cause of right supraclavicular pulsation is a kinked tortuous carotid artery.",
"   </p>",
"   <p>",
"    Occasionally a pulsation is visible over the left second or third interspace. This is usually due to a dilated pulmonary artery.",
"   </p>",
"   <p>",
"    Retraction of the chest wall anteriorly with each cardiac cycle may occur in patients with biventricular hypertrophy or constrictive pericarditis. Retraction of the ribs in the left axilla (Broadbent's sign) usually indicates adhesive rather than constrictive pericarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PALPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of precordial palpation is to detect the character of the right and left ventricular impulse, which is helpful for assessing changes in cardiac dynamics and function. Palpation of the precordium should include the apical, mid precordial, lower left and right parasternal, pulmonary, aortic, suprasternal, and epigastric areas (",
"    <a class=\"graphic graphic_table graphicRef73890 \" href=\"UTD.htm?16/34/16941\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Left ventricular impulse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left ventricular apical impulse or apex beat is the outward movement of the left ventricular apical region. It is normally localized to the fourth or fifth left intercostal space just medial to the left midclavicular line, and is no more than 2 to 3 cm in diameter. The apex impulse is best palpated when the patient lies in a partial left lateral decubitus position. Both the systolic and diastolic portions of the apex impulse should be analyzed.",
"   </p>",
"   <p>",
"    Generally, the apex beat is the point of maximal impulse (PMI), but occasionally a right parasternal pulsation or pulsation associated with a dilated pulmonary artery and aortic aneurysm may be more forceful than the left ventricular impulse. When the right ventricle is markedly dilated, as in some patients with a large atrial septal defect or severe mitral stenosis, the left ventricular apical impulse may not be palpable because of posterior displacement of the left ventricle.",
"   </p>",
"   <p>",
"    The normal torsion of the left ventricular basal segments (counterclockwise as viewed from the base) and the apical (clockwise) result in normal character of the apical impulse. A sustained impulse is associated with abnormal torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic correlations between the various components of the apical impulse (as recorded on an apex cardiogram) and the left ventricular dynamic events have been studied both in experimental animals and in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial upstroke of the apex cardiogram coincides with the onset of the isovolumic phase of left ventricular systole; the upstroke phase is usually completed before left ventricular ejection begins. During the isovolumic phase, the intraventricular pressure rises, associated with increased external cardiac circumference and alterations in ventricular shape. The upstroke portion of the apex cardiogram in normal subjects terminates with the beginning of left ventricular ejection.",
"      <br/>",
"      <br/>",
"      There is a counterclockwise rotation of the heart in normal subjects during isovolumic systole, which brings the lower anterior portion of the left ventricle in close proximity to the anterolateral chest wall, causing an outward motion.",
"     </li>",
"     <li>",
"      The apex impulse on palpation normally corresponds to the onset of ventricular ejection or systole. The normal outward motion of the apex impulse is very brief and is followed by a gradual inward movement resulting from a decreasing ventricular volume during the ejection phase of systole.",
"     </li>",
"     <li>",
"      A more rapid inward movement begins just before S2 and continues up to the opening of the mitral valve; this corresponds to the left ventricular isovolumic relaxation phase.",
"     </li>",
"     <li>",
"      After mitral valve opening there is a rapid filling wave followed by a slow filling wave, corresponding to the rapid and slow ventricular filling phases. A palpable rapid filling wave is always abnormal; the most consistent hemodynamic association is augmented early diastolic filling and an elevated left ventricular diastolic pressure, as may be seen with mitral regurgitation, patent ductus arteriosus, and ventricular septal defect. A prominent rapid-filling wave also is observed in normal, young subjects.",
"     </li>",
"     <li>",
"      Atrial systole occurs after the slow filling phase. It generates a relatively small wave that has an amplitude that usually does not exceed 15 percent of the total height of the outward movement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A palpable a wave, due to an increased amplitude, is always an abnormal physical finding. The most common hemodynamic association is an elevated left ventricular end-diastolic pressure and reduced compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/6\">",
"     6",
"    </a>",
"    ]. This may be present in patients with left ventricular hypertrophy (aortic stenosis, systemic hypertension, and hypertrophic cardiomyopathy), myocardial disease (cardiomyopathy), ischemic heart disease, and chronic left ventricular aneurysm. In patients with angina pectoris, an accentuated a wave can occur during angina pectoris or stress. The absence of a palpable a wave, however, does not exclude an abnormal left ventricular end-diastolic pressure.",
"   </p>",
"   <p>",
"    An a wave is usually absent in conditions associated with marked restriction of inflow to the left ventricle, such as mitral valve obstruction or constrictive pericarditis. In patients with acute, severe aortic regurgitation, premature closure of the mitral valve can occur due to a rapid increase in left ventricular diastolic pressure exceeding aortic diastolic pressure. The a wave also may be absent in these circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outward movement (systolic portion) in the apical impulse can be classified as normal, hyperdynamic, or sustained.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hyperdynamic apex impulse is appreciated as a thrust of large amplitude that immediately disappears from the palpating fingers; it otherwise has a normal configuration and does not extend throughout systole. It is frequently associated with an accentuated rapid-filling wave.",
"      <br/>",
"      <br/>",
"      A hyperdynamic apical impulse is found in conditions associated with an increased stroke volume or volume overload in the absence of significant left ventricular hypertrophy or depressed ejection fraction [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/8\">",
"       8",
"      </a>",
"      ]. Examples include after exercise in normal subjects, in hypermetabolic states (thyrotoxicosis, anemia), in primary mitral regurgitation, in aortic regurgitation with normal systolic function, and in some patients with a large patent ductus arteriosus and ventricular septal defect.",
"     </li>",
"     <li>",
"      The sustained outward movement is characterized by a plateau or a dome-shaped or rising movement after left ventricular ejection, in contrast to the normal systolic decline. A sustained apical impulse is felt as a prolonged heave throughout the systolic phase.",
"      <br/>",
"      <br/>",
"      A sustained apex impulse is usually found when there is significant left ventricular hypertrophy, as in patients with left ventricular outflow obstruction or systemic hypertension. A sustained impulse is also appreciated when left ventricular systolic function (ejection fraction) is depressed, as in patients with dilated cardiomyopathy, ischemic heart disease, and aortic regurgitation associated with depressed left ventricular function [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In hypertrophic cardiomyopathy with midsystolic left ventricular outflow obstruction, the apical impulse may have a bifid outward movement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Along with a prominent a wave, this may be felt as a triple impulse, although most frequently a double impulse consisting of a palpable a wave and a sustained outward movement.",
"   </p>",
"   <p>",
"    Various abnormalities in the apical impulse may be appreciated in patients with coronary artery disease and a previous myocardial infarction or during ischemia. Early systolic, late systolic, or combined early and late systolic movements have been found [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/11\">",
"     11",
"    </a>",
"    ]. At the bedside, however, these abnormal systolic motions are difficult to appreciate, although they may be precipitated by stress (eg, hand grip).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Right ventricular impulse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, an inward movement (systolic retraction) is appreciated by palpation of the lower left parasternal area. In children, or in occasional adults with thin chest walls, a brief, gentle thrust may be palpable over the left third and fourth interspaces. A prolonged left parasternal upward or outward movement, palpable throughout systole, is distinctly abnormal.",
"   </p>",
"   <p>",
"    A sustained systolic left parasternal lift is most frequently appreciated in the presence of significant right ventricular hypertrophy. Long-standing, severe pulmonary arterial hypertension, whether precapillary (eg, idiopathic pulmonary arterial hypertension or pulmonary valve stenosis), or postcapillary (eg, mitral stenosis, cardiomyopathy), produces right ventricular hypertrophy and a sustained lower left parasternal lift. It may also be associated with a palpable presystolic a wave preceding the right ventricular lift (heave); this finding suggests decreased right ventricular compliance.",
"   </p>",
"   <p>",
"    A hyperdynamic but not sustained left parasternal systolic impulse may be palpable when right ventricular volume is increased, as with an atrial septal defect or tricuspid regurgitation. The left parasternal impulse becomes sustained during systole when pulmonary arterial hypertension is also present [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A left parasternal and midprecordial systolic outward impulse, similar to that associated with right ventricular hypertrophy, can be palpable in the absence of right ventricular hypertrophy, for example in patients with significant mitral regurgitation. The systolic pulsation appears to result from left atrial expansion due to mitral regurgitation pressing the anterior structures forward toward the anterior chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/13\">",
"     13",
"    </a>",
"    ]. In some patients with Ebstein's anomaly, a right parasternal systolic outward movement, presumably due to a large ventricularized right atrium, is appreciated.",
"   </p>",
"   <p>",
"    An inward systolic movement and an outward movement during diastole are also palpable and recorded in some patients with constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/14\">",
"     14",
"    </a>",
"    ]. The diastolic movement usually coincides in timing with the pericardial knock. The precise explanation for this unusual precordial impulse in constrictive pericarditis remains unknown; it has been suggested that the usual outward movement during isovolumic systole is inhibited by the constriction and the outward movement during early diastole becomes accentuated. In patients with severe, long-standing constrictive pericarditis, the precordium may be quiet and no precordial impulse may be palpable or recorded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other precordial pulsations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal pulsations may be appreciated in other areas of the precordium.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A chronic left ventricular aneurysm can produce systolic motion and an accentuated a wave in unusual locations, such as over the left midprecordium or at left anterior axillary area [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9909/abstract/15\">",
"       15",
"      </a>",
"      ]. This abnormal precordial motion indicates decreased systolic function and compliance of the left ventricle.",
"     </li>",
"     <li>",
"      Pulsation in the left second interspace is usually associated with an enlarged pulmonary artery resulting from severe pulmonary arterial hypertension. Pulmonary artery pulsation is also palpable when the pulmonary artery is dilated from a marked increase in pulmonary flow, as in patients with atrial septal defect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43815443\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection and palpation of precordial cardiovascular pulsations is best performed with patients supine and with a modest elevation of the head and chest (not over 45&ordm;). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A slight abrupt inward pulsation normally can be seen over the left ventricular apex at the fifth intercostal space in the left parasternal area, particularly in children and thin chested subjects. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Inspection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac pulsations that are visible lateral to the left midclavicular line usually suggest cardiac enlargement. Leftward cardiac displacement may also cause visible pulsation beyond the midclavicular line. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Inspection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The left ventricular apical impulse is normally localized to the fourth or fifth left intercostal space just medial to the left midclavicular line, and is no more than 2 to 3 cm in diameter. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Left ventricular impulse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A hyperdynamic apical impulse is found in conditions associated with an increased stroke volume or volume overload in the absence of significant left ventricular hypertrophy or depressed ejection fraction. Examples include after exercise in normal subjects, in hypermetabolic states, in primary mitral regurgitation, in aortic regurgitation with normal left ventricular function, and in some patients with a large patent ductus arteriosus and ventricular septal defect. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Left ventricular impulse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A sustained apex impulse is usually found when there is significant left ventricular hypertrophy. A sustained impulse is also appreciated when left ventricular systolic function (ejection fraction) is depressed, as in patients with dilated cardiomyopathy, ischemic heart disease, and aortic regurgitation associated with depressed left ventricular function. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Left ventricular impulse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normally, an inward movement of the right ventricle (systolic retraction) is appreciated by palpation of the lower left parasternal area. A prolonged left parasternal upward or outward movement, palpable throughout systole, is abnormal and is a sign of right ventricular hypertrophy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Right ventricular impulse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/1\">",
"      Foster E, Lease KE. New untwist on diastole: what goes around comes back. Circulation 2006; 113:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/2\">",
"      AGRESS CM, FIELDS LG. New method for analyzing heart vibrations. I. Low frequency vibrations. Am J Cardiol 1959; 4:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/3\">",
"      DELIYANNIS AA, GILLAM PM, MOUNSEY JP, STEINER RE. THE CARDIAC IMPULSE AND THE MOTION OF THE HEART. Br Heart J 1964; 26:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/4\">",
"      BENCHIMOL A, DIMOND EG. THE NORMAL AND ABNORMAL APEXCARDIOGRAM. ITS PHYSIOLOGIC VARIATION AND ITS RELATION TO INTRACARDIAC EVENTS. Am J Cardiol 1963; 12:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/5\">",
"      Sutton GC, Craige E. Quantitation of precordial movement. I. Normal subjects. Circulation 1967; 35:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/6\">",
"      Voigt GC, Friesinger GC. The use of apexcardiography in the assessment of left ventricular diastolic pressure. Circulation 1970; 41:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/7\">",
"      Fortuin NJ, Craige E. On the mechanism of the Austin Flint murmur. Circulation 1972; 45:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/8\">",
"      Sutton GC, Prewitt TA, Craige E. Relationship between quantitated precordial movement and left ventricular function. Circulation 1970; 41:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/9\">",
"      BRAUNWALD E, LAMBREW CT, ROCKOFF SD, et al. IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. I. A DESCRIPTION OF THE DISEASE BASED UPON AN ANALYSIS OF 64 PATIENTS. Circulation 1964; 30:SUPPL 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/10\">",
"      TAFUR E, COHEN LS, LEVINE HD. THE APEX CARDIOGRAM IN LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION. Circulation 1964; 30:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/11\">",
"      EDDLEMAN EE Jr, HARRISON TR. THE KINETOCARDIOGRAM IN PATIENTS WITH ISCHEMIC HEART DISEASE. Prog Cardiovasc Dis 1963; 6:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/12\">",
"      Armstrong TG, Gotsman MS. The left parasternal lift in tricuspid incompetence. Am Heart J 1974; 88:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/13\">",
"      TUCKER WT, KNOWLES JL, EDDLEMAN EE Jr. Mitral insufficiency: cardiac mechanics as studied with the kinetocardiogram and ballistocardiogram. Circulation 1955; 12:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9909/abstract/14\">",
"      el-Sherif A, el-Said G. Jugular, hepatic, and praecordial pulsations in constrictive pericarditis. Br Heart J 1971; 33:305.",
"     </a>",
"    </li>",
"    <li>",
"     Craige E, Fortuin NJ. Noninvasive measurement of ventricular function in chronic ischemic heart disease. In: Atherosclerosis and Coronary Heart Disease, Likoff W, Segal BL, Insull W, et al (Eds), Grune &amp; Stratton, New York 1972. p.221.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1081 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9909=[""].join("\n");
var outline_f9_43_9909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43815443\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INSPECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PALPATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Left ventricular impulse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Right ventricular impulse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other precordial pulsations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43815443\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1081\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1081|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/34/16941\" title=\"table 1\">",
"      Charateristics of precordial motion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_43_9910="M-mode echocardiogram of pulsus paradoxus in COPD";
var content_f9_43_9910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of pulsus paradoxus in COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 218px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADaAdgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCjrt/wD2Voeo6j5Xm/ZLeS48vdt37FLYzg4zjrivLNL+NltP4LuPEl7baMYo7eOVNP07Wftd6JZHVEjkiMSCPJbk7jjHQ16tq1jFqmlXlhcM6w3ULwOyEBgrKVOMg84NcXafC/Tk8Hv4W1HV9X1TQPsy20VpdfZ18jaQUdHjiR9ykDBLEeoNADdd8d6v4a0iCfxD4bij1C9u7ex0+1stRE63E82cIzsiFCu05O0jGME846rQbzWblp013SbeweMKUe2vftMcuc5AJRGBGBnKgfNwTiuf1D4d2mraM9hrmua7qjLLDPb3VxPGk1rJFnY8XlxqoYZOWKknPJOBiXwL8PNK8G3Wt3NjNc3U+sNG121wkKKdgYDCRRogzuYn5eSSTQBtv4gsl8UxaAPNa+ktXuyyrmNFVlXazdmO4kD0Vjxxmr4z8X6X4RtIZdS+0TT3DEW9nZxGa4n2jLlIxyQi/Mx6AfUAxTeA/DLaY1hZ6TBpduZfP/4lRNi3mbSu7dCVOdrMOvQ4q3onhfRNHvZb3TNPt4ruSNYDOFyyxIFVYlP8EahFwi4XIzjJJIBn6p8QfDGn2VvcjV7O8Sd0CLZzpMxRj80uAf8AVogaRm6BEY9sV0U2oWcNvdzzXdvHBZhjcyPKoWDaoY7znC4UgnPY5rJt/Bfha2uprm28NaJDczq6Syx2ESvIrghwxC5IYE5B655rFtPhn4dhmit5NNWbSbVhcW9tNdTSq05zveVXYiU4EYUvu27eMUAW4/iR4SNrLNPrlpZSR53Wt8/2W4Hdcwy7XG4FSuRyGBHWtvw/rMOs6VY3ixS2sl3EZRa3BUTJggMGUE8qSAeeCcHmi/8AD+jajqEN9qGkaddX0G3yrie2R5I8HI2sRkYPIx3rmtX+HvhebVJ5m8NpcNrU2zUXSVkQKMzFmXcBhpYogwUAuSC24ZoAtWPxE8NXmszact/5LKHMVzcIYre62NtkEMrYWQo2A20nBPscXPCXiyz8Sw6hNboYIba8NrE8kiEXKYUpMm0n5HDZU9xz3q5qHhnQdS02107UdE0y70+1Ci3tp7SOSKEKNoCIRhcDgYHTisXxP4S8NtPba3dacUu7CNLeGS2keIpFkqAFQgHaHbaSMrnK4PNACXPxG8PWvimTRJ7iVDG/ky37REWcNwQCLd5j8olI5C/hncQDJpfj3R9U8RXWnWFxbXFlb2n2h9ThuUe23hjvi3A43ou1m9Awzita18M6Fa+H/wCwoNH09dG27TZfZ1MLDOeUIwcnkk9TzVHWPAvhjV9Gi0m80WzGnRMWjht1+zhCRhtpj2kAjggcEcHIoAh8XeO9K8M31tYzRXt/fyxtcPa6fD58sFsv3riRQcrGOmerHhQx4qle/E/wymp6XY6TqNprUt5cJFL/AGbcJP8AZUd1jWWTaThTLLCnr8+RkKa2vB9hpEWm/wBqaNbRJ/bGL+a4Xl7hpPnDM3JIG7AGcKMAYAFWZfDujSaZfacdLs1sr5WS5hjhVFmDAg7tuMnk89aAIPFPifTvDOjf2hqTu5dxDBbQLvnupicLDEnVnJ4x25JIAJGB/wALW8KHRpbv+0Yk1KNXB0SSRF1EzKSv2cQFtxlLDaAMgkggkEGtDwr4U8K6Pc7dC06BLjS1+xKzM0r24b96VVnJKlvO3MRy2RnOBjdfSNNkvvtr6fZtebg3ntCpkyAADuxnIAH5UARaRrllqdnDNHPFHK9sl09u0qGSFGyMuFJAwVdc9Mq3PFc5a/FHwbc3c8Z8QWVrFEcpcXUiw290uSpeGVyFlUOCpKk4II9DVe7+Gvh19ZRIvDunHSLqRr2/QlgJLhCPJzGPlZP3k5Kn5cnOCTXW3Gh6Tc2tpbXGl2E1taAC3ikt0ZIQBtGwEYXjjjtxQBheEvHeneIba9uGVtPgjvxY2r3ThBeh1VopYs9VkDZX1xTdY+Ivh/SdW+x3Nw7wROsV7fxBWtdPdiQi3EmcRliMe2V3bQyk2/FXhi01HOpWWmaXJ4hggNvaXd1Fho0OQyb1G5RhnAx03HHU1s6Rpen6NYR2OkWNtY2cedkFtEsaLk5OFAA5PNAHLad8Q9K1HxBdW9ncWE2g29q0h1qO+jaEzoA8kIx/ciZXLZwASOxq14k8aW2kzNa6ZaXOvakii4msdNKPLBb4BMjZYAZB+Vc7nJwoIDFdzWdG0vW7eODWtNstRgjkEqR3cCzKrgEBgGBAOCefc0aLZ2ltbPNaadFYPeObq4jSNUZpWA3M+PvP6k88UAcVL8VtCvb7TYvDV7Z6rbSPE1/cpLiOyhkKohc44cu6DYcEYfONta+teOtMtreGLRnTWdXu3eGz0+2f55nSRo3ZiAfLiV1YNIRtG04ycA9Rd20F5aTWt5DFPbTI0csUqBkkQjBVgeCCCQQapaTZ2FpLPHp+mw2X2dY7MGOARhokXcirgDKL5jAAcAlsd6AOKl+JsVxZHSrGzlg8dP8A6ONHngllW2uCcBpXRceQM7/MyA0YJXnitix+I3hW60GLVI9bs5Y2ES+VE4ebzZFJWERLljKdrARgbsgjFdfVCGxsre/LQafDFI5eczpEq5dsBiSP4mwMnvigDk4/iGthKIvFeiapo8k6iazEVtNfebEez+TGfLlX+NDkDK4ZucO8MfESx1CRrXX0XQ9We5kSCwu3CztB5bTRyunWMGJSTu4VlZSdwxXc1m6vp0V2olFlZXFzxCWuIwf3LMvmrnGcFc8dCcZoA5Ob4lWj3sU2k6bfar4ZQul5rlnG0sMLjOBGiqWnXKkM8YKrkcn5trJPiVYxaml3cCSy8JiHY+pX9nPa/wCkneyqPNRQU2ROC3d3jUZJxXoCqFUKoAUDAA4AFLQBxmp+OYpGSw8K2h1rXnRZGstxhW0VkLg3T7T5BIGArDczEDGNzLm634+1B4bY6BoOro8GLzU/7S0qeJIbVCPOjR+FefBO0RmRTtbGeCe+sbc2tuImkaU7mYuwAJyxPb61PQBwT/E/R76wdvCsdxr2oSs8dla2qHFyV8sM/mY2pCrSqrSNgAhgNxABzrjxv4ntNJfSr/wtqJ8YNm3insLOSbTDK3Ec5mONsOSpYMd6gNkEDJ9FiE41G43xRi3MceyUH5mbLblI9B8pH+8as0Aec6V8T9Kt4pdN1mW8m1vS4o4dS8ixkIN0WEaxxoAWZpGDOgUHKAtkAVJH4x8Q6U0914l8MahJYXh8zTodJtnuriBBj93dKvCyEYbKkr95S2VUt3Fy04vrNY4Q8J3+Y5xlOOPzPFWqAPP9B8eCC5W18Yn+ydR1KXz9NsZoSsgtSOA5BZd67XZ+RsBGQBjNeTx3rl/dJqvhvw7Pe+DbdFae5kikju70OAQ9nCQCyICCSwG/OEzjLegai8kWn3LwwfaZFjYrD/z0OPu8+vSrFAHnD/EaZdVhu7vR7/RvCkL/AGe8v9YtmtSJJATFIoY8RgrsYsAd00fTDVZ1Hx62rLBY/D2GLWNXuIYrkyTrJHaWcTjcrXDgZVmXlYx85yDgDmu+qCzZnSQtB5JEjjH94bj8349aAPP5/iBq93p/2TSvCGuQeJ2QqIL6xlFnHMpO5WuQNjL8p2upw2V6ZwNSL4m+EpNKk1BdWRoY5UtyscbyO07KG8lFUEySAMMqgJXnOMGuzqm0Mx1VLkXS/ZVgaNrcxg/OWBD7+owAQR0OR6UAcQnxGvrWNX1vwR4ntxOBLaiys2vS0LdPNCD9zKP4oznGRhm5xZ0Lx1suhp3iqCXT9XmDXcUH2aTalqU8wF5OUBQZRzuHzrwMMue386PBPmJgd9wqjfz293avFBqUMEmVYSKysVwwPQ8dsUAcg3jbWbm4Gq6N4avb7wpGgR3MTQ307sMiWCCTbuiXgHdtZtxK5CfOreN7qweXVtd0vVtP0WaPyrS0ewMtyZlySX8pn2+ZkKittOVOcZGe0Op2AGTe2oGM5Mq9PzpG1TT1GWvrUDbuyZl6evXpQBymreJ9c1DUpLPwPpcN4lkzm9vdQDw27MjFTbQtj55SysC4ykeDnJ+Wo/8AhK9Y1ORJLHw/rulW9i4uL5tQskbz4hlXhiWORnaTneCisDswM7gD1FprFobGOS7vrBZgqibZcKUV8cgH61I2taWqgtqVkAeQTOnP60Ac/deL5NR0y0bwlp9zfXl+SLd7m3kgghUMVaWYsAVUEHCcO5GAMZZdTQ9Q1Rrp9O1nTpRcQoWbUIVRbS45GCgLs6kg8qw+Uqw3EbWac+IdFG4nV9OAUEk/aU4x179qnstW02/maGx1CzuZUG5khmV2A45IB9x+dAF2iiigAooooAKKKKACiiigAooooAKbKxWJ2GcgE8dadUV0u61mXJXKEZC7iOPQdfpQB8WXP7Q/jRpwItVaOAl8N/ZUJc4yB8u/25Hb1NZ837RHjdInS21vBIJBOlwL8xOScZPr7/jVI/Drwrb67ZabqvibXtJnuA7CXVdDWyiXacnLTTr7jvzXPeKPh4dGmRob69exktzcR3F5o9zbBlGMn7rAqNwywJA/GgDpLj9ob4hPPiHxEyQhj839n224rjjgqRmqjftBfEz+HxOfx0+1/wDjdcfp/hvTb1reMeLdBgmlcKfP+1oq5/vH7PtGPXJq9498E2XhLT9Okj8V6Lrl3d5Jh0qTzkiUDks/GOSAAQCeemOQDoh+0H8TcHPiY57YsLX/AON1Kv7QnxG8shvEUxfbwws7QDd648np7Z/wrmZ/COiw+B7bxA3i6wFzOMDSdga6Dg4IKo7bV4JDPtyMcDIq/onhrwHqGkQ3Vz4yksLhdwngu7V1fPYoI1kBHI7k9eBQBsv+0L8RC+Y/EE6rzw1raE/n5AqGf9oL4kuV8vxJIoGDzZ2p5/CIflXIWHhL+2rSWTw3fnUr1CdulxWNy92y7sZASNo8Y55ccA9+KtX/AICk0u1gl1rWrHS3lAzDe2OoRujY5Un7NtJHIOCRxwTQB0Y/aB+Jmwg+JmJ7H7Fbf/GvrUR+PnxMJJ/4SiTn/pzt/wD43WTpXw8GroW0vxNpN6qnDG2sdTl2nrg7bQ4OOazv+EX0nPPjnw4D6GDUOP8AyVoA6QfHf4j+U6HxNcDJBG23gUDAxj/V/Tpio2+OfxILA/8ACU3QwMD9zF/8RXFaZpdpeahcW9xrum2EMYO26uUuDHLg4+URxM/PX5lHHoeKn1nRbDT7MTWnibSNUkLhfItIrtXA5+bMsCLjj1zz060AdQ3xq+IjEn/hKr4EkMdqoMkfRalHxv8AiJu+bxTfFe4Cxg/nsrk7HVNNigjSfQdNndEwzySXOZCP92UAE+wx9KtrrmiC52f8ItpBiLYEjS3gwM9cCf0oA2pPjN8QZInR/Fep5YdVdVx+S5/Woj8X/H5fP/CWavjjI8//AOtVxdD8C6rb21zeeMNL0KQriW0sNKv7gqc4zmViDjrww47E8VXg8O/D+TUHtz46vI7dUR/tU2jSKrEnDKqqztkDB5wDyM+oAwfF7x2Af+Kr1r2/0r378c0j/Fvxwy4XxVroJOSftp/w4rXtfh34Mv7a5bTviloxmiAwLyymtVbOcY3jJ6c4BxxmsPVfDnhew07ULdvE9s+tWOSjW3mXNtqAIyBGwjXyyAQDuJGQeR2AA/FXxxtz/wAJZr/mhsq3298Y7gr0NQt8TfGzOzHxf4k65XGpyjH1557f5NcbUkJjEqmdXaPPzBGCkj2JB/lQB1bfErxqSx/4S/xJ83/UUn4PqMNUkPxM8Yog3+KfEUrbh97V7gcDqOHHX1rj1MfmZdWKegbB/PH9KsL5DNhILnblcqJAcj67fy4oA6xPih4vV5D/AMJHr7o2MK+r3Xy8c4IkHfnnNTTfFXxWyp5eua4hCEN/xObw5PPP+t7ccVy8cMEiFU06/O5wFxKOSeAP9X15qC9tvIXc1pdQgkqPNYdf++R2/rQB0kfxN8ZKp3+JtdkbnDNqt1lfpiQf5NS3PxQ8XSXBaLxFriRAkhP7WuyCMYxkyZx3/wAawLDSre80aa7W72XNu+ZoZGhiXyeMNGXkDSPncPLVDwM55xUax6QXLSX1+Pm6LZJ07/8ALX9KAN7/AIWV4t2oG8QayzBQrP8A2pdZbp1/e49uBirNp8SvERkBm1G/fG0bm1W9GPmHJ/femR+NW9M0D4bzrBJqHjnVYC0amSEaGco3GRuEhB79q1tU0v4P/YRHY+KPEZuSADMbEMq4xnEfy5zz/Fx79KAKOv8AxL1ma6uPIYwxCdxHJDqd4w2/LgYMxHHPOM5c+2OQufFuvTyM6atqMIOcrHeTEckn+Jye+Ov611Hjay8AaLFBL4T1tvE5mwJYbu1ntnt8Ds3yqQ2T2JBUdcmuElmtRI3l28sat1VZ88c8A46dOuelAF4eJ9YDAtqN44HZrqUjr/vfh+FOHiXUxKZJbmWdWUqUlmkZcnuRu6/p7VQQwiCQbiCy5z5h554XG32+nTmups/ht4rvbaK6h0aSWCZRIj/aohlCAc8tx1ByaAOYk1W7lSVZJS3mHJz29h6VEt7MM7juyQcMTjgEevvW7qPgXxDp0Uj3mnrEsWzzCbmI43nC8Bu5rJ1TRr3S9Vk06+iSG7jxuQzIQMjP3gdv60AVZrjzUwYow+SS4yWbJ6HJ7UyOUxyBwEJGThkDD8jxWpofhzU9cnjh0yKGSWQsqK9zFGWKjJxvYdAaq3ul3dlbRXFzGqRSyPEh8xSSyHDcA5wCevQ9qAIvtbEDdFbkjAz5Sj09Pp+ppgndY1QCPapLAmNSfxOMn6UBTEhMkSncON5II75Az+vSnQtABKZo85U7ArYwf8KAImkLAgheTkkKB/8Aqqwt9Ku393bEDHBt05x68fn60jTxqqiCMggEEyBXzkf7v6/litrwprVrZa1Hc6y12LdFwPsMUPmAgfLjepUDnnjmgDES8kTZ+7tztYPzChyR68cj26VZi1eaPzP9HsH3IUy9nFxnHI+Xrx19zXT3+r+Em06ZLJPEAuTJ5iiT7KEYhsjJVMjqfWuc1TXrrU4BFcwacijGDb2EMBGPdFBoApS3bySpIUgVlAACwqAcDHIxg1LFqU8cvmCO0ZslsPaxsCT7Fao1YtZYIyPPthMM5xvK8Y6cUAT2N60MgJMC7Vwu62STPzA85H69e1djb+Ir2OyEkFrBiby98SWIzIV/iBA4znPXt9McZZXUMF15rQMUwRsWVk7eo5rS/ty3WKLbYsswUb3F5L8+Ceozwce9AHpfhzxFqdgl7eW6Rwi4u0kMU2no7uAmBtBHBJJ45Hrmvcf2etU1bVdbuLnUYEW2lsmeKT7OqSZ81flkbO4n0A+XH0FfNmneMrN2DtpNkqxyhwr3t1hCerA84/P86+hP2bPEUOpeI7my8qA3Q0952kilmbYvnKAjB1AB5z689uRQB9EUUUUAFFFFABRRRQAUUUUAFFFFABVbU5Ei027kl8wxpE7N5Qy+ADnb7+lWar6gFNhciRnVDE24ocMBg8j3oA+Frzwn8J9XjsRoPjfUtHuppAJl1yDzcKQccxIFUg4B3MABzVW/8O+GY9Sisb74ryyWD2fnR3aWEs0WGYqYiokLqfl5UqOCKbrNl4bspb5h4ZuLS4hfAj8TXty08xRQzny4EQLu3KCXcDLLtIG7HbT+EfB9p4buNVurTRda0s2UbzJpczpJpV43AjaSF53KFfMJaQMu6NcMd2KAON1fwb4PtPCyXdh8RNM1ewhuPMktodNS1v2T7p2+Ywdu2EJx/EK84tp9NRHint2kjkkJEuD50ajoB8wUg9+Px6V10moeAtH16VZ/C17rFtEw2LH4h/cSKVB+8LZXPJPdfTHHM39maXJI974w8G614a0VIisc+jW07bpWK7DIbqVhtxu4UqST7UARWuu/2rpsLw6N4G08258pvMh2Szng72DsR/3zgdeOBTL+HwPLcW15NeXU4k/f38Wmxi1EJ3EGKFJQd+flIbI2jJ2noG6wmj6HDDJp/hea+04RC2kvdbWW3llnbcxeOOOYKoC8KDvxjJySKj1Cy8HahbWFxo32/TLG0ULqct5dQXNxLIx48iDMRkRehYbeDkgEcgEN/wCFY9Uu9Nn8NQmysdXnFvp9tqOoRSXEreZ5e75VXam7jLADIYZOM1g65oN/oV0trqtvJbzvhlBHBXv+Oe1dJ4j0Dws4s5fCGq6vqolR2uI10tlNu4BKpgucjAJ4ZsAEknGDlXmgQLcWw0bWLbVJJSN0NjbXXnQdBhleNQSWYKNrNzjkZoA19D+Hk94039rXkOktAZhJDdSIkqqgGZGV2XamWVck/MeFyc4dY+GvCF9Z3Vxb+JblVtERpVuoYYHfdwfKRpcvjuBzXL2lrYGa5Gp3t1bmJiSgt8vKNyjAy3DYLHngbevNW72XT7+EwWdhpVrM21o2thdtK7YwIwHdlyTjPv0PqAdhrvhDwDoultK/i67vtRj2lrS1gRlmUuVZo5QxQ4I6Z7HGRzUen+F/AphsrnWPEF5Y2dw8imSKS3uZIwn9+FGLqGPAOD64xzXL6h4cGgzQf23fR2tyLgJNp/2d2vIU5IkeJgqDOB8jOG5GQAc1DEsT2N1JZ6dPcTyB2dntsxxRhtwkTaflOFKkHcuCecgYAOzudH+EUEronirxPdLj5Xh01FGfX5mB/QVntovw6vb2KDTvFWqWMfls0lxqlgQm4FcKoh3tyCx5AA29eazU1/S9MWNYNO0zXGQGEG/037OqKp+RgYZQZGOSTvGeACW7XrXVNLjiGp6x8N7KTSZGMEc1pdXsETTAgkCRpXUnbn5RjHB7cgDrvRvh3axrat4q1a5vWkObuz03zLVU6LkSNHJkHkkKeOgNZEdxpOlGOG40qyurmN1Iu1umnjbDDJaNWAKnB4ODg1veFtO0/wAQeK2+weCNdvfDkpANlp05uJoJMY3ef5YyBydrYGDyeM1oyeE9N8L+Irq41Sx8T6bpkagwJq3h+K63J0YyfvkGA3QqDnPbuAaWo+IPCsVxa3MXiDQJpmgEhs7TwNb/AGSKRQD5TvJiVgxGNwBPzZ46Vi6jqnhzxfKLix8MeHPD+oR24a5je6uWhu2JAzBFCP3ZBz8mScEYzgk8/wCE7rQt93LqXhp9bu5pl+z2UF3JbhM7yQFQMzpwM/MpHy4PU0kieHbNdPvryyN3bTtM8lhaXvkTwncuxHZhKCgAYD5Vc85I+WgBdZ0jTvt9pLpd1o1+9yY0TS9K+2SMSQARmVAdxPYE8npiumsfBVpeeCLffb+H7PVb1ke2nudXlS6/1hjaL7LtOTkBicdGBUnkCDRNI8L6n4HuZrZNaS4RoftSpoxvZlbI3mK4WRI0QgZw67uoy3WoLvwnoFnoEctjd6td+JZb7bY2E9kAt1Ej7GR40ZmjkLAttZgdoxj5lYgFYeDPDa6dLd3XjmytJYtwksJbKX7SrqcFNq5UnPcPj361RktPBlpCv2q416aeR9wjiWFfLjKgjdywLHOeD2wQM5qVR/xJotF1CxubbThMZo76Pw/EbyRckEGQurFQ24bd5HGM8YGPY6QI4Jn1PTdZ23Fs8mnSQw7VlYEYZtwOU55Kn09c0AdPp8PwogtRHq1142ubzgmWzitY4unQBmYnHrn8K7jTfhf4EufCEXi3+27u30iaUpDbapdJDIU37C7NFHIRhuMbT06iq/hLXvGnhPSb7w7YfDsalqdlseG7fSGeW0WQNnzBGuJQSDsdj/CT8w+VamveHtEltv7bTRvHFjqEzIbjVNW063tNMSRyVkchIiEUE5UKGYngfNgkAo2mn/B8eH2u9UvfE5v4JPs7QaY6MJcMQJMyxALuALY3djwOlJZaj8INOMz2K/EIGWIwv5n2BgVODjlT3A561JZeE9JvTpqa54vj1TXZ8xWun6bbG/jmhVlWJGZJI2jZiWbDEHAy2CcHYsvCugWVk2jweEJPEmoNAWuNb0DU11Frd8g5itFJyqsUU+YVJ55wckA4WTU/BMmipdr4ejhv4XWAWK39wTMmMmd3Klc5+XapXqTgcV0Om/E3SZbxLW78LeEdP00RsXuU0GK8uAQDtCBgikk7RlsgZyc8itbQn8QaNpdtB4e8I6N4mV7dPN+zwvrSKCuWMu2ZlikLZzGEVT2LYzVjVNZ0e18JyXln4Y8C2N5qlkGF3aahFcywM4UkG0fcUyCybVBKNk9uQDmdT+I6ahPHp9nez2OipJHLFcXdjbzXVo4wW+z+UiLEhIUeWuARuyfmYHo4PB9trviFrzS/FcWo6pdQrqUNzp9vbWQjdlbdFMV4il9R0yecnkZel3N/qFzo8WifDzwvaabqTSG3hvdkpuowcAiWeVZMqQRlHQMcKewqLxP4PsfD+sR3t/4ZbS1ZRP8A2W/iO3R4DvYbSLmA+YOM4AcBWXJOaAMPRvDaaXqzJ4mntNKtbu1ufJm1KFbpTsGWwI3yHyMK3fPHOKp3P/CuX0uz+yjxZFqRTdc+a9u8KsB91MKGO4jqcYyOvNTPZ6Fr+p3dxPMtmUjWbalxbxmYEBVhhhiiCeYuCCSVDY3YUtiuv8Mv4gXV4nln8TPo1wjXK3/gy3SB5PMZslkREJCmN1Kt9xlbHBGQDk/M+FZ0t2+yeNhqIiysZurXymk3Ebd3l5Axg52nnIx3MOl6/wCELa2gtrnQbue08pvPWWSJpzMeMpOsalUAwdpBOc89K3vEOr67rOtSnTLG+m0YzQRR6j4kt4IrhTCQP3l4FQxHcCpIkDY4LE113hbRPGHhnxHJqk1pqk0bWE0UE3hfVbeWK1hjBkaIrKsowS0ciruUgMSoJG1QDhtFk8Ca5cQaZd2l/aqdzwSRywWojOMnz5nVi6AKTkAH0BJxVpLr4bWt9HaX3hTWbbTZJVcahc3jySzQdmiUIgUkENyGGCRxwR03j8WXiG1sNQvbH4uavZz3gP8AxM5Io4AjBhmLbG6q+SuBgAjPTIrj9a1Dxbp+nWV+ddvfsVpJLYw2v9rzM9lKq7ArF8IXCuMiLjA5Cg0AdNJ4m+B2mawFsvBOranZqN4uJryRTv4wojL4K9eW5z2IrD8Tax4N1eeHU/Dnw7mtdBiKR6rcsbiTyGZ8Dy2SZY1JXoGABbtXNRXN/YWd1ol7dTD7P+88yy1pXgQcLllQyLIASpxHhgA2cgfLuaZpPga30DWxqPjTULowvbrb2VjG0K3JZsuR5i/MAuQGYR4YcjkZAK8HizwRp0SWuneAIdQKF0N7quoymWdSxKsUjKpGcYzjP171NLq1lBaSX1t8M/DscMflIWnu7uUEvnZtX7QN2drcgHoc1WFt4LQZubHxBJZwQEjfeWVncOxw6jYUZmUqwIfJJzgDFR6j4XknsINVlgm0TT5VRY7zW9TS4HlFCEURpCJW+ULgqhwB0AGQAS6f4nvbu5kfS/h94cmt4WBlt00uWZVOMYZy5cZPbcOaq3eu2kM0cUngvSLG7i3CeymluY4JVJUqSrSiTeDu6yYwRhQQSY4NM1DTZJLfQvE2kTSGVAX01pFlIU43KfLV9q/eOPQtg4zVS5s9Z1U3uq3zy63ZGRrYalcTkeZIEby8PJh/VghwWxjGRgAHXah8RdA8QaWmnL8OfB9jcxqpjucyW6gKh37mjZHZiQu3LHuDuJzSyfF/7ToWo6Xf2WpXNpLH5drbS30bRRrt27HbyRKwx3Dhj0Lck1geFT4H1i3ay8Vi68PzrE0keq2u+dZGDYWNoNvTb/EGBypySWyNDRPDFr4j0S+XQdLvLi5sbiPe66lBa2stuobMsqSuWSVgDwG2glsYxggEvh/4jaLotvC8fgDw3M0c4MLz7p5AvBk8zeSWPPyHKgc5DYrbn+KOjSXVxdWfwm8KTWqyeWJFtGKcngfdABPHYH2rhDH4ev7WKI2B0meTz5YJY7hrgsvWNJwfuADPzqORg7V5Y9/4R8OeP/EPguS08P2mqSeGhJxbprdvse5ifcfs+5SygEbgASPlzuY0AdP/AMLb0u0gWaf4b+DZLySOJEtIFUXEcikjDqYuMbQAvUErjO4Y9g+CPi6x8TXt+U8GTeHrvDvDLHZGOCWDcmFMmADICw3Lj3GecfOlxceF3urzT/H1p49nuoMedJcavFPJHcfKr+ShCgybjjBLHaCcensn7NCandai97qWqR3cEVpMtvBdXjT3cfmSx7pByQqP5K70LvtdcjZvYEA+hKKKKACiiigAooooAKKKKACiiigArO8R3K2fh/VLmSWaFIbWWRpIMeYgCEkrkEbhjjIPNaNZPi6PzfCmtR+YI91lMu8sV25jbnIII+uR9aAPz+1rXRri3c+raxf65epbxtJcvpsbBNsgUAyMwk2bXzn5cvgEMDuDNIn0u68SwXY1Oz0CyRfNa323ZgEuFEkRMRZ1STBG5GPyjtxXOS2s+o+TBpWm35FvbrJJGC0x5xukwFG1SWGOMYKjJPJsrNrms6hbwSyy7zLMltAybIVkJ3vDFEBsXcxA8tVAyyjABoA6/WINH8Z6pFc6a2rWui6dD5d35jJJb2QLttEU8zozKxJKq4Dn5gM9qcfix9K1ebX30qy16C5Q2EVxqdlHHE/lmI8RR/cby8IRuOVfk44rMt5kvvEUa+ItctbaeziKNeXNo14rsvCxkYbcAuFGRtAUAcAVnaRod34gmu76eezsbKMmW5u7hlhiTcHYBUHLE7HCoinkYwKANeTxhDe6Ze6cPCfheK2aI/ZysJjmtsc5WYv5kh9nZs9AMcVxkrmWV5GCgsxYhVCgZ9AOAPap7yzmtgjON8D58uZclHwATtJ9NwyOoJ5wa0tP0yGCO2u9ZnMWnSyqNkRVpXGfv+WWDbCN+GAPIxxnNAGZJe3D373vmGO5aQy74gI8MTnI24A/CpDquo/bTefb7v7YybDP5zeYV27cbs5xt4x6cV6n8SvhOmheHk8SeDtVOpeGJFxLNPIsThiSwwDjcNuwAHDEnheeOM1mPxLr8kF54lvbudYrRLlpLqXe8NqXSMSbSR95mXH8Tk7ud24gHP8A22VkgaZopWtygjWVNxKjPBOOVHTBPoBxXTeFfH+oeHNF8QaTBbW1xp2sqvnW8m9ER1cMGUoyt0yMZA55zjlviXwDqujGJYY5L5/sgvbmGGEmWyQqZALhBkxny9jnPHzEAna1cxZ6feX0sUVlbS3MsjKiJCpdizNtVcDuTwB1OR60ASDUpjbNDMkM+6ZJvMmQPICu/wCUMeQrFyWHQkA9qS1awjtXa4SeW63gLGMLHsKtuJbOdwO0gYx1znodKTw1cJo0l150f2+G5EEumlWW5VGjDrMEIyUPIJ7fL1DCsrTrS41G8hsrNA88zBVUuFBPuSQB9TigDd1DxRb3+gpp02g6cksUflw3cJkjdAGUj5FYRscKQzMhZs5LZArTtdYs9RtdKtdWF1a6FZ2zJcJY6WrqGY7fPwZQrSthVMhxjaowduK5xtC1e2s7nUo7SZrOykjSW8tyJIoncbkHmISuenfg4HWtm2e08PaXmYa5p2tXiQzW9xa3CmBrVxh9y4BfPzcB8Z+VsFWoA7DXtZj0fwDHY+H4PGdn4e1C881LXVESGyvYFBOfOXDM7AJuRCF64JIFec6xbvIINTt4RHZ3rkooiYJE4JBhjLMzOqDb3PDJu5NdTpaax4u0iPQ7VtQ1ovdNBprahquyOBUiLsUti/DBRy+4oAduMkGuBQLFcKJ18xEf51Rx8wB5AYZH480AbreK71bWyS23Q3Vpa/ZYbtZGSaFNzlljZNuFZXKkNu/i5G41m22oASs95ClzCCzLakmOLey43bUxjGB0xnA7V1vgfwVdXlo2s6lqFpo+kSW8ixXE6RzvcM7GDy4omYZYsT8x27Mb8jANb994J8PeKr62ufDFxDoEGpKFsbe4Z5IN0QAuXkkLM8SgsCpYEHDdAM0AedW99YR6TFatFqYkecPdiO9VYZ4weFEfl/K47MSw/wBmtM6hpdpqOtQeEbbWj9rZI9NuHufLuIo85dZEjGJNw4wCMYB5rVb4b+JYNTstM1L7NDNPfpptnDNc7o55DIQwVlJARSTu5By/AJJxqR/Cm61qPHhm3vnup7mUW0NxJC8bQpI0f+tUjLkxTEDaNwicgcDcAYOkePNY0nRbmDTPEGuac4BhtLG0nYWscbkmU5ZyQxJ4wM5OdwwAefuLaVbPTGtRqLSXFu+5XhKoQJHBERBO9MDk4GG3Dtmp77RdZ0bWL3Rr2yeLUoSbeWGSPcyjPJBIwFzj5h65BwTW54J8Haj400m5i0bU/M1e0cC20l9y+bGQXYo5OwNuAOzqfmbjbyAbHhL4teKPDGm2mj6N4jltbG33P5osopSQyDKYk+8FKKFPBwSOmFGX4y+JPiPxM18bzxBfXK34SK4gMCwxlIydgUKxwDncyjALHndgGuYi+0WmsXEWo6c13fuZIWgulkEiztldxUEEurc4bIJGCD0rodA+HXiTU9VOmXVlc6K0gfD6nDJbw71UsEZmGATwBnuw9c0AbXw91Q6vYajpmoaRqOp6lJbg6bfaRYrc39rLEUwzEMrlAuFBJ46D2021Pw54GnjltNI8fS+ILgD7bPe3baS5U4JCCPezByCTuJxtGM1wFpHqvhS6M7xmzvZI91q7K6zf60p5kLqMowaNgDkdD1q7Z+KtQvNYtbhLnUILuOKZp7iLV5IZZ2MXzuZJCwDNtOQBhshcZ5IB1vhq9TUbjVINA09tB1V7U4/s37bMZIifmtmWGR2ZzlTvkwMgghcAjN0W+1rTIjquqaVc3cvh63jkgh1Y3G23BmSPfHho9nzsMfe5HAGMjlZdL1LQbyzvL6OTTorqEXkUcNyI5JISw+VWyxVscgPzgA4ORmPVr3U/FmoCby72/u4YGMs7yS3E0qKzMZJCzNjAIBxheBxkkkAWXWb6y8SfbbzT7MTRvI4sbu0DQosgJKeW/RfnJHoTuBzzRBrTzzWkOvQT6hpsaMlvbee6mBW4BiJJxjaAAcggY9CPUdT8N+DfCE0A0O41PWdc8p7Bp/s6T2JvzEVa3MRAZg4fAZWO0sGBO0rXMQ/C7W9S1DSZNJv9JvYNSie5GoWUz/Z7VYxmUzllDREcHG3B3YX0oA4O2uIrYQTJaCSQeYr+ed8T5GBhcAgjOc5PODxVlJLO1ayUJe21zGri6ljkBL5J2+WOMDaQDknPJ6cV3Pg3wUmtQ3dlqmh6kdS03Tp7uKDTCHub5jcpDGrJg4VHMm5uuwDjABOF4x+HXinwa9tH4j0+W0tJ1Eq3APmQgZAJYrnaQWAIIzyOORkAzprdta/tW8tBqOofZIEmaW5nXzI0+VWZl5ZlDHHy9AQTjmrOnzWHh23ubfX/AA19u1GRopbeSW7eONFVzvVlT74OCpGQVZSMggiqpsFm1eL/AISKcaYkrbLhorLBtTtITdEoUDOM4HOATg97Hi7wte+GIxFdvY3sUjgrdWkxkERAP7tgDhGIwSrDd8oxgZyAUrjXppryR7aIWVosnn29hBK7W0EgIOQkpfPQ8E8k/hUegXelWeoxz6tptxf2m1laCK9+zsWJ679jEDacYxz69qtReHPEGoaBBqNtpE8ulROYEuYbYAM5UuVLgZcgKepOOnHArV8S+A5dI8MaVrttqMU1pqSIYLW4jNveOTnJWEk7owQPnBwcj1oAym1CzsdRs73TNIlh05XB8m9lM63gRw+yUgIGUkKCFAx9au2Piq+t9PtDDpdnDYWjSW8slvEUeVJ8mSJpDn7yKyjrhc46nORomgajraXX9mwRzfZoDdTFpkj2RKwUt8zD+JlGOpJGKdrHhnWNHS2e+smEVzCLiGSJ1mR0ILA7kJHQE4znANAHpmifEHxnofh62tU03Rr/AMO2tmUXS9Rtopg0LSlfMwCJHBZgNwIUk9O9eaalHeaFr1wtxZpaTggy2hB2orjd5eQxbaVOD82cEgnk1Vt7mOxurWW0uLtlB3TBT5DD5iNqsC3VMc44LEYOMmxZWn9u+K4rLRIvsS6jeCC1iklLiFZH2qrOBlgAwBOOeeO1AF6HxVr1jpl1FpGsXmm6beO6y2FpeOkfJJIEe7ITBxznPIJNc7LJ5mzKIpVQuVXGcdz7/wCeuTVhGm067eC6hYBXAnt3ym8BgSjYwcZA/IH0rT0tNP060stUuGt9RuGmdJNJmjkUNFtwHLjGQTvGFIZcAg5+6AUINZ1OC1gtodRvEtoJPNihWZgiPyNwXOAcE8+59a17TwzrjeFl8Uw6TC2i2T7JLpmQqzbwAGQtknLAYx09q7LT9LtvEWmabJqPhuPRYdcu4rCDV4oJJlUmTG2GEFV6qqgsxbaJuXO0Lm3vw5sE0zW9Ws/E9tJpdpDFNZma3eGa68yTywDG+NoVuGYbh0IyOgBz41FxcaufM0H7Jdv1NoBHvjBZGiQJvTPQfKFO7DcZoXxj4hmV4LTU7mxR23Jbaaot42kLg/cj2gHPPA/hUdAMdhF4EguH1GyuotNs9Q0i/Om3oNzIJpWchEmSEbsqHAUBc7jLk7VAxzd94F8ReHvFkuj6jZXUN9AhuEeCHz43VRuEoYfKYhwWf+EZyMgrQBBceK9a1zS9N0fWtbF1ZRTB4nvpJX+x9QScAkjBzgBjgAAdj77+y1q2r6j8UNV+1vF/ZzabNJGtiFWz3GS327VUABlQgYb51UqpC4xXnPw+8G6O1lc3PjQ2lrBbebaWssVyI3knCM7SqzEJMYjtG0PjIwVO6vVP2ZPCWoeFvH1w8rSrYalo73EYhnWWzlxLCFeKQN+8Iy+QVBjDKCTvBIB9O0UUUAFFFFABRRRQAUUUUAFFFFABVPWZbWDR76XUGVLJIJGnZmKgRhSWJI5HGeauVQ19bhtC1FbJ2jujbSCF0hExV9p2kIxAc5x8pIB6ZFAHyVYa9pN/4J03R/Bl/eRa1r+rW5m09rlvtFlEJQQ8E7gFm3orZ34DFjtBUkZfjzWbDxU9toWs+ENQsfEFqxS4hguhJqc5gjDebO7QqrgxPIykbmkYDkDG7uvhN4d0bwfHqOp+KpZdO8U25ubbSZvEVg1jYWyHdt2lT5J3l2LKshOCQuACzavxD+GMi+JtN+Ifheyk1aeZ4WudOhn83ccHZNHNuBKZEQOP4MnpkAA+XdD8JnV2a6g1Gxg0VLs20l5fzrbmIbGkUuo3EF1RwoUPllYDPGfUPFdlon/CkNAttGivbO+vLP8AtUwIkdxb30kEhSXLj5kmSN2kYgABFIYDoO71j4bL4/8AFen6Z4j0WfS/Eqsl5rV7p0qG1lhIKmQ/IBvkaIqijlT5zNkKN3ufgHw5oXhm0Gk6LFdNJpifYzNcxybgrMZtquwClcyZ+XjgA8rgAHwFJq+jw+Gp9Pi0p7bWnHkzXsUpaOdA+7DRSD5TkJym3GzvnFe//B74QWcOkSDxb4VW71fUX8m3lWYXFrbwrGC7OyOQjEjrncS2ECgMa6Px78GItLm0G48NQX/iGcXkMLadqc0UqNbKXkZfOkGYkA4G3J5xhi2R12ufFYeGLGI+PvBmsaHZXC+TNcRPFdQCUoSIw8bZOVXG7aOeMYGaAPIv2g/CE/gnVIvEHh3Rmj8JxLEptLdiLeO9RiFlniIIKFXKhlxycFlLfNyPgnQrb4ny3E95dnRbZoU0yEm3gW3W9dysEUecGQeRGAckPuVME/IK9+1z4tfDPxb4d+wanqF0LDVy9nmaynSPIX5iXK7Pk3oxIb5cqxx1GX4B8c+EE8EaWmg6JJf38UVqLrS9MsLu9igAZSxQ+WUVxnzD0JbqWbBIBwXiTTovg7YNN4p1rV/FB8T2l1ayNGoiwpjVQwlZy4cfICCCCrHjKc+S+GrGbxf4vu9K8PXEGl6Rq9/JLMhgUtY2qOJBKx6KiL0AccqRnnJ+k/ij410Xxz4c1Tw/feEfG0bWwjnEwtIraSFmJSMgSvu/eFmjxtywZgAa828FeHl8L6n4o0pfA3ig61dTBtDnVElKRHc0SXJ8wRmMlAXHIIDAngUAcX4j+F2o+ALKHxNqE9nqehtcKsCW8rRXM9u+dk2MHyQy9D8xVyoKkZrGsNV8LSXkgsNE1C2ul08JYRQ7Lh21IyJtclwSY8DG3BySSoUsMfUl74v0/wCIfhF7KfwZ4puNM1K1kiEcFvaLKFVlUtGHn3AJKuQSuM7c9OfMvhF4AvPBvjH+29e8KeKNRSOyL2Un2WDzLZwwXzPJ85iSq42ry3cKeCADmPG2oeJvhIIfDFh4iZrH+zklhto4LaaMtOALlLgEHPzB9ud/G3B615lH4cujqsEF/bnSklhFyqag7QBoSpPmK7LjaSCFPOSVA3Hr9meLbXw38TdA1Pw/p+qgeIrdJprS3uoHsbnzCCQGjlRWaE/IpwmMKOcivF08QeMdZaD4Y2N0bqSS1ezKxxqt5ZKkbLLaTSNhTEHUAsDlkjUjlgCAYHw81uHRPC3iaytvDz3ccmmXAN7bIi3qxywth3yrbo0OzJjdQqncytyBQ+EPgiT4j6s1pem7s0ukdZNTawNwkzq6yFRKzgRyFeMgE4653Gvqbwf8KPCPhK30LR/7Ia91C2lXURq0kbfNcx4GchspkHKx/d+XPJBNcR4u/Z9kkk1OKx8QTW3ha8vmvhpdnYLvt5myEKhfvqpdht+XCd/loA4b4GfC7TfGMt3rE2nyTaNpU89tbWlwy7NS3JIyJJImCJI2kGZQCp+UKBtOfS/GHwu1y105YfDMWiRaRDaTSFEVoLqG5k275LZwMRZChdpYJgEMRu3L1lnb6v4T0+28MfDTSbC5stDijF8+pSPEbh2XdsiZFI80jEjsRtHmKACSdtqfx7dSXV9o2o+BdaubqG2R7y3tntbhGSTK4XdKpdDgjlQfVRQB8xfDV734janb6VceHtUvtJW5tZJ7xbmQx2DAh7qRAqBVedlB/vAbgCdxNeja78L7Hw54K1vXfAWt36aVJ9muFnjkLi1iRv8ASLmDaeXG1Wz8rbVkVThq7Ky8S+B9G0o2lquoeFr+1cxWySaPcrJb3E0SqN6hSlxKevViw5BxzUp+NlgbaG1tPD2v3OqBljEa24tIppxndGjzFSxJVgEC7zgjb1wAfMUvia/XUZ7ey1fWb7xbeWqabBeW2oi5juI5pdxhZmG77rKMgg7wenWvVtQ+EPjTRNPsNa0yW21Ozj0y2TVtAVfsktx5aBmiPkrtkcEttfhxhcFiMnoZ/D1/p/xTsfEFj8MUiv57W8lkij1e2EtzNlAJMbgsQXIBdBkmbDdfm6ix+IfjPSW1y28Q+D7iV7CeS7+1NdRRRRWT+ZLHucAqSiRuhI4yigncwyAfNFj40u7XVo9c1SzWLXJ7y2uNP1PWhPdJaWgDD90rKzOqlwd7Ox+VSo3/ADV6FoXwu1jxl8P/APhLNB1u8vPEhuZbuxlviI5ti7UWKQkt8zIAynO1eMEKxNWtT+F2s+MNdt/FJ8Mz3UOo3aXs6v4njliubViH8tMQqRFypHOQARj7pHs8nizxbpN7bJfeBLeHS5D5Sm01iF5twUkKkbKgY4XgBhgAkkAHAB4V470LTI/hxpeu6toaXeoyajDpMF/cTCJ7e12KNl0FG1ZotrwEmM4aMtjoKztY0zwz4R8YfZPCvg+PxPa/ZX1PVbO6EhnsoMKUQFs+WFO1iSu85w2FYCtL466DpGseIZbmO+1bw1qGqSxMunXmmTiCa7CuhLOilNxGBvjZ8luQMFq9Z+H3g3TfCawXFnpOoXF/cNDb32oKDLc3M0rh5XkkY7Tb4WJiUJ6sMbsggHhep61qPxM8d6xeWeh2Gpy6XbJcNDq0kSJZ7VKT7hG4NxErszK3JGEGMHa3Had4C8Q6f43h0XTbWxvLu6geM3O2Q2kKO2xbgSHhkCvFIr4I+dMDeAK+pPGPwufQ9ZtvFvwrstP0/XLeM28uneSFtbuJuOVBUBlOGyCM7R1PVfhj8Ib7Qdaj8QeLvEeo6z4iRGhM63UnlyQnAWJ9x3OFKB+w3NyDtBIBgw/s7eGIPC2qpb3l1fa/NE0aalqEbP5UoUxsViHBUnfjIcjKlSSoJ8l8beH7638dX8Vx4Yn0/WLxgIdB0Qky3UAicPcJchGUK2GDIEDMCARnc1fVurf8Je2oS3uhS6a9kjbDp19CytIqZyUlVvlZzkZYMAAp29c8jex+JU+IMWvap4Ea+BsBbpJp+tI7W8av5jL5UgjDSFiucHBCjB45AOY8NfDHTdT0Tw6L+bVYdd0/TobuWOa4nthbvJBh42bO4LI5cOEI5Q/dO8SeF/FDxj4pXXf7H8b397FqOgyx20dvpzGBJlVi/nmRujH90VITBABIUgZ+g/EHxP1rwjqGrXVz4F8SXWlX0L36m5WNWtpI4wjo3ll1EWEjbcTkbnOGAwMTxFpWsfF7Sbq/bwN4W+0y2kRtLm51hpJgoMhWRTEobY25tqsVBK5YHGAAecfCTwTe+P8AwZrej3V7Pa/2vNBf2l+bESJK8HnJIs0iZ2sWfIDsGIBbB3c8/rc+sfDvxUlt4vt9Nvm0gxfZNMn053tL9WjWKSRHdVP3Yky+DuZRwQDX0hYWnxRTWYF0PTPB2i6ZpyLDPYrJKsF1I0KfMu2LICDaB2GMZODXD+N4dW+LMehSvZeHtXggnMEn9lahcN9kWdU2mePasm0kRucKCmw7gMMKAOG+Fdxr3xR8X6Qk08Vjb6LHIsSR2iyWcKsCI4DCzKADh84JZlyMjAxo+NfCmv8Aw+k0jSPFWtaW/huZ5BYXyWP2qe1CoWNpGkpwqyMwXLMRhVJZQCK9N+HHg34ieBfCzaJ4bfwJJ5crmWaYXRkkmzklyMAkLtAGBwKr+PbjxZ40sLbwdqN/4ESTXbM3MNvm9Fydnzh1XAKbSpI3dSrDacNQB8qRy39xfTaXYWirqesziFooQg3eYykQeWoCr+9CnB5UouAmDn0H4n6RYfCvX9T8MXFnDq2m3drHc2kJu5dqvsaISzICMShsuCpwASAMP8vb+APhf4m+Gl7rurW+leHPE2qQWsLWcjzyDyZH348vcgUy7ljO3hiCAGXfgq/gXS/FvhLxfYTW3iJvF1pAupadZarCVurUSBXZEw5V0dwV+YBl3crnkgHht58P9X09raXU2htNLubEajDqTLI9u8JwFOUQsCXZFwVyCwJABzWz4H1HXbXRvEOk+EIrW5TUJbbTmkFw3ml5WeMPErbfkkyVJZcruj5DDNddo3hjW/FsHhrwRbeILDUdOlP2m5jjlmuPsaKjhJ5MDEDKjGMQlh84XcDuyPpzwv4G0PwjrOnRaX4dXzGjmYalbAIsJO3csiFu4WILjcSVYnbjJAPjrwLZW11aX2neLdSl0LTbD9zPIbNiJJjMuLa58thI8eUJGeVIbBGBXr37NHhAahr9145srKF4Yr+ezs7eRGhhhtmJPnQyFCZGXJjCkKQM5YcCvUPiB8FvDviTWk1qGK2sb1p/tF9LJGZUnAGQSjHZkEAk45G4HhjU994Z8Qi3htPCet3ui6JoUENra2dtDC8l+ixKxbzJAQCcooJGMo+fvZABrePPAEninwtPocGtXVjBdStLO8m65blcBF3MMKDjg5BGRgEhh8p+EvCnjrxx4nm0W7ig1G00KaLSZNQuJW8nTlhdVPkfMu4sI8EAEkNkgZDD2FPjrfeFfHknhPxlpt1qToY47e7sbExXE7OqbQ0BbBbJZSUJDH7ox13NJ8X6zqiala+AfA9/DdXEYuZ7nVriKxSOScFhL5SszMWxuyMHjB9wCv4t+EWm+IptN8S+DUk0bV7eJpoJ2iktfNZSPLgeDCMi7dybsqygKPm4x80eOPG/iPxjIfD93dLq8qzQmz8myaOaOQpsktolA3bSzAFT94wqRzwfftEX4leD9cTTZdKsX06KYW8N5Da32pKsUmwg4Ei/JGscMWSpYbCQDl2PQ6l4Z8TpImtF/BWk6rDqo+z3Z0eSGRnllWJzuErbjKDt5GWBHKk5UA5nw38CItZ8G6PY+KYptN8R2G2Zb2F4pYCrSFmhEQbBZRhWYrjOMM4Fdt8MYoLH4i+IbKTT9Bs9UjVxcLZX7GXbmJ1YWrZEcb+a0m5Gxuchhu+Y2rfSviG3iGC7TxFoV5ZXMEmbgaRhbUrgIqfvtzCTOSc4+T6Vc8E6VHqvi9vGseqaVqe+xl0sz2tnJbyMVnG5WzIRhWjYDK7jnrgDIB6JRRRQAUUUUAFFFFADZXWON5HOFUFifQCuI034r+DdSWFrTU7grPbzXUDSafcxC4jhBaQxFowJNoByFyeOldpdxma1miUgM6Moz0yRXifw3+EWteDtR8J3kt3p+oizs7iy1C2ubiWWOESOWElpuQ7GIIVlwoIB9SaAPTbTxx4dvJ/D8NrqSzS69E8+nKkUhMyKu5mPy/IAD/Ht7jqCK6SvIPhL8Kb7wb4u1LUdUvra70+3iez0KJCzNa2zzPKwbcow2WAyCeM844rqvGvgD/hKtVivv+Es8XaN5cIh+z6PqX2eFsMx3ldpy3zYz6AelAGfr3xe8N+GfG0/hrxS8+k3ARJYLqZN1vOjDghhyvO4HcAMqea76wvbXULSO6sLmC6tZRlJoJA6OPUMODXx38VfhJ4k8QfEMaR4Wm8S6/b2MCJPqevXvmRxu3zFEkZVGAGUkLuOSeOK9Z+CvwMuvAN0moX/AIpv5LokO9lYSGK0c+jg8yfXC0Ae3ozMWDIVAOASR83uMf54rj7+yGjeENZ0bwbpsctzBveHTob/AOyORM3mOUk5MZJeQqeACAOAOOzrnfEvhv7fdRaro8ltp/iK3wIr57YS74xnMMoBBeM7m43AgncCCKAOb+Cn+jabrulmPXIpLDUSskesyQyzo8kUcrZkjJ8wEuWDsTkMMHA49GryjwxN4o8L674hTxHY6p4i1W+l3afPYQqto1srOyx7nbEJQyPkSMSRtCs+AK6Wbw34i1VWfVfF1/YLcKRNY6RHAkUYIxsSZ4jLkd5AVJPzKI+AADoY7yyu9VuIIJy13ZgRS7eiM4D7M9C+1Vbb1AIJADDNXxroj+I/CeqaRFPHby3cDRxzyQiURP1V9p7ggEHsQCORUdv4U0i0k0lrO2MJ0ySWW3KsW+eQESMxbJZmDNliSSWJJzW/QB8seE1u/Auq2V7rNlP4Z02yvTA9lqUzPp810InDy2LllMRkXzSN4aM78b+FA9K1nxXB8OtB0u/t/D88l1qoWE2MksVu1qE/5Z5ClSA8kjFmYnLsS2MAep6lp1lqlqbbU7O2vLYsrmK4iWRNynIOGBGQQCK4b4neCIPHukJbNqaWUunXTSNJcWomiwcOVZCyhhjbznHXINZ1ebl9zc68E6CrJ4lXhr33s7ba72H6f8RNDfThc+KbePQ72WISmGWRLoSxK2FaOWLcsgyTwDuB3cAcmqPHPglvGUF5H4ogWSaBYvKWPEMhOCsjS7eQFYgfNtGT3rn774Jy6vpun2d/4islsrZJsQabo0dpDIZF4bYrlRzgtj7wVQCvJPN6t8JNf1fxzd2OoavaWVleWKf6dBap/pXl+WrIkPmAxkcN0ZRxjPQYuVdOyS/rvqelCjlc4uU5yTSd0u91ZRvG70vvbVfM9J+Iep3Fh4o0Z4otTsLa0P2qbVB5a6eQVdTFdMfmVcD72CFJQ+47GSwtp9QF0szbZ4TFJGsn7uVWHBx2OB94YJAxzgYZp9vpF/oB0yGS11PTYkNhKjMsytsGxkfsSMEMD3zxVq3t7fSrSxsrGGK2s4tsEcUahUjQKQqgdhwAK6jwiPV9PivHsppNwltLhZYmUcqSChH0KuwPtXzx8PfD+nfDb4j6peeMH0vTNW+1rKt1bTNFamymgn+YKzYUGaIAgj5W2hflZc/R2q2Mepadc2czzRpMhQyQSGORM9GRhyrDqCOhFedaX8Opb/xw2u+LfEB8QvpLpDpdq6BI7XCqwlljX5TcfMfmwByrAD5VQA9D0nULHV7C31LS7mG6s7mMNHPEQyuvbn8/pzU9xJFBbyzXMqxQohaSRm2qqgZJJ7ADvXM3Wl6roV9d3vhW2tbu3vZDLc6bcXBt1WY9ZonCNtLfxoRhj84KtuEmZq/gGPxLo1wfGTzanfTkSm1gu5EtbcqdyRxR5VXAIGXcZckk7RtRQDrNB1K11nSY9R0wSC2uSzxvLEyFwCVD4ODtOAQe6kHvXjnj6S28OeLvEOojwb4w+1XEaXB1HSbiaWxnCIAsk0SSIDgja8bA5VSeckn3UdPSigDl/AWvWXijTf7V0R2fRHVEtGMZjUlQQ+xSBhRwuOcFWHavJP2ivCPizWfEWl6jZ2+o6jodo8c0TaPIEvdNkU/O6RkjzS3ysCMMCmMoOW9y0bTbTRLWLT9PTy7Zd7pHkYXLljgemXPsOBVuC5guJJ0gnileB/KmVHDGN9obawHQ7WU4PZge9AHzxffGO98OafoulaTqOn6jHbRLa3Osa1FcRRzOox5gcDc442khWJYE8jk9drXxM8MXPhlNP8dWEV4l9FEXjs0+12l2rniSFjgsAyjggOG4AJGa6D4neE9C1m70fU9W1q+0S+gnS2tLmzuY4Xd5GwqKXVvm5YjaAevbpzFr4J8HeJ/E97FH4u13UPEemRCCSU3SCa3kjkH7xT5YUyKVVTwQu4EgM4Y87jVu2mt/wPZhXy904RqRldRd7JfFfR3unbv+Ftxuh/E7wpbC80nQodSsb2eTIe9i8uFLlxhA4DYiDsvIVVH3jgHJr2G1ieG0gjnla5mjQBpWUAuwGC2BwCeeBxzXh1t8H7G18YXF74u1iV7a81FH0+G2bYtw4DyEXH7vK8rxtcA9M5YLXrcPizQmvdKsG1ez/tDU4fOtYPMG+ZNu7cq+hAJB6HHGaul7S37w5cw+qe0Swl7db9denXa3b0OO8au3if4dX2q+FL8gS27ywyC2Rhb+VGW8uRCQwIkTHRmR2IxjIrZ+GXimy1zwPY3dxr+nahdLaie7lgUW4iUlusZO5FGCMnGdpPFdlHFHGXMaKm9tzbRjcfU+9YeseEPD2r3tvc6lpNtNOhADbCN4GCFkxw6AopCvlcqpxkCtTgMuPxPq+q+bP4S0q01XSgxiiv57/wAlZpM/eQLGwaBc43g5JB2qwG4waV4u17WdLl+yeGHjvDcS2sdwl7FNZjZIYzL5mVcqGDfLsDHHTHNdwkaRoqRoqoo2qFGAB6ChEVF2ooVfQdKAOe12HyvDFtbazeatPKuwTXelxyxyu6DczYhyVVtpGOnzAdSKoeD9X0/XVvZNIS5a9sLqQSW+qpLBcweYofBEgLhGyCuRjaAAAEAHZVBdTQWiGedo4wzJGXYgZJbaoyfduPrQByPxg8O6r4o8C3um6DNbLdsQ5gukDRXSjOYWPVc/3hgggcjrXlngXR9C8MaDpfhPVvDniiPVroeVqOnxWqXC3CSOQGmuY1CtEhyykOGUbhzlgfe5NV06LVYtMkv7RNSlTzY7RplEzpz8wTOSPlPOOx9KuZG7GRkc4oA8k+O99ruheBLWXSp2sySftM9nIwmExAK7TkblP7zOeSdnvXEaN8TNT8H6BC91c39/LcNzDrN7Dd8lSFaG4gG0DdjdE53jK4xuzXrN54z8HXvh2Bta1Czv9G1Ka5jSS4t/MtpFilKtuJUpsU4AZjg4BBOa1rPwj4R06SD7D4e0C1lEguYfKsoYzvTpIuF6ru+8ORn3rnnRlKTlGVrnrYbMaNKlClVpcyi23rZO62at0779rHhlh8TdU8ORaeml6FoGm297ZLdtbQySeRHy3CIjbI3bHKqOGyGJOTW7Jqln4hvn8beKtBu18NXumxWVncwbrho0kVjMHSMEogcY84bG+6OQeOwvPh34Fu/GaT3FlpyvYWvnvpnkxfZmSQuBJJEVI+8rkMMc5JzXY6Xqui6noC3WlXWnXWgiFk823kVolVRgrgcAAZBHbGMVVKE4tuTuZY7E4etGEaFPla3emui7ed9fPZbC6JpzWTxyTStcXUlusU0+9trhGJTahJA/1jcjnGAS2ARLPpMTaraX6b/PhMq7mlZsJIo3AAkgconHbB9TVnyQLu1liuGSBIniFum3y3ztIbpnKhCBggYZs54wmrX6aZp095LDdTpCMmO1geaVucfKiAs3XsK2POPl2C78V/Db4129hqL6ZqkupW5W6vrDSpC00DyvIZZ4IAN9xiKTB+bCliS3Jr3jwv448G3mLHSNeWU28TOPtU0uSuRu+eX7xXK55JXI6Zqbwp4RtbXUD4j1Wwi/4Se7DSXFwX3tEX/5Ygj5SI02xhgASFJ6sc9Dq+j6brMEcOr6faX8Mb+YkdzCsqq2CMgMDzgkfjQBgan4wl+2Xlp4b0G+8RS2q7Z3tJoI4Y5SMiIySuoLYwSF3bQRnqBW9oY1IaZF/bZs/t53GRbMN5SAk4VS3LYGBuwMkZ2rnAo6nZ3GieFbqDwXp2mxXkaE2ls6+VbhyerBMccknHJ/Gti1njurWG4hbdFKgkQ+oIyKAPn34tfDvxf/AG/qdz4W0u18Q2euOslzPcTRw6jYbWBMdvcMRsjIVQow4BByv97rPgRO+v6WmsXcGt217ZwppU41Ftsk0kO7LPtC+aV3lNzDPy84bNet1FLNHFLEJJFTzCUQMwG9sZwPU4BPHoaAPPfjJ4d8Sazb6Zd+GFsr4WTSi60i7Pli8SRNuY5gQ0UqjdtYFfvn5sAq2l4O8UPqs8WkJ4d1ize2gCX00+TDbSgYMQnY5nbIPzpnjBJBNdPZ6lZTX01hDfRXF5EvnPGHUsqGR0HA7BkdfqpB5qbUL2202wuL2/njt7S3jaWWWRsKigZJJ9MUAZ3iuxu7vwtqFhpFtpc1xLAYYrfUVY2rA8FZAvO3bkYFYfw0vbi301fD+saWmj6pZKSlmt412skAOBMkjEsVLEjDHcMYI6ZryfFTwlZ3mgae+pTSTatBFLbMLeVgY3JVHZivALAgk8qfvYrtzdW4vFtDPELpozKId43lAQCwXrgEgZ9xQBNRRRQAUUVwHxa8W654Uj0h9G0ySezuJZBfXy2Ml6LJFXKkwxsjHceM7gBjvkUAd/RXj0nx48MaZpNhLqN5HqN1PbvdO2mhYkWJZWjB23Do+75f9WNz8HAI5Ope/Gfw9aXeoKbLVpbGweyW5v44ojDGLpA8L4MgcqQecKSD26UAem0V4/oHxgmW38R3PibRbqG1sPELaLbyWixHqyqiyAzElxnLMo24xjJyK2ZPi7oovZLSHTdXnuV1uTQFjjjiBe5QZJBaQDYexJB9QKAPR6K878K/FrRfEeraLYW1hq1s2sC5FrLcxxBGe3/1sZ2yMQw9cbT2Jq/41+KXg7wRqsWm+J9Y+w3ssIuEj+yzS5jLMoOUQjqrcZzxQB2tVtT+1jTbs6abcX3kv9nNznyvM2nbvxztzjOOcV8q+Of2iLjQ/Hj3fgrV7fxB4buokd7O6tpIjbyD5WCMyqwBwG/iGWPFeieFfjr4P+IOk3uj32nahHf3VrLG+leWZTdqUO6ON1wCSOBu2cn8aAO38I+K7q48Qjw9r6xf2y1guorPbYW2miZyAsQLFmK5wxIB4BwARXZxXEM0sscU0byRECRVYEoSMgEdsgg/Q18ry+OvAXhjxTZvoOseJdR026tZbG8edpLmHTbRztSSITKWBRti4wwC7lILcGaDw9qujavpUHw91zUNATxTcM0jm1Wb7VbiQ7JkiESrbtGHO6IFcRmM5yHVQDRs/G+r6Hr3jbU9P1q71HTdOaMWdpd3BngkR5nBOWy+VUJghh1+bNXr34369HpV2p0vS11OAQzqwkfyzHIpwuzO5mBxkjI6nGBmu3+GOjaLrGgPLrvhrR28Rw3FxpWrXLWEYa7lQlZJGbYN4kADnsSx64rtL3wj4ZvVIv8Aw9o04dI4yJrKJ8qgwi8joo6Dt2rlVCaVlM92ebYacueeHTfm/JLt5P7/ACPEpPjnr+2x8u08Ps0luZJyjTMqOrMGQE7SG4xjGM9yOa9dsfHujt8OrXxnqsh07SZIEmkaQGTy9zBMfKCW+YgAgc5BwK5bSvCHw58d3yazoEVjeWmktNpptYbeM2JkAz/q2Ta23fkMnynOea4/45+M9B1XwBZaVpWsRW1q9h/ao+zq53LHuW3jCoBhTOmCwPyGNcjDZGlKE4tuTucmOxOGrRjGhT5bbvvotNPPr57LY9K8P/Fbwp4i8bSeGNEvWvbxInl+0wgNbNt25VZAfmOGzwCODz6+K+Pdavm8XfEDw34luv7C0XxBdWrWb3RiUSFSLcsNzDETCAM0mcqsYwMuoPl/7Ol5Bo3xR8O6h/aEAa5uvsDWYLGR1mR1Dk7cABvL4znJ7Crvxau4fGXxE1fUpNU+32mnkQ3sT+bLFYRmZ4TLAEK7o0AgYkEbnkzggmtjzTtdA8Y+LdB8KW+jal438OaFHpEbx2gWM3s12Y3BjjYAllTGxVwuTGxJBwKxNb8Y+Lf+E28LeMr3Ut1nYwJa6hqdrpsgisXl+aa1mj3FS8fmBf4SflzyOKvh/X/GHgbW7bwpp13/AMJZaKIrqzTTkW8hYHM6LtZMoWBbcwIZVkLfNtTGv4s8ReK/FGj6hpXk26HUpR9rtdM0hoFtL5WV4cyOwdZ3KqJDJtAX7pYqRQA/SI/GnhmLX5/B2+3+Hmp41lG01VmlgglcjEW4BvMCRbXUZMYwTggZkb4gX8/wl8Pa9q5knn0fXrVb1zP9ne4NvKXS2SMJhwI2VzvIO5s87SBwlldaZ4fu9LvvC/iLXbpZreS4VxGqR22oFCZ2aN/kIWFokbh9wZzkAAV6/qnji3uNGl8Ua14GEmuPpH2a408aqNl/YsD5sqJGG/1eV3blBVXcEnyjgA9W8PfEGCXxfb+GtVntZb3UIptQ066tc+RPal8wKGP3pDHuJ28fIa7OMwXC3gsWERlG57q3CHMmNme4LqEUfMD0Uc9K+FvA1npvxIutE8PXb39hrdnJHbw3dqjTRpZRxncgAbCu0rbg2Ao3nJ6CvpH4TWXh3w34r8R+DfD89vd6E0BY25ladluIAkV2Zty4DP5sI2jK/I3C9KGNaM57wv8AFzX9L0bUtU8RNFrMCaiNPiijiW3lU+Ur7ty8EEtjbtBHXcelbmqfHiKy0xZ4/DV1LdR3DWtxCbpEWOTAIVZCMMSCT2+6etbGteBvht4U8JXupavaTW2hq0U8zy3t3MFbeAjBd7MDlgPlHIODxWTY6d8HPGnimfStLaC+1WdTqUgsru5RTkKD86MFB+7lARj0BzXKqdZKyke7PG5bUqOcqGjbemmmulk0la66dPOwk3x1gs7ww3Hh+YW0EUc08yXsUhRGVTkBcq5yeisR3z6eq3niPRrG0sLm+1O0tYL9kS1aeUR+cz42hQ2CScjivLP+FNeF01TU9UvYmudItYGjj0cO8SxMnIJdZBuUoF+VwfvZJNfNnibVta1jSn13UryHVr+S2zb272hY6VZjaBKqxnZCS7BVLJyArA/MK1pKor87ODHVMJLlWFjayV99XZd2+t+3ofQ37RniO78NeKvAuowRXL2Vo91LePGrFYUZUQSHBAJXLMqk8lQO9edfDfUNeTxFaaX4e8YyX+oeKt13rEUbJdNp68/vRcDKrIIyo+7y4VcD5cbv7UGtXOv3Wk6FpWuwWdjPpq6l9kkkYf2k7yAQw7UBLE7GIz8ucZIODXkt2fF09/qviDwHbXejT30v2LU9H0KOSKbT50bhHjX51VthYOABuLpxgg6nAdVLpvi/4n+I00mDxLeeINLtIZbiG71GxNnEFGIjLsjJctu3BVOHyu7GMgx2ep3XivxLp+vDWr/w1rlm0lrfWmmxzXEoiLu0t2vXer3UmzyUDbQB1C8dDrPjDxfqV7ZaPfSXFj4hW8iuLWwt9OB1K4txb7jcyo0nkb/KWVTD3dyCowtc34gsPEj6/N4Q8O6xa2ejaPA+v2bPdpcyokZkfzHuIl3LJvZ2Cr0808kYJAPSrTRdZ1Xw/wCKNPe81zUY1iRr3/hKdFcwXUf7zJs4kIlWSMg4G4kkJtxwa8/k0QaLpUfhxNcj0m90S6/tKJ7by4pbm1VfPNy0bDzftSxuDtyFKxFM5Wuh1v4y+L7aRtL8YWtvoVy9gjwJFueR5sDbPlQw5b50i4B2FWYAhqwNHtr/AE7xJpstnpn9qyXdyv2rWPFunz7WvUaQW2yRgsiFwIsgl1RpFBJ4yAeweB/ir4nuPEem6X438KDTY9Uci1urOZZUQsoMSyLuJXOyYbj1K4A+ViL/AO0fqd1pPguC50nU7ux1UTEQra3LRvIuxt3yg/MAdnY4yPU5888KywaSJNR8MW/iLTbOXUooFtJr6Oa1jnXY8lnPEUEsBVQUUk5DDAJUjf8AQepadpPiITafrmm2eowRMlwkF7bLKi5UhW2uCM5Dj1HNRUhzxcTqwWIWFrxrNXt0vb8bP8jxXVPivrPhvV7mzNvZatb6Rbo73tzxczxMEyNyYXcSRyFA4HBNJL8cNcXX7+1+x6FFZJFI1u0kkpdn2F0UFco5wORle4yCMHGufjN4V09NS0+T4YNJdQmS1kihsohC+noxZSx252gDdsK7O+RXudz4H8J3jTMnh/SY5ryF1e7t7WOOYqwAOJFG7kHrmsXRqdJno08xwd0p4dW0u769L9N3Zvvra6OH+FnxavfFHiSDR9ZsrOKa7t3uIGtC37vYeVkDHrjnI6cevG98U9Y07Vvgx4h1TSpU1SxFs7xyWjl1kMcmCQynoGQ5YHgAkHjNeX+LvC17o2qDwJ4Mj0fTtDvbO3s9X8QXcMYv2NxO6+XuTaZN4KIBsIG4Aleo1PB3iex+H/wh8bW9hLNcx+HdTmsbdJY/LKmQptxG7ZCiSRjgn5trHvgbU4uMbSd2ebjK1OtVc6UOWOmny3+e559r+ta74y8cHxB4nurjwPF4ehiltkEayXMZKhpHCHDyK2GwORt7MFeruoxa1babdXWr/EW9fxjc6bHdXljZWqR+fYyTKqpFKyKGk2SsVQc73CqB1Pn19qd54z8C6Dp0Ok3FxOL4Q3eoS+XbW87wRlYbeGTiOLbbtkq2B8pYAknd1ngjXvEfh64k0bx/pNwNJ0i5W+0691qZpP7Kn8t0tmyP9dFnAwgAB+YYIxVnMYlz8Prbwf4ibQvH+u2cNmbFr1pfs08iQmXMbGCPaAzqUhOflwMgAsoAksNAfXbPR7Cwu/GGq67bBbG6jS1E6aG21ozuuNp3RMfmWJSAFLZbcOa2vnVfD2lLrdhMh1CwlaSXfrX2ry45Z3aIQoGIeOKZfn8wsTIfmXbnOvZ3/wATPh/8Nhd3FlaJoOpNb6kmpQyxxTK8pLspKYkMkgcISQdoHBABIAMjxjZ694Q8ZtrNpJ4f0vWbNjYmezjmWFrgx/vGVrhdkjFDhv4V8wZGSGMukWHjS207X7rwvf3KaTfqLu403QoH+V543BijiIIChgyF1JKKgOPuil8U+I5/HTaV4ktbTWtSvPDscAi068sxqEFzCpDPJPLGFUE4bzMqDjYPUrd8Dat488MX2o63ovheG609Lm40+fTYU/ewz/ujcrGtvhojmNWGQQg6ZPJAOz8Ma74h8OW3h6XSNTj8Qxy38dm8balA0rWyeWkCCByDbSYuSkg5O8KGPzhq9Y0X4yeHtQ8dXHhK+tNU0fV4mkAGpQrEjhAGyDuP3lyy9iBnPIz8+XWu+IdbfWbmz8L2ereIdwabU7aOJWkHz/ZriMZJEkbSRKPL5GzbIXZl2ReJPiPZ+NrFW8XrpU1lcQWz38WlWJW4hUERm4M8i586ORiFjAKGORxuJIYgH2Ppmp2Wqxyy6be2l5DFIYXe3mWQLIv3kOOhHHHWvna18a6voPiDxvqNhrV1qOnaa0Ys7W6uTcW8iPM6khiSx2qFwVYdRndmuy+FOm2vg7xJqWleHhEvhrUrRLu3t1kdpLO8jiiMscu8k+ZIksb9sBMbR1Pba7oXgzR7DWPEGqeH9GjTyJZ7+4OnxtJKhBaTeduXz3Bzk1jVpudmna1z0MDjaeGUo1Ic6ly6Xts79nvseTXXxy1+DS7sHStK/tOAQzA738to5ASFCZ3FgcZIJ4JOMDNVoPjdr8NppsUVroTn7LmZt0rAOhZWXPy4Y7RxjAPciug0r4h/Czxp400vw1pmg2ery6jBta4l0tBFEIo2ZIm8xQx2qpxgEDIweuOl1D4feCJ9ZXV9T0/T7Sx0cG1+ySJCLFg6KwZo2XaCDIcYI59eKzlRqdJndSzLBL+Jh1p2e703utOu219upmXvx98I2vhKw1VHkvdRu4Wk/smxZZ7iHYpMhkwcIqgE7mxlRkDg40PjDqd+/gTSfEnhaaACzuYNSWadCY/IZShZsAsoCzbycHAU5FfNXxP07TvDPxD/ALZ0y/g0a8lWSW807TdRR3tL1AJUXpxGx8s9GAkDjGAtdv468R33i74R/D2xN9rKXGq2s0crWKs7TzRbYmaRFBeSMKJWYKOQQQDjA6jwm7vQ5nVtSi8WeJtS8R+CfFOt2nidrnYuijz1uGtdwVlURcu+5DM0aEqEPUFTjftNI8Q+J/FFroHjNNfsdRSOSKUQasEjv7hZFaO6EGAUhRVZ/NC4Z1C7g/B4m58O+K/EfjSy0aCCe21nw1psFq1vZultcy24BKSJkjDFJIy4d9wMjccFR6bDc66ui6X4Lm0rTdJt3AhHha3vzcXl1C7Bp/tE5DG3iwWfIwxDAA5GCCOV1bw5pem6zq3gXXPGVxLqduTJZXqWQDRyTxl5GnmDsRCTuVoiOTKGwcmvbfhRovi7RvEstrr2naS+h22nLa2OqRw7btwrjbExaV38sfOwDf3lPynKjx7VdE0eDStJiudN0+fUJb5Yda26rHeakIryUGC6a7CKmeDxg8SRsSC2a9t+E2meJtIur201n+xG0ZZLj7G0N41zeBvMVZPMfy1Em51d2Y/NvbBHQKAemUUUUAFZGveHNN12S2lv0uRPbhhFNa3c1tIgbG4B4mVsHaOM9q16KAOQX4b+Foksls9OlsHs4mghlsL2e1lEbMXZTJE6swLEsQxPJz1rGg+EujyeMdd1vWJZtSg1CSzlhspZJQkTW8ewGT94ROTgHMinHPXJNekUUAcfefDXwpeDVVn0yQpqlyLy6jW8nRGnBB81VDgI+QPmUAn1osvht4Us54poNMfzo9ROrLJJdzyMbojBlJZySSOxyPauwooA5XSfh94Y0m70m50/TPJn0p7iSzb7RK3lNcf604LENu9847YrqqKKAPIfHPwVtPiB48fXfFuq3EmnQxJBZ6da/IFQcku5zklixwoHGOeK6x9H0D4a+B9avPDmi2tnDYWM10yQrh5fLjZsM/3mPGMk5rsqZNFHNC8UyLJFIpV0cZDA8EEdxQB8S/E34qS/EnSLyy0qxW0jSE3l4s2okvIgCkxoGVQyoyo+wZP3ioxuNbXwlt9W1CG4uvCnjfUtJtzZiOeyW1S7khmceZ9ntomkZtrAyMrqQwER34OSPZ/F37P/AIH13w9Z6ZYWJ0V7ORnhubPmQhjllkL5Mgz0ycrgAEDIPlbaJZ/BJ7D+29EOraLmax1m8hVWMu877W5RCd0TAPLFncAdrYOcEgHs3ga4vLaLxRpEz/bde0+aC8kkRSovEMarC5J43yJb/NjKhmOM4IHNfGjw7bfE/SvDWq2d0b3wtaRSahPDaXaW89zG2wbkMo2KUXcTvx1K5U815j8btSnh1/RvFXw8uddljvrS2mt5IAyWqkSu6R4OTNIW80mIj5RuOCM4wNAm8aad4/l0jxJ4mv8Awi3iGKW8tpbYB4I5pGaRothYFPmaVCincJNvBPNAHp2hTaZ4dHjzwvoqR2VpL4fheFfsc1vJHKyOpaWOViTIRLGTypIj+7wTXzz8RPDD/DTxOdEh1JptRj3faLlAiKI5IgoUKCzKSryZz1DLxxXv+u6Pq8fg3xBqtv4i/tDV73TXin1G4lSLcsTtJKvkxqcSxhCu0kiP5gDlucf4D+FR8TvF1z441yOzbRrNTYppvltKksvk7T5hl3GTCy7i7EszknoOQDlPGvgjT7/wxomsWckWhavDpqMbK3SOWORgrtDI1zEqIJpggKocsS67RwQOp+GHwTv/ABL4X0u4bxLd6f4M1aGS9uNNtWxMJWbaIwxBBTYsZLHOSg+XoV5f4t/BXVvhxpF9qOm6vcXvg53i+1wLLtl3Y2oZExsYb2wG5K784PNfV3wqsf7N+GfhW0JBaLTLcNhsjcY1LYPpkmgD5B1vWj8KbxvD9pBqFv4r0nU/muLaTyrbVLRUdrV51DHc6mRflAAKkqxyAR6Bpvw91347NpnjTxLqUmlaZc4thY26Dc1tEP8AWB+BveXeRlCAOc4Civoa/wDB+i33iQeIJLJV1yO2NtDfAktCDn5kU5QOOm/bnHy5xxW/GpSNFZ2kYAAu2Mt7nAA/IUAfJniHSE+Cur61HaeDbfxR4cFvE/mXgEj2hkMgjmdirBQx86JgFAIiiJYE4ONofxA1abRJZvh74QliOif6XqbXWyYW9n5hk+yJJsVzG0heUgndwQMqtfUnjPw1NrN5p11YvbJIu6zvVnDYnsZSvnRgqQQ+URlbsQR0Y1tSWNw+txXq6hNHaxxMhs0RNkrkj53YgsSAFAAIxznOcAA+GPhtfQ+OPGbaFeRR6Hb6hcm9QaUpj/0hUJeJSzZCyqrDYHAD7MYA2n17wnLovwr8bafDouswHwXqd3O149zKPM064hRo3t5CBxzPbk7j/Bn0z6f8YvC+kahphvLxLGyMp8qbUJIEBhk2/uJnlOCAkix856MVPBIrxPX/ABlF4m+Gurpc6Fp7eIrW7F5BFBbyC01GEgKbkIx+dvndtucjYmfubaAO413xx4K+IngJfDn/AAkqW1vJqEVtcXEibCI1Mk0bBZBghxAFAwSCwBXPFcH8Pb210L4i+A0tPDk2jiS9urS6aa2RI2mK+RsilBMhO8F2ikYlCQq8AE8L4i8IaT4E8QrqviGMa5aRX6xX+ltbmxyk8DSIFCkYdBksE+RT5YDckD1eyOhXng7RIvCWpNrumeG3fXJXkg+0X6yNMHigeJSM8uWd+c+VjgUAZvxW+Ll+t14v03wfb3dtefaXtr6CW2+0R3FsiNC15G4/1f3VRgQwIEbAg7webt/Cuq/E7wtJqmlJ4V1DUbGyt7dhBdTRyGNUZViMGUWIqFzlgVZlBQ4zm7Hq2j6JpfjKO6n1aTW49Tn0a0bBlmumId9ihnPl5n2mQoArLtUqS1dAnwk+I/w9mNx4HutM1fT4oTILWdBHI0phkQs0YwrsBI4XLMDkZBxQBlfDlfFvxI1gS+EtZHhqfw1o1lobNNAJTNEWYSsWI+9mIkcDJUcqcmtL4u6VJ8FvPvNCGqXWj+JrUWmoXQv5Irxb6Ml1n+0AEhnyzFcYba4wAcV1f7JNtLNpGv6vLdC6EjW1j5hkEhLRRtIx3YBIP2gH5huB3Ak4Br3PUdNstTiji1Gzt7uOKVZkWeMOFkU5VgD0IPQ0AfLHhjw34i+NNhNb6xp1zonhPToBJpe9ZI5r7732cPcSB9+1MqZApADfdJIxV0bw62keOvEMfgTw3GNR8Naja2EcWoXBha8t5IZA+8thSZWibBxhhcD+FVr68rx7wpZHUfjF8ZbVZWgkkXSPLmUZMbi2Yq4HfDAHHfFAHkFlr3xHbVY9O0nwjcaNp3iS7ms1u76zkkuVmkYA3EsgAZXiRWKgBVVUJwQnHUav+zux0ua+8QeKL/V9cuZpo5JZpSsLtJG0duSOW3eb9nJy2MDGMDNfQWn6XcW9ja2tzqE9yIY498zErLLIrBixYH7pI+50wSOnFSeJbCbVPD+o2VpKkF3PA6W8zpuEMuPkkx/sttb8KAPkXUvFsHiGW7tJtauvD3i+bTl0PVYbzEcE11Cp8y5lYEhmYRmJflDKxTBIxjkF8f8AivRNQFno3jK91K81KxghuLi8kKCCRXZjFHKzkEK25BKCFId8Y4NegftAeFtY1HWZ/HnhzTljaysbebUp7S5Be2vY5XRyoHJMQjCsRgYw38JNcR4u8DabpvhuPUZNY0zWDq8FvJb6hHKsTWExSWQxTopwTLsZBI3eNt23HIB33h/XdV1r4P6tceArG1jItGsbvSnD3Dbo4Fje7Rgo/eyRMAEYAHy2I3NuB9Q8J/EPS9G8H/Duw8QTzaVeXnnaYftJGVNqGgfzWPCkyKn4n2Jrzj4OfEK0tf7Il8e2ltpvihrEWuh6xcwtDFc2bPtCSFML8pU4LADAHIJy3FfESGKz13V/Beq36aHZR2sflG6j+0Q3M0DOVnUjJt9yM0ahMk4w/wAxJoA6O5+I2u/EDxfq2qeBfC13d3ccKW+n3sRX7RprFGDscgrskXfwdvIGCDXM6pYeIvDV1f8AgawWd/Eeu6tb3kLmNYdiozNEUO8+WxYk9SBsOCetc3pfg74k+E7fVdR0G01K1ihSOG8uNPkzIgeJJhGdh38K6bsDAOMkYFdZ8PNL1S++LXhDTPFtvLY69FJEsMRVopbazt7ZjH1BU7gAB/EChJ5bNAHquqfDrWdGe51XVdYtb7WdeGIQ9qkFtaakBE9uAm4x4fyWiZyMsWjUffOfK9b1bxF41+JdrfaN8P8AUINSs/Ks7i0u2muLO0lIAikKKiiFR9/Byp2hsdSfsvWtLg1nRrnTr/JiuI9jMnysp7Op/hYHDA9QQD2ql4X0/ULbTnbXjYPq8su6e4sIzEs4U4jZs87tirkcjOQOMUAeWw/s7eDNOt7+606wubm/EiXFnFfTh443iJITGMNHIQAwcN8p7GvI/Hunava2+i6NpXhSC6u7u1uL3QrrT72VoPLG2UvFbSZ/frD8pHLZ2MuWHP2Si7EVQScDGScn8647TfC89t4knmmSGSxtUmGmuzElFupA9xGy8fdMYCEfwvt/hJIB4T4C+H/jn4naRp+u+MPFeoQ6NcmVZdKhme2eTYrRhmAXYCzg7jtPyk85OBTv9Ph+GXhjWLbWdN1XVvCl3cCC4ktpxFc215HNIN8hzlBPA0ZJ7q4TIyCfq1IMQvDJJLIr7uWbBUHsCMHjsevvXnPxB03RV1a4sPEotDoXiQRAx3L+WpvomQLhsfekiAHUH9wAOTQB8s634/n1/wAA6do15ouoyWmkNImqXEECI1rAzhbeBZirEKHVGbfguygZ4Brn/hLqFumsWVhDokN9rj6jBdWssk+0TCPJNqyt8pEmeDkfOEzkdPvgeE9B+xXlm2kWL295DHBcq0KsZ44xtRZGPLBRwuc47V4N8WfglpY1yCfwnHb6PqN9b4tZcmG3S5hJkY/LxG7RqSCoAHktxyTQByWleN5vBHxItZZ9WluPBd9eyXGpB7PypLW8dJI5opgu5xIh5IyxYKhy33j6r4m8f+DvE/wbRNT1xo7fUYo4Z1s/+PgotxHFKURhu75wVztOcGvnTxX4xufiB4RnsNQ0jTj4h0QpNcarFOAJ7dF8t3f5tskhkZTkbs7ztAGc+dXGm3OjXdhc63p7GORhO1pKrQmSMORg4AKhtrgY54J9KAPojSNcuNBsvDVtY6Pbf2BZeILWVNYjvIonCFXIS6txjbMYHfc2RkhQQTkVmftD+I/GV74m8T6VYWbz+GdUuYNIj8iIyeZPb7Zdq45EhZyDx8wXaM7OL+jL8P8Axj4fh0/QLrxONaSJri08Otq8gFnKpUG3hMgCuhyzkg79qsRtOQOI1C28Tr/wmmjwaba/arnWLSWOyN6bi6tLidmmCRn/AJaNgKsjNzmMenABm/Dm28O63o+s2V/aaxJqbQqRHYW9q7IoaNWl82b940ju4RYY9pYkLnL5HV/Dzw3qHi/x9aeGJ7y/8PHw1bXkGl36R7bgyxygMG2kodrs7Mqt0YrvPBr0uX9nW21nwp4OuLbVJvD/AIg0+ygW4lhhDlpOXYnBVg6u3DZ6KB6EUP2abC7s/ix4wtNShjk1HSoHsrvUN8rSXr+cNsjbmIGVjB4AJzkk0Ab/AIv+Fz/D3wvY+JPhsjy+JtDVnuHnUSvqMLbjLvXHLjcSCMNtyoJ4xxPw7fxd4x1S9tLLwg2i+BvFU6TXzszkHlZLhxKRvIlQPGoGFHmDbggmvrGigDgrb4U+F9P8Daj4Y0exWztr2J0a4HzzBzgrJvPJKsqsOcfKKwvhJqfjbUteU+MND0eJYNNa3m1W2kjea4njnKhSFb5BkTFk2AB16jO0etVSstK0+xvr69s7K2gvL5le6njjCvOVGFLsOWwOmemT60AXaKKKACiiigAooooAKKK4Hwj4r1nxFN48tYobBLvRtQlsdPOxtrkRgoZfm5+Y84K8elAHfUV458PPirqnjXX/AA1pllZ2Ucn2Ca68QhkfNrIjmJY4xu+UlwThtx2kfWuu8a/FLwd4I1WLTfE+sfYb2WEXCR/ZZpcxlmUHKIR1VuM54oA7Wo7qeK1tpbi4dY4IkMkjt0VQMkn8K+UPHP7RFxofjx7vwVq9v4g8N3USO9ndW0kRt5B8rBGZVYA4DfxDLHivVPhp8fPCvji5h06SO60vV5eBbToZEc99sijGPdgtAHrsbrIgZDlTXG/EvSre+0mcXulahrFjdw/YrmwsSBJKGcGNs5H3WB5LAAOxPSuxTfvfft25GzHpjv8Ajms3xI9u+g6jFLe3NqpiaJprM5uI2K8eWACfM5G0AE5IwDxQB8q/FLV7TwXexeGtNsoXsLG6TVbDSrmdx5ccsZ8xNyyDbKknngAbj++yDmNQT4P/AA/8O/FrSdZuL+HUbTUbezS3eeaVpQbqRnkF2u5t2WGCyE7SXJHY16z/AMIx4D8WeCLHxDqukLeP9kmKwXVyWn3XEwkZSyZfzPMf5QOQZSAAWxXrOk6VY6RZQ2mm2sVvBDFHAioOdiKFQE9ThQBzQB8maH4IuPhxqh8E+L7q6u4/FL2sVg1jczLZnNyiXKunygyeXsOSCMcZ5r6w0XSNK0W0a10PT7LT7XeXaGzhWFN5AySqgDOAP0rn7238J+M/EltDcrbX+r+HLj7QqxyBmtJCSoDlCQNxXOxuTsBI4rotH0mx0a2kt9Mt47aCSZ5zHGMDe53MfxJJ/GgBniDSdO1/SbrR9ZgjubG8jMcsDsRvXjoQQRjg5HIOK0AAoAUAAcADtVeSyikv47tzIZI12qPMbZ35K52k8nnGeTU8g3RsCGPHRTg/gaAIr+8tdPs5bu/uYbW1iXdJNNIERB6ljwBUkBiaFGgKGJxuUpjaQecjHr1rPutV0xdKjudVlhs7S4Ij26hiHLMcBCHxyTxjv2rQhjjihSOFFSJFCoqDAUDoAB2oAjvbu2sLWS5vriG2toxl5ZnCIo6ck8CquhatYa7p8WpaNeRXmnzFtk0ZLK5Vtp2n0BUjjr/PMtmutVn1/SvFWiWzaVBIvkXMxSSC9hbLcxnJUpwrbuCRuHBwNfS72K/iM9mI5LJgpguIpFdJkx1Ug9M5H6igBNd0q11zRr3S9QQPa3cTQyAqDwRjIyCMjqMg8gV8yfETWtP0zwlol5pOhzWw0uN7VbX7VETfWzyLmdLi2ZlEiXccTOFIYM/ON4z9B+JfHPh/wxq1vYeIdQh05ri2kuop7l1jiYRsoZAxPL/OCFAyRmsHwNeaBrnijU7vTNHS0mG6R1kVUnWR3XfJNCGJjMnkQMu8K7eWx2jaSQD58+Gia54r8b6FovxM0y5l0m9v7iSzg1Jm3I9tauJItrAu2A8GWcj/AFZ5Zs11Oh/B+/8AhH8QrLxVY6slxoR1AWPllP3kVvcLsV5iSFwkjIDg8gBuCdo9B8UaRq99+0D8OdTVw+nW2n38klsHBFuQnlvKGJG4M08C8DPy5I647fxrZaNrmmapoGry28IvdNmMkjSojpCCAXGTnCllOcbQcZ64oA8c+Gnw21K7+Lf/AAmGtfZNS8PzwS6nYzRBUjF1JKQrGLOTJsy5YjAZhg5UY+iCQOSQB05rl9BttQ0a3ddT1TST4ZtLVI7QrCY5BGqgbppGcoRgD7qqOfz09dSS8ltNNjKrHcMz3DHIYQoOdhA4fe0Y7EAsQQQKAMz4e+ENP8F6bqNjpNsbe3udQnvNpfdneRjHA2gKFUD0Xqc108kiRRvJK6pGgLMzHAUDqSaisbSCwsre0s41itreNYoo16IijAA+gAqTeju0TY3YyVOOQe+PTtQBDFdGaWDyYXkt5Y2kFwrIUGCu0feydwYkEAjCnJBwDn2Wjafo2ra3rEaxxTamyXF7cSFQR5USxqM4+4FUnk8Esf4jWtEqouxAQq8AY6ew9qwrfX9O1jXdY8O/Z3uHstsN6HCPGPMiV1Vl3Ftrq7AErtJRxnpkAS28YaHf+KLnw5p+orcazagPcwQqX8lR13tjaOwxnIJHFdAuedxB54wMVk6Zqei/2te6Hps9quoWKpJcWkYCtGHGVYjvn1/Orer3v9maVdXv2a6vPs8TSmC1j8yaTAzhF43N6DvQBBPDDFei3g09fL1Bnlu5VgUo5CKuJOQSzKFAJDcJg4+Wvn66/Zj0w+Om8qSX/hELmB3dRcBbq1uMnaqExndHgjAJ7HdnA3dd9m8Z30sfjUW2oRXc6PKuj3mo/YbaztI2xHFLEoYyTSI7yEuQEPynG0BvUtK1Iana2F1aTIYboGcK8LI/lY+6QTw4YrnPuMegB4t8WfBPgSHTBpfimGaxt4Cp0N9OXbNuldRJbxRhdjnzAH2kHAlJG0A48r8QXs2saUIda8JXGua5aItr4hS0Eqy2l3HJNFG7MoKt5qFGJQ4Z40JJCha+tfGGu6Z4c0kajrM9lb28UqYku3KIpLBSQQrHcASQAOfUDJHPeHLTRdE8T+INY02+bU5dfMdxJ9mRrhl8ouhzIpICjJVV+XHlsBuIOAA+CfgJfh14Fg0hrh7i6lkN3dMwACysqhlXH8I2gZJOevsKX/CL6drPxk0zxxp0sOpR2tjNp8ksF2jJazKTjKjJZisrqRkbe4549DvLqK2s7m4llVI4EZ5HILBABkkgc9OcVg+CfDUnh22uPtdzb3uoXJV7i7itEtjMQCBlE+XjOAeuMAk4yQDpay7jXLKHV003fNLeOVHlxQu4TduOXcDavCk/MR0HqM6h4FNjBAJcLvJ52jt2/SgB1YfifxBZ+HkhuNWuYbawZXy25mmeRcMqRxKpL5USE45G0cHJK7Em6O3bykMjqp2qW5YgcDJ/nWVp1891p0epaxpkukzIzqsV08cjxKTgMWjZlGRgn5uO560AWYtSWSytbuO2ujbTor5eJkeMHbjejYYHk5BGRg5rO8cGO30K4vljja9t42FozMoZJXwilA4KmTJAUEck7f4jWvFDG8gkSRhtfzCi/KNxUg7h7hs4PfBrlvEVzcPqrG4sp7TRtBQ6i9xOYUiu2WM7FSRpMKF+csXC4IQ5A5IAngDWItU3W1pLrNxHYRJDLLqlpJbzBgqgCTzI18xz8zEjhcj1FbPjHRv7d8P3FrHHbyXKkS263I/dtIpyEfgny3GUfAJKO471RN+2rCx1vRb2Rba0nlhvreODzftMY3KVGBuJV8MrLnI3AA7qd4z8ZWfg+Wxk1i0v/wCzLjeJtQggMsNmV24M23lVbdgNgjI5xQB84/HC70+xtGntfDw03xPtkuLwlUhmfS7geWyOMsJH/eLHuGShRipwpNcl8NdB1b4h+LhaQXV3qvgxri0s76S8iYMsEavOkeA7tFgRvEHD8eZjd8+K9o+GvjXw74m+IuvWU/haCwl8QQfa4Li6lMlxqEAQKqvGciPKguFLKCjIQpBDH17wfb+TpckjaBb6BNPPJLLaQmNsndgSMYxtLsqqT1x0ycZoA+bfGXwstfA3iC48Tz6tcXd7ZyLqMCxahHbXV3bRuvnkqEQ+YsZOXVyZGYMQCWB7D4ZfDvTfEfj6D4rWeoFrKe7vHtrMwkiRVLW8cpZsHc21pCSM5Ze4JPffE7xv4J8PPHpHje6s1g1G3kSSF45JZDGeBlERiFPzDdkcjjPJFjwH4Yg0210u40e61bTtMt4TbJpE0okiMalwCwYEiQsdxKsOgU5A5AOw1C7isLKe7uW2QwoXdsEhQOpOATj1PasjQNPtV13W9YsTp7xag8cbyW8GJWkg3RP5kmfnwRtAwNu1uuaXxTbyalosel3NnFMmoyLbXSMGkhSE5aXcwKkAorKrf32TIIzWpYWyQW8KRMvkRLsgWPIUR4AUHk5wB1oAtVTstStb2e5htZDK1u5jlKo21WHBXdjBI7gHI71NPM0UkKiGSRXbaWTHye59vpTY5FDyQW8YxEMZDDaGPO045BwQenRh1oAsUVFdNMltK1rGks4UlEd9is3YFsHH1waegIUb9u8j5sdM0AOooooAKKKKACiiigArmLLwLoVhrt1q9jFf217dXBu7jydTuUiml/vPEJPLb6FcV09FAHP+HfBugeHNW1fU9F06O1vtWl869lV2bzXyxzgkheWY4XA5roKKKAPIfHPwVtPiB48fXfFuq3EmnQxJBZ6da/IFQcku5zklixwoHGOeK9C8LeE9B8JWJtfDekWlhFj5vJTDSf7zn5mPuSa3KKAILKSaazt5LqD7PO8atJDvD+WxAyu4cHByMjrivLviJ4Dvr281zVBr00lhdiBoPD8cMcMN3cxkbI5pTy6u3BHy8EZJCgV6E2tRxeJl0a4iMLTW/n20zOoWcgkOijruUbSfZh707UY7WfWdKScztPGZZ4Y0/wBXkLtLP9N4A92zjjIAOU+Gvgqx8N3WpXkOn6VZahMFjmisrRFjgkKq8ojkwHaJiUIQ4C7AAOM1v+INSt/BvhLU9TZYhp2l2RkhtVxHxGhxGGJx82FUDHU981e06xisNS1WWNJVF9Ml1JI7gqZPLWLao6jCwofctx3xS8Z6VYalpcc+rC7ktNNmXUWt4JCBOYQXVXX+MBgrBTwWVc8ZBAOR+GkOl+DdRsPCU8Ej+LNTsG1jVL7Cv9on3jzN8g5J3yNtBGAvfJ59IuomntZoo5pLd5EKrNFt3xkjG5dwIyOoyCPUGuV8C+CtO8Poupy2Nr/wk12jvqN+kYDyyyv5soyP4N/QZOAqjJxXXMwVSzkKo5JJ6D1oA8n8UX2o2fiR/F1tqd1daPoMyaXd2ahxGqMFNxdOq4DlN65IG1VRm/hxXrNcd4EeA+ENJjudRU3GrGXUIhIyeZcJLK05UKc5GyQAgDgHjHGFj1240PxDFput3cVzY6gpOlSw20hndkBaSNwm5WwuGVgFyFfK8bmAN29lt7zUP7M3wSzRxpcywSKrhU8wbGK9QSUfaegKE84qTRb+3v7RjbRPAIJGt3gkUK0RU4wVB4yMMPVWU96yvDUMMmp6vrkcizpqkkYt5FiIIgijChScZ/1hmYZ/v8Ua/f6rpXiDSZ44oJ/D9wzW96S4jktZCB5UoJ4ZCQUZTyCyEZwRQBf8UWi6hoF7p7sq/bIzbDdKY8lhj7w56Z45z6VX8Nq9lcXWktBKiWkcBilwqxSIU25RVACfNG2UHTrxuAqPV5La78QaejPbumkF7+5YSqWt2MbRxhkzkBlklYN/0yI70alqwvNAt9a8PahDc2MLC6kaB0dbmBc70V8EA4yR0yVCkrksACl8RNH8H31hFq/je0tJrXQib5Jpwx8n14Xlgdo+TBDEDgnFWfD+laZNqd1rMWn28N5K3yt9h+zzRrJHG7JIf+WjbiWLdtxXqGJPGFtous+Hra51Czg1a0E0E9rtO9WdnVY3Ujg/fBHUGt6cIs0DtG7OGKKygnbkc5x24HtnB7ZAA4W8QeJ1QK0SlE28BVOMjHpwPyrx7w/pHhz4h69P498RQiWMyCw0VZXPlxwK7RrL/dLvN5pXOcAx45Oa0/iVfx3XxT8CeFbmbzdN1m31GPULIXMke9FjSSMsqMuQTG6/NlSrSLg5NdbfeCtB1LStJ02azUadpE8U9hDBI8YgkiyFPyt82OeDnvnJoA6SJFjjSNBhVAUD0Ary/wAUaf4x1aW90y21GDRdS1edxDeWoaX7Hp9vyGB+T97JJIgI7K7Yztr1KudsEWbxtrN44IFrawWiMeg+/I+Prvjz/uj8ABfAN5qV34Wsxr6RJrNvutr1ImLDzUJXcM84YAOM9mB71F8QPEEGg6PbxyFjdapdw6XaIkjREyzOEB3qrFNoJbdj+HHUgHI1zUtRtdUl17wvqOl3+i28iRa3ZSPzEqqGaaKQHAkEboSjcMqrgg9aGgeOtF+IviiwtvDp1B7fSZHvbmeS0eKORdhSJPmAJ3NJ5i982+cdKAOg+H/hW28E2Umi6fdazeWYxNHLqFz5yxA8eUnTaBjOMd+tcp4BcRfHH4vyMGKoNJY7QSeLVugHWvRPEg1RtFuT4fkgXVIwJIVnXdHIVIJjbkbQwBXcPu7s4OMHx74dK0fxT8fOY9ciTxKLWa1ubmB3SIpG3nQtKMoHjdzFtBOwqFByCAAep2GjxJrMOs2zSlZ0ceVwiRrJhy5BBYsWUZUELli23dknoHJVGIUsQMhRjJ9uahguraSaS3guIXmh4kjVwWTgdR1HBHX1rlNR8VajoXh3VLrVNL+23+nzMrR2MqKjQkkpOxdgI02fe3H5SrdRgkAxPFuh+KtbfU9WsHubPUtMv7d9GsheeXFcxQnMnmlDjbMHdSp6BI84+YV6aeRWRpKJJoNubWFUW8Vrg4QxhWl3SFipO4EsxyAc5PbtPoOoR6npcNwhkD42SpKoWSOQcMrqCQrA9RQB4F4iS31TxdcaD5OqeKvDHhu5E5tLk77iXUJXZVslkkK+ZCiFpPm3EBMFmGBXtPg3wnZ+EhqEGlFYtNnlR7ayjjCR2qiNVIB6sWcO5Yn+IDtk7zvC11HE21plBkUZGVHTOPxIz9ap+HtFsvD2kQaXpUZhsYMiGIsW8tSSdoJycZJ6/SgDL8bXrW62UElrdf2eZDeX19EVEdrDb4lO/Jy28qqbQDlWc8Y55z4fp4v0nVbSHxHLJf2etwSahIZm/e6ZdEqTa9dpjCthSoHzIxwAwFd/qUMd1am2lOUmZVZd2N4zll9wVByPTNM1iC6ubGRNNuIra/XDwyyxeYisP7y5BKkZBwQcE4IODQBbclVyBnkd8cZ5NeMW2lav4rCePdAvb9dQu7vbb2/2uSGFbSKUrEGiztdTtLOpIyJHKsCFB1rj4havpNlJo994e8Q6l4jXfBFeWWl7bSdmZlhm372REb5Cct8pJyODXdeHrBNB8N6Rp08yh7aKKBpFOFeTAB/76OcD3GO1AGwM4G4AHuAc15V4x0pPiJ8RBoM5aPSvDcAubvLMHkuLhGEEkS42kxiNuXDIfMZSpwava/4p1rwLq982rWd/4l0a7Yz2UelW6y31oMkusseV3QjICyDkYw2SQTp/Da+t9S0W78UESwLr959pSO4UK8aAJBEhHY4jUkZI3O2DzQB1emG4NlH9sjEc4yrcj5sHAY44GQAcDOM4yaxPFtzbTXFjoN3Fpt02qyBUtLxN4ljj+eZih4bau3HuRms7xdf6x4e8SWWp2t3YS6HcJ5V7YXMjC4LLkIbQZw0js6KUI+YhAMFiawfB3iC/8ZeOL++1XQLvTItEtll0yxuUVbxzMHV3lG7EZITaqMRnJOTjIAOr8OD+xdXm0K6nMsbB7jSnk+ZhbjYJId3qjngf3GQDO1iH+OPB+m+MbW3tdeuLw6TC/mT2Mcwjhuccr5pA3EKQGADDkc5qXxNq01tos9/okNvqV1ZP5j2qENIyKR5yJ8wxIFJxnvgHrTNU1hNR+H8uq6dAkwv7AS2kF0mVlaVB5SOozwxdVI5696AKD6d4fGr6PK1jZn7feHULJUgWAxziBi0zdC8jKcHPOAvHyk10F7ZSXekXNvfX00DOZCLm1fyWiXcSpB9QuOuQSOR2p89tb29rZebCs4tGTy5JdpaI42F8nodpIJHOCfWtAjIwelAHzlF4p0K78baj4q8SjS9U0632Wuj6hqSrCj29u2biW3BBWWfzWyNoUkJ8uPun6LijSGJI4lVI0AVVUYAA6AVj3Oi6Hf6G+jPYWz6VERA1nFHtjUcfLtXAxhunTmr+kMh0u08pp2QRKoM/+s4GPn/2uOffNAHDfEXTJpdOn0CHULn/AIq/UY7PAKg2sHk7rkISDw0MEuMg4eT0PE/wr0PVPCQ1TwxcC5uNB07yTpN/cy+ZLNG4YtG3YeWQFAAAwRxVm6lkufi3D5ixJY6Nock0kjScmS5mAX5ccBVtJPmz/wAtMetaGuX19qelLL4J1TTpL/5XiMw8+1kVl3AyFPmClclWUjnHUHFAGn4h1QaNol5qH2ee7aCMsltAu6Sd/wCGNB3ZjgD3NZPhfQG0q1tprcPazTkz3kDSmbdK/wA0hZzjc2do3EZG0AYHFZeo+OIpvFdn4Tg0rV3vL0f8f5s2SyCqu9yJW+/8oONoIJIGRmu4WWNpGRXUuuAyg8jIyM0APrOtY3uNSkvHN3EIt9ukLthGGVy+0HB+78pIyAW7HA5EeJ9U8I2ENj4qjuvEGqNN5UE+k2W0zxbQRLMGYRw87wxLhQF3ZAOB2Wj/AGgadb/brmK6unUyPLCu2M5OcJ/sjIAzyQATk5oAu0UUUAFFFFABRRRQAUUUUAFFFFABXO/EeTyfh54olEph2aVdN5gZlKYhY5yoJGPUAn0roqyvFthbar4V1nT7+SaO0u7Ka3meFS0io6FWKgA5OCcDB57GgD5z+CXxT1/xZa3FjfXOj3l/pMrahBLqbNHcPDhlK+YE8tCXkSPfkEK7Da3FfS8dsTffa5QvmeSIlA52c5bB9zt7fwj8Pzw0DxRqHw38Y3VvpdzFqFhZX7CWJ49kd6I2KqXU8/7Sg52sFOMrX1Rrnxu0zSfAfhrXr3S7mS21IySCCDUB50TRyEIDuIaRSVOTyvHcGgD1HxfqmpaVDatpcdnLLcSC2jjuhMFMrMu3c8SPsXaJOWXG4oMjPPnV38Vp9c1fw9pWk+Gr82OoaktrdahdIPsmI1MkyxOD8+ApwxG1gr4zjNVvg18bdB8SWf2TUlm0q8m1B4bZJ2lnSQyMXRPObPzkswCkjphRgAD0eGHRfDej/bru5gstLtXMsM894ZIkVyTuDSdCxkYcZOG2g4wAAX/EEIu9C1KymurtZJYJQXsDsuIlbdtZMHIYdAe5H5eD6r8JZ7fVdZsL2+1rWdAliivrd9W1XbaQzqv783jKwYybEXYVVlAb5gQM1z3ib9oW50/xc9s0WmXEdvMsc81mxubZtpLCeAgoS+CEO4lTtHQbs+a+MPipc6h4l1HUobOxuor25S7jtrtd8MGYvJdTEGKM0kQXcxyVyQCrbjQB2Px/+KkL/EN7Lw61rHFpMPkQarZR/wCkwzBXykchICx7iFbaOQG5PAGv4U8d6Xrmi6Rq/iWPxHqNt4eUX8l9dXSCQXcTRkrbhcCQM0uGRzuCmPBwDXzE7PM0k0rl3ZsszNlmJ7+p+tXNY0250PV7vTdRCi4t2McghlV1J7EMuQR0PH6UAe9+Pf2hYrmTSLLwZZ6na6DaIzzRz3LwTzTYYKrSI7MYwWViMgseCQKo6D8f9S1LRX0Txvp8eo6D5JilisYSs9wmMbJHZiFULubcoD5QcjJYePeGvD174gu1EEUv2cTRQySRIpYtJIqKkakqHkJbITIyATkKpIhuTqnh+6v7BZbyz3P5U8Z3RFmjkztdf7yuvvgjg96APSNS+KNnafDO58P6Fb3f9tayQdX1OW5diI0c+XBGWJYoEwoyeFJ4JY4g+FnxNj8KeIjZOupyeDbuNrWbS573zFVZMB5MgIu7gnovU8968z3tqOpmW9uAjXEu+adlJC7m+ZiAPfPFRywHZJLAsslshVGlMeAGYEgHkgZ2tjnkKT64APvbwta3k8mm2NzdWF1oHh9Eu4J7STdJdRhGFsGHA2hSSHz85jVsYYUnw1+IH/CztG1nTLm4XRNd2JJHb25kWZLZ44ys6F1UsGYsQV6K8eTyCfkfQ/iPqsPgbWvCzXKxf2kIIUuSOViRRGYmbPCFAOx5z03Ejs/g/wDFzSfDfi/+2fEf2uXy9F+xvMIzNdXUxlhOC7P8wAVyGYjC4XHyqKAPY/ihqF1o/wAUfD3iBPBmsane6DZXrGWxO5JoWjVY2eUpzgtMDGPmBbdkjCt7bosU0Ok2iXUkctz5SmaSNSqvIRl2APQFiTj3rL0m/wBJ8Z6Zpuq6a9pqWiSpJIjspJLkbMbT22tKrKwyCcY61yPxH+LOheDLnT7mW6S+hleS1eK1u428p/MCmSSMfOVXZIpYZww24ywIAOH8d+M/iT4K1jWGiAu9CuLn7FY3mrx21tDaO4Vo5BIjZkXHmKd6gDahJJLCrfiDxuPg/wCFLeDxVqt3rfijUp571pbcKolBO1flztVSqqAQDs6hTja2br/x68FahaQ2mjo9qpkW7+1S6ZHLHbzs0jOzxuVywALhkbcWZcZO4V4J8WvFFvqvjOxt0uH1bS9Kjgt/Nv02PcFfmkDFMMibmZdiEYAGORmgDb+FvjjVNN8B69ptmnmxC1NnJLdaikMNss8gVSsJGXJJYFx9wNknGBXqfxH+PT+GNKvPDdhpWrab4ptbKO3Sa+ZZjBLuAcszHEgMahlkwdxIOOTXyVMqxzyLFIJUViFcDAYeuDyKtahqV/qt5cXmoXVxeXMqqJZp3MjlRtC5ZsnAAUD2AFAHp/hr4yePprvTbay1+Q6o0gs0e5WJllSRycu0nG4MQATjA4yADn0tPjZP4L0e6s9T8KWUOvXcA1SOVNVS6t5rl2JacopIjDkmRVjJ3BgcgNvHzJeQwQwWcsdys9zKpklQLxFzwp7E4GT9cUl3qN5e21rbXMzSxWylIQQMopOdueuM5wOgycYyaAOqsviTr9n44j8WxTga00/nXUi/u1uhuUmJlTaPLIRQR1PJzzx6/ZftBXmqeKIIfEHhW3v0u5Y7QQaZMZBPbSrteF4/mW4b5wVQ7cMSpxkivDbu30n/AIRyKVhKurzL5yypcwtEwVirRGFQGiOCGDMxztwF+bIr+G9e1Lw5qdvrWhTxWd/aAxpIArsd6srHa+QflJBIHGR60AfYNx8b9I0z4gz251FF8OobfT2t2hA8qcswMscmQPKQcS5B2lU2FtxrtfEtuPBmo3+ueHZNLguNdkjint9SuHhtmusERzb1DCMlQwYY/eFUAIc/P8A28WpT2El9HbPPY6e6GSQwho4S7HarHGAGIb5ehOfevq/4SfF7UtV8H2VlfaVqbSSGXT4r+0WIWyyJCGVGY5MbbVGGf5cuzH5VwAD1/wCH13rupSavqPivS4NLvElS0iSGbzopYUQN5yScZV2kYgYBAUA8g1h/GK98aaTcabqfgcXNyqRSrc2MVotz57qyNGCjMjIh/eKzoSfmX5TwRteJPs+n6Ha2OmPFoVzArXgSCSOKG0TawklkQlUliQuWZMjPB4ODXF2Pxf0/XtGuI9BN3rUsNn5l1eWUQtXtFyxkdzJ8qnYoYAEqWVhkfLQA3wrr3ibxHfJ488b20Xhzwjo1vLdW2mlmkmD+WyNPIQoLYRpAEwD8wO3oT5Br3xk8fJ8SZtK1lLbT5bZjBLp+nXEUSu2CRmZhJmT7gGeAVAwMsK0vEV74Z8C/DfVoNA8R6h4htNdj+y3s2nSpGsMztKzSuDuCmUKsYTA+RJCDk14fDoWiW+hWdxqWvxw6ne5mgS1AnS3jVZPlnCnckjOIwoAOFJJ7UAfVg+Nw0fwpaXdzY31zO+pSaXM2sMNPeCdIombeiCTAJdj/ALI444FfPfjz44eMPE2p3zWuqXFhpkryrDbRbVZIWZCELADJHlqQ33gS2DhiK5DxJ4uvPEtuz66gu9UaZZDfF2UsAhRg0YwhYgRAvgHEYznmqkFl5cWoW+qhLaW0tvNRJnZZSzPGFVF6FvmyQcfLvPUAUAex6D8ePE8tpqmqX9hp+panZqUtrt5VgW1SR12okKgNIMqASDnGAxx15r4ofGPXfF09iixx6dFZyyS+VbyCRFuCCnmRsOwU5U5JDs7BuQB5ZNJIz/PK0m35QSSeAABjPbAA+gFXvDyWP9uaa+tJIdJNyn2rY20mIEGQA467fTnkUAepaD8eddtfCt1oniBR4ht2eBIUvFVQIFYtIGYDcXICBWzlck5yFrofHnx+hn062tvAcWp6TNDOC80zJIJUTAQuTlpSVVQfMJwBj5uteH+JdPs7HWp4dHvFvtMZt9rOSAzRE/L5g/gcdCDjn2IJjgu4ZtejutXtkmgMwaeC3C2yuAeVGxcID0yF49KAO+8AfFy+8K+MotWSxgj05jI93p1kTFHO7c7huLeWSyxZCYUiNRg19ffDeKDWLbTdSj87UdNewglgubuQl4ZRyYyoUK7Bi5LfwsNuBgY+GPGMnh3UJbS48G6XqNlDHZq+oQzyecsU2/aSjddnKAFsckDA7914K+Mep6VZa89/qmo/bZtJMFuxnkkEt55qbZcZARvLGGbq2zJJYnIB9nRXlnrHiDV9IudQhuFW3QnS3twGRN7qZGLZLBmUgcAAKDyGBPNavr/i3TLIvaw25ubm6nuZptaRbWz02zjRV2s0cjnLHBU5O7MmdgAA+WPh98a7zR/F9hrfii2bU3sNL/s2CSElJioOR5jBgJM99+7BwwGev1hpfxA8PaxrGkWmo2V1p2tXEK7YNQtGjeESoZPLLkbcnyh8ueSqnGRwAbvgCe8fwVpNzrIkjv7iI3F0s7DKSOWd1Xr8oJIXn7oFeN/HPwJ4zOpax4n0HxLc2ljbos1hY2Ms4uPOYIkkSIrBMOd77gNxZsY711nxp+LNt4B+yRw3MB1JbmN59PkG55bUrLyhH3SzKoy3AHbPXx/WvjTdeM/Bdzc6l4S0a40SweBLqO71MCa5nDh4gq4DEYSTK4O4bsEYZSAbl/4h0r4OeDtdtrayuT4u1GeO5VLiczyyx/MFa6k5UlcOXjQkZkAzhiR5N8HfHXjs+I7XRfD2t21tbzeYDDeGJLW2jZt8kixkqo2/M21OcA4Haua+JPi6Pxj4ltxBYQ6DodkotbPT4UxHaJuJdiqgDczFmbAyeBzjNcbOsaTyLC5kiDEI5XaWGeDjt9KAPpG3/aA0/wAOeGp7XQv7Sv8AXLmFp7m+ugPLlvnPzybCfljGCUCheNoK8GvKfDHxP13w4b1Y5LbUHudQjv5prhGZ5pEYHJkyG2soZCp4KyvwCa4CtvStN0260ieW71KK2vzdwW0Ebk7FR9xkmkwpOxdqjjJy3Q0AexJ8VPiDoti2oamYdZ0m7hhS4ubiKO7hUOSV4TY0YKjHlydTubuK7z4BfEDUPHvx11u9eaW30p9Gb7NpizM0VsElhRflwF3Y3NkD+MjPavlQSXmj35EMzwzxMHV424yOVdT+O5WHqCK98/Ysty3xF1e8a4hZzpciGIyfvTmaE7sdxx1z1x6igD7KooooAKKKKACiiigAooooAKKKKACuZ+KDbPhp4tfcybdIuzuVtpH7l+QQDj64NdNVbVLC21XTLvT7+ITWd3C8E8ZJAdHUqy5HPIJHFAH5t67ZT3j6WZ9Qjn1KeCXzoJjtlt3jkkHlyE8mRypYA8/OozWPYfZptUgGryyRWQP71oEBbYOoQdMnGAemTk96+8f+GfvhjxjwzjHQi/uv/jlPn+Afw1nkLzeGy7nGWN/dZOBj/np7UAfGmneMbfwl4g1H/hD4pb3w5cNG32LXEDeaUGVMqxMASjlipBHY4B4Fi++Iz6v4Z1nTde0q1u57yc3cMkRaFUunkkZ7lwp+d9r+WBwu0LnO3B+0dG+Cvw60eWSS08K2MhdShF4z3SgcchZWYKeByAD71nN+z98MWYsfDIyTni+uQPy8ygD4SvLC2t9Kt7iO/huLmVvmhiB/dDaCd2QOfmA9M5wTg4zzGypuIAXtkjnryPUcHmvv5P2fvhijqw8MDKnIzfXJH5GTmrur/BH4datLDJd+GLZTDH5SLbzS26hdxb7sbqM5Y84zQB+eR9qmmuGuJ0kufn2qiEKAnyqoUDgYzgDnHuc198f8M+fDD/oWf/J+6/8AjlKP2ffhiDx4ZHpzf3J/9qUAfEHiTXftFpHoek3N2fDFncyz2UFzGiS5fGXl2cO+AFzngDgDJFc+cnk55719/f8ADPnww/6Fn/yfuv8A45R/wz58MP8AoWf/ACfuv/jlAHwJHNJHHKkbsqyqFfaxG5cg4PqMgHnuBU1gbIC5+3rcnMLeQYWUYl427sjleoOMHnPbB+9f+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAPgPYfk6fNyOR6459Kti6jsdUt7rSS4Nu0UkbTor/vFAJJUgqV3AkAg8YBzzX3kf2fvhkQAfDRIAwM6hdcD/v7VnS/gX8ONM1CC9tPDMQuIHDxmW6nlUEdCVdyp/EGgD5D8D/GTXfBum29npNtZBIp5rh8qVErum1CwUjhOSFBCnOMcAjz/AFG6Go39xdFI7fzCZPLDO4yTkgMxZiSSTlifrX3/AKx8D/hzq+ozX174Zg+0THc5huJoVJ7najhc/hVMfs+/DEZ/4pkf+B9z/wDHKAPhCXWNTudMj0ya9uZrFHDx27uWRWA2gqD0OOOO3FR6ZqEmnTrJGkMwVhIIp0EkRcAhWZD8rbdxIBBHqCMg/f0HwP8Ah5bxypb+H2hWVFjk8q+uU3KvIBIk9effvVP/AIZ8+GH/AELP/k/df/HKAPgJSAV3AlQckZxV+fUEivb19ISays7lTGbd5vNPlkg7GbA3DIBHHYdxmvu7/hnz4Yf9Cz/5P3X/AMcpf+Gffhif+ZZ/8n7r/wCOUAfBLzNNqTT2scdozzb40icqkJLZAVmJIA7Eknjk96W2dIllkWJzIR+4dZMNE6srFuOvy5HbrntX3p/wz58MP+hZ/wDJ+6/+OU//AIUB8NNmz/hHG24xj+0LrGM5/wCevqKAPgS5nE/lnylR1XDvuYtKxYks2SeeccYGAO+SZ4J7J9WSa9s2WxL5kt7SQoQvorPvI/HNfeX/AAz78MT/AMyz/wCT91/8cpP+GfPhh/0LP/k/df8AxygD4k0rxTcWdk+nTxmTRro241G2jcI94IWYx/vCGMZAYrlABgDIJzmKzu9d8OWcM9rLcwafftHcIQG8m4aFztOCMMUcMPY57Hn7h/4Z9+GI/wCZZ/8AJ+6/+OVraD8H/AegR3a6V4figN0oSRzPK74GeFdnLIDkg7SMjg5FAHw34/8AiN4h8cXlrNrF5Isdtbpbx28TssQwm1325xufkk++OgArntE1WfRr7z7fbLG67J7d2cRXEZIJjkClSyEgZGe1feC/s/8AwyUEDwwuD631yf8A2pVyy+CPw6sra9gt/DMAjvAqy755nOFYMNrM5KcgZ2kZxg5FAH59SXU0sbRPKwhLeZ5SDCb8YztGAD2zUTbQEKM27GWyMYOT0554x6f1r9BW+BPw1aG4iPheDZPIsr4uZwQw3Y2nflR8xyq4B4yOBiv/AMM+/DHGP+EZ/wDJ+6/+OUAfC920GnraW1xo0kGq2jsLoXLuFmGcqGiIBVhnBw2CAvAO4tlymSQmaTexZjl25ye/Nfff/DPnww/6Fn/yfuv/AI5R/wAM+fDD/oWf/J+6/wDjlAHwNBbTXG/7PFJKY0Mj+Wpbao6scdAPWrX263N1clrLNk/nGC1859tuzjCsDnJK4Xr97aM196r8BfhsqoqeGwm1WUMl9cqxDDBBIkycgkc9jiof+GfPhh/0LP8A5P3X/wAcoA+B7ea4ijnW3klRJI9kwjJAZNwOGx1G4LweMgUhlXyFRE2PyHcMfnGQQCPbFffX/DPvwxxj/hGf/J+6/wDjlOf4AfDN5Hd/DZd3JLM2oXRJJ6nmTrQB8Bi5mXz9kjRicbZVj+RXXcG2kDjG5VOOmQPSogCc47c19/f8M+fDD/oWf/J+6/8AjlSxfAT4bRRyJF4ddEkGHUajdAMPQ/veaAPgN5ozaJCLaESKxJnBfew9CC23H0ANb1l458R2VpDa2+pMtvFB9mCGJGDR/NhWyuWxuIG7OBgDAAA+20/Z++GKOrDwwMqcjN9ckfkZOa6HxP8ADHwZ4ns7K11jw9ZyW9kNtukG638pcY2jyyvGAOOnA9KAPz81DXrnxT4lhv8Axnqt/dLI6rPcACWVIs5IRWIHGThcgc1jTJIsaMUlSByWi3ZwRnBIPQ9MEj0r78j+AHwyjJK+GFOf717ct/OSp0+Bfw6Sy+xjw+5tPM83yW1C6ZA+ANwUyYBwAM+gxQB+e1FfoA37P3wxZiT4YGT6X1yP/alLH+z/APDKNwy+GFJHPzX1yw/IyUAfAUriQhjvMhyZGZs7myeenHGPXnJ74DSxYkscknJJ6mvv9v2f/hk23PhhRgYGL65HfP8Az096b/wz58MP+hZ/8n7r/wCOUAfATMWxuJOBgZ9K9/8A2Kzn4qapgAf8SWXp/wBd4K+gW+AHwybr4YXoF4vbkdP+2n61u+Cvhb4O8EarLqXhjR/sN7LCbd5PtU0uYyysRh3I6qvOM8UAdrRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode echocardiogram in chronic obstructive pulmonary disease. Pulsus paradoxus can be seen on the arterial pressure tracing superimposed on the image of the interventricular septum. Respiration causes septal motion comparable to that seen in cardiac tamponade.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Settle HP Jr, Engel PJ, Fowler NO, et al, Circulation 1980; 62:1297.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9910=[""].join("\n");
var outline_f9_43_9910=null;
var title_f9_43_9911="Biochemical mechanisms involved in blood-hemodialysis membrane interactions";
var content_f9_43_9911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biochemical mechanisms involved in blood-hemodialysis membrane interactions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9911/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9911/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9911/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9911/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9911/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9911/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/43/9911/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contact of blood with dialysis membranes elicits an organized inflammatory response that involves the activation of the body's defense against \"non-self.\" A biocompatible membrane (BCM) has traditionally been defined as \"one that elicits the least amount of inflammatory response in patients exposed to it\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/1\">",
"     1",
"    </a>",
"    ]. It has been suggested, however, that \"adsorption\" (ie, binding) of low molecular weight proteins or peptides on certain types of dialysis membranes represents an additional mechanism of clearance during dialysis and may also be important in defining the biocompatibility of the membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the pathways activated during the interaction of blood with biomaterials and the contribution of adsorption to modifying the inflammatory response resulting from this interaction. The known interactions between blood and the new hemodialysis membranes will be emphasized, with only limited attention to the effect of reuse. Because hemodialysis is a repetitive procedure, minor reactions induced by the membrane at each treatment can eventually lead to adverse long-term clinical sequelae. The acute and chronic clinical sequelae of blood-membrane interactions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the broadest sense, all aspects of the dialysis treatment affect biocompatibility. These include dialysate composition and temperature, the",
"    <span class=\"nowrap\">",
"     permeability/porosity",
"    </span>",
"    of the dialysis membrane, the type of clearance (diffuse or convective), the initial sterilant (eg, ethylene oxide), reuse procedure and sterilant (formaldehyde, hypochlorite, peroxyacetic",
"    <span class=\"nowrap\">",
"     acid/",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"      hydrogen peroxide",
"     </a>",
"     ),",
"    </span>",
"    and residual materials from the manufacturing process. However, it is the biocompatibility of the membrane itself which is most important and which has been most closely studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPOSITION OF DIALYSIS MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis membranes can be classified into multiple groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cellulosic",
"     </li>",
"     <li>",
"      Derivatized cellulose",
"     </li>",
"     <li>",
"      Synthetic polymers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative popularity of the different dialysis membranes has changed over time. Previously, cellulosic membranes were the most commonly used membranes. According to the United States Renal Data Systems (USRDS) 1995 Annual Data Report, the distribution of dialyzer membranes used in the United States in 1990 and 1991 was 61 percent cellulosic; 18 percent semi-synthetic (derivatized cellulose, mostly triacetate and Hemophane&reg;); and 19 percent synthetic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/4\">",
"     4",
"    </a>",
"    ]. By comparison, in the USRDS 2003 Annual Data Report, approximately 80 and 20 percent units in 1997 were using synthetic and cellulose membranes, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cellulosic membranes are made up of a sequence of repetitive polysaccharide units containing hydroxyl groups, similar to bacterial cell walls. Cellulose acetate is a modification of this membrane, in which 80 percent of the hydroxyl groups are replaced by acetate radicals. Another derivatized cellulose, Hemophane&reg;, has diethylaminoethyl (DEAE) radicals substituting for one percent of the hydroxyl groups.",
"   </p>",
"   <p>",
"    The synthetic polymers are further grouped as \"hydrophilic\"",
"    <span class=\"nowrap\">",
"     (polyether/polycarbonate)",
"    </span>",
"    or \"hydrophobic.\" The hydrophobic membranes are generally apolar, have a low energy of interaction with water, adsorb proteins, are more porous, and have high ultrafiltration coefficients. Hydrophobic membranes include polyacrylonitrile (PAN),",
"    <span class=\"nowrap\">",
"     PAN/AN69",
"    </span>",
"    membrane (copolymer of acrylonitrile and methallyl sulfonate), polysulfone (PS), and polymethylmethacrylate (PMMA) membranes.",
"   </p>",
"   <p>",
"    The side group modifications on derivatized cellulosic membranes and the high adsorptive capacity of synthetic membranes generally lead to a decrease in the intensity of blood membrane interactions. As an example, the PAN membrane can vigorously activate the complement system; however, it also has a high adsorptive capacity for complement, resulting in a low net level of complement activation products reaching the systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BLOOD-MEMBRANE INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When blood encounters the hemodialysis membrane, several reactions are triggered including the complement cascade, the coagulation cascade, and the contact-phase reaction. In addition to these protein-mediated pathways, cellular mechanisms can also be activated during hemodialysis due to direct contact of cells with the membrane and to byproducts of complement activation. These pathways are often interrelated and the activation of one system leads to the participation of the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complement activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement activation proceeds via the alternate pathway during hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/6\">",
"     6",
"    </a>",
"    ]. New cuprophane membranes activate complement to the greatest degree [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/7\">",
"     7",
"    </a>",
"    ]. The hydroxyl group on the surface of the cuprophane membrane is thought to promote the deposition of C3b and the association of C3b with factor B; this is followed by the activation of factor B by factor D, eventually resulting in formation of the C3 convertase C3bBb and the C5 convertase C(3b)nBb.",
"   </p>",
"   <p>",
"    There are several sequelae of complement activation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Release of anaphylatoxins (C3a and C5a)",
"     </li>",
"     <li>",
"      Formation of the membrane attack complex (C5b-9)",
"     </li>",
"     <li>",
"      Activation of neutrophils and monocytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    C3a and C5a are potent, biologically active agents capable of producing intense vascular smooth muscle contraction, increased vascular permeability, and the release of histamines from mast cells.",
"   </p>",
"   <p>",
"    Substitution of as little as 1 percent of the hydroxyl ions by DEAE residues (Hemophane&reg;) results in significant attenuation of complement activation. However, other membranes, such as PAN, appear to activate complement locally but do not contain hydroxyl moieties.",
"   </p>",
"   <p>",
"    An alternate hypothesis for defining the complement activation potential of biomaterials has been proposed. Instead of defining an activating biomaterial as one that favors the deposition of C3b and the subsequent initiation of the positive feedback loop by C3bBb, the new hypothesis emphasizes the important inhibitory role of factor H. Discrimination between activating and nonactivating biomaterials depends upon the relative capacity of the surface to bind factor B or factor H [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A membrane that promotes preferential binding of factor H (leading to inactivation of C3b and termination of propagation of the complement cascade) and that does not favor the binding of factor B has a low capacity to activate complement.",
"     </li>",
"     <li>",
"      Cellulose membranes, on the other hand, have low affinity for factor H, an abundance of hydroxyl radicals, and little or no capacity to absorb anaphylatoxin (C3a, C5a). They are therefore associated with the highest levels of complement activation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Activation of complement is maximum at 15 minutes and lasts up to 90 minutes after the initiation of hemodialysis with new cellulose-derived membranes. The rate of complement activation decreases as dialysis proceeds. The mechanisms for this decrease have not been well defined, but coating of the membrane with protein films is thought to be important. These films consist of fibrin, albumin, C3 fragments, particularly C3b (covalently-bound) and C3c, C3d (non-covalently bound).",
"   </p>",
"   <p>",
"    For the same reasons, reused cellulose has a low complement activating capacity. It should be noted, however, that reuse techniques which employ hypochlorite (in addition to formalin) remove the membrane coated protein, therefore abrogating the potential benefits of reuse. On the other hand, reuse with a mixture of peroxyacetic",
"    <span class=\"nowrap\">",
"     acid/",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"      hydrogen peroxide",
"     </a>",
"    </span>",
"    allows the surface of the membrane to remain coated with protein, improving the membrane biocompatibility with repeated use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7096?source=see_link\">",
"     \"Reuse of dialyzers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients dialyzed with some high-flux membranes may have lower serum levels of factor D because of enhanced clearance due its relatively small size. This feature of certain synthetic high-flux membranes may therefore contribute to their biocompatibility. Thus, although both the low and high flux configurations of polysulfone are manufactured with the same membrane (but different manufacturing process), the overall complement activating capacity of low flux polysulfone is much higher than that of the high flux membrane, particularly when assessed in chronic dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Importance of factor D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor D is the essential, rate-limiting enzyme of the alternate pathway of complement activation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/2\">",
"     2",
"    </a>",
"    ]. Its molecular weight is 23 kD, and its plasma concentration is increased approximately tenfold in patients with end-stage renal disease due to reduced renal excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/10\">",
"     10",
"    </a>",
"    ]. The high level of functionally active factor D is directly responsible for enhanced activation of the alternate pathway in the plasma of these patients, a problem that can be enhanced by many dialysis membranes.",
"   </p>",
"   <p>",
"    In vitro and in vivo studies using specific blocking antibodies against factor D have shown that blockade of factor D function impairs alternate pathway activation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/11\">",
"     11",
"    </a>",
"    ]. It is therefore possible that adsorption of factor D onto dialysis membranes could inhibit complement activation. Both",
"    <span class=\"nowrap\">",
"     PAN/AN69",
"    </span>",
"    and PMMA membranes remove large amounts of factor D due primarily to adsorption. Circulating factor D levels are reduced at the end of a regular hemodialysis session, the degree of which is membrane-dependent &mdash; 80 percent with",
"    <span class=\"nowrap\">",
"     PAN/AN69,",
"    </span>",
"    50 percent with PMMA, and less than 10 percent with cellulose acetate; adsorption accounts for 98 percent and 85 percent of factor D removal by PAN and PMMA, while no adsorption occurs on cellulose membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Importance of terminal complement complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of the terminal complement complex (C5b-9, also called the membrane attack complex) may have been underappreciated in the past. Kinetic studies of TCC generation suggest ongoing generation throughout a dialysis session, in contrast to the transient release of complement-derived anaphylatoxins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/14\">",
"     14",
"    </a>",
"    ]. One potential complication of TCC generation is amplification of non-complement-dependent cell activation through L-fucose-dependent steps [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/15\">",
"     15",
"    </a>",
"    ]. L-fucose, present in the cuprophane membrane surfaces, provides the signal to activate mononuclear cells in contact with the membrane. Using transcription of beta-2 microglobulin as an index of cell activation, induction of beta-2 microglobulin mRNA in mononuclear cells by contact with cuprophane is increased further in the combined presence of cuprophane and serum but blunted in the presence of serum deficient in C8, suggesting that the costimulatory effect is due to TCC.",
"   </p>",
"   <p>",
"    The TCC has also been implicated in the rapid decline in residual renal function in patients initiating hemodialysis and in the decreased half-life of red cells in patients dialyzed with bioincompatible membranes such as cuprophane. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Contact pathway activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contact pathway is activated via Hageman factor (factor XII). Negatively charged surfaces are potent activators of this pathway. PAN, with a negative charge of -153.9, induces a greater degree of activation of this pathway than the neutral cuprophane membranes. It is thought that the negative surface charge induces a conformational change of factor XII which promotes interaction between factor XII and prekallikrein, which is facilitated by surface-bound high molecular weight kininogen (HMWK). Once activated, kallikrein is potent in liberating bradykinin from HMWK [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This sequence probably explains the high frequency of anaphylactoid reactions seen when PAN membranes are used in conjunction with an angiotensin converting enzyme (ACE) inhibitors. ACE is also a kininase; thus its inhibition can lead to persistence of kinins activated by the PAN membrane. Support for this hypothesis is provided by the finding that administration of a bradykinin B2 receptor antagonist prevents this reaction in sheep dialyzed with a AN69 membrane and treated with an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coagulation pathway activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coagulation cascade is activated rapidly by surfaces of all membranes. During hemodialysis, this cascade is purposely blunted by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . There is little information on the relative degree of activation of this pathway by different membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Activation of cellular components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils, monocytes, lymphocytes, red cells, and platelets are all influenced by contact with the hemodialysis membrane. Activation of neutrophils leads to upregulation of adhesion receptors, release of proteinases and other intracellular enzymes, reactive oxygen species, leukotrienes, and platelet activating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. Activation of monocytes leads to production of monokines, such as interleukin-1 (IL-1) and tumor necrosis factor. Activation of platelets leads to release of thromboxanes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. These factors may be important determinants of the consequences of bioincompatibility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Properties intrinsic to the cuprophane membrane may directly cause cell activation (eg, synthesis of interleukin-1 mRNA by monocytes); however, it is primarily complement activation products (C5a and C5b-9) that greatly enhance the synthesis of mRNA for these cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/14,23\">",
"     14,23",
"    </a>",
"    ]. Several observations support the dominant role of complement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cuprophane membranes, which induce the strongest complement activation, are also associated with the highest cytokine induction [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blocking C5a reduces the increase in IL-1b mRNA expression by peripheral blood mononuclear cells (PBMC) during hemodialysis with cuprophane membranes by more than 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It has been proposed that endotoxin in the dialysate may also contribute to cytokine release. However, although endotoxin is a potent stimulus for cytokine release, there is little evidence that endotoxin can cross intact dialysis membranes in vivo. Thus, increases in cytokine levels during in-vivo dialysis are membrane dependent. In one study analyzing the production of tumor necrosis factor-alpha by cuprophane membranes, no cytokine production could be attributed to the presence of endotoxin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/25\">",
"       25",
"      </a>",
"      ]. Furthermore, TNF-alpha levels did not increase with the use of biocompatible membranes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interleukin-1 has a variety of actions that could explain some of the signs and symptoms associated with hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intradialytic fever (through the production of prostaglandin E2)",
"     </li>",
"     <li>",
"      Central nervous system symptoms such as headache and lassitude, also due to generation of PGE2 generated by IL-1",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Increased tissue catabolism",
"     </li>",
"     <li>",
"      Hypotension (through the production of prostacyclin)",
"     </li>",
"     <li>",
"      Increased susceptibility to infection, as chronic activation of T cells by IL-1 can lead to subnormal T cell responses to subsequent stimuli",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors other than IL-1 can also contribute to the increase in risk of infection associated with maintenance hemodialysis with bioincompatible membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/3,26-28\">",
"     3,26-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ability of neutrophils activated by the membrane to respond to a secondary stimulus is significantly abrogated [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Monocytes harvested from hemodialysis patients dialyzed with cellulosic membranes are chronically activated; this may be responsible for their decreased ability to respond to stimuli such as endotoxin and phytohemagglutinin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ability of peripheral blood mononuclear cells to express high-affinity IL-2 receptors and the activity of natural killer cells (NKC) are reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although red blood cell survival is significantly reduced in dialysis patients, this abnormality has not been directly related to the biocompatibility of the dialysis membrane. However, complement activation, particularly the release of C5b-9, may induce red cell membrane fragmentation and hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, platelet activation may be partly dependent upon the biocompatibility of the membrane. The exact pathophysiology of this phenomenon is unclear. However, as with red cells, C5b-9 can induce sublytic damage in platelets. It is also possible that platelets are activated by the release of platelet activating factor from activated neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275385986\">",
"    <span class=\"h2\">",
"     Thrombocytopenia and electron-beam sterilized membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe thrombocytopenia has been reported among patients dialyzed against electron-beam sterilized hemodialysis membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9911/abstract/33\">",
"     33",
"    </a>",
"    ]. Subsequent to the identification of an index patient, a retrospective multivariate analysis of 2131 hemodialysis patients from two Canadian provinces, demonstrated an increased risk of thrombocytopenia associated with the use of electron-beam sterilized membranes (odds ratio 2.52, 95% CI 1.2&ndash;5.29). Following the cessation of electron-beam sterilization, the percentage of patients who developed postdialysis thrombocytopenia decreased from 7.2 to 2.1 percent in British Columbia, and from 7.3 to 1.6 percent in Alberta. The mechanism underlying this association is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377501050\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The contact of blood with dialysis membranes elicits an organized inflammatory response. A biocompatible membrane (BCM) is defined as one that elicits the least amount of inflammatory response. Other aspects of the dialysis treatment that affect biocompatibility include dialysate composition and temperature, the",
"      <span class=\"nowrap\">",
"       permeability/porosity",
"      </span>",
"      of the dialysis membrane, the type of clearance (diffuse or convective), the initial sterilant, reuse procedure and sterilant, and residual materials from the manufacturing process. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialysis membranes can be classified into three groups including cellulosic, derivatized cellulose, and synthetic polymers. The side group modifications on derivatized cellulosic membranes and the high adsorptive capacity of synthetic membranes lead to a decrease in the intensity of blood membrane interactions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Composition of dialysis membranes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several reactions are triggered when blood encounters the hemodialysis membrane. Such reactions include the complement cascade, the coagulation cascade, and the contact-phase reaction. Cellular mechanisms can also be activated during hemodialysis due to direct contact of cells with the membrane and to byproducts of complement activation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Blood-membrane interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sequelae of complement activation include the release of anaphylatoxins (C3a and C5a), the formation of the membrane attack complex (C5b-9), and activation of neutrophils and monocytes, which causes intense vascular smooth muscle contraction, increased vascular permeability, and the release of histamines from mast cells. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Complement activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The contact pathway is activated by negatively charged surfaces such as the PAN membrane, possibly by inducing a conformational change of factor XII which promotes interaction between factor XII and prekallikrein, resulting in the release of bradykinin. This may explain the high frequency of anaphylactoid reactions seen when PAN membranes are used in conjunction with an angiotensin converting enzyme (ACE) inhibitors. The inhibition of ACE may lead to persistence of PAN membrane-activated kinins. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Contact pathway activation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The coagulation cascade is activated rapidly by surfaces of all membranes. During hemodialysis, this cascade is purposely blunted by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Coagulation pathway activation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutrophils, monocytes, lymphocytes, red cells, and platelets are all activated by contact with the hemodialysis membrane resulting in upregulation of adhesion receptors, release of proteinases and other intracellular enzymes, reactive oxygen species, leukotrienes, platelet activating factor, interleukin-1 (IL-1), tumor necrosis factor and to release of thromboxanes. These factors may be important determinants of the consequences of bioincompatibility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"       \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H9\">",
"       'Activation of cellular components'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17537100\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Nuhad Ismail, MD, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/1\">",
"      Hakim RM. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/2\">",
"      Pascual M, Tolkoff-Rubin N, Schifferli JA. Is adsorption an important characteristic of dialysis membranes? Kidney Int 1996; 49:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/3\">",
"      Bour&eacute; T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant 2004; 19:293.",
"     </a>",
"    </li>",
"    <li>",
"     United States Renal Data System. USRDS 1995 Annual Data Report. US Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, August 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/5\">",
"      United States Renal Data System. USRDS 2003 Annual Data Report. US Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2004; 41 (Suppl 2):S187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/6\">",
"      Hakim, RM. Complement activation by biomaterials. Cardiovasc Pathol 1993; 2:187S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/7\">",
"      Chenoweth DE. Complement activation in extracorporeal circuits. Ann N Y Acad Sci 1987; 516:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/8\">",
"      Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A 1990; 87:3982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/9\">",
"      Kuwahara T, Markert M, Wauters JP. Biocompatibility aspects of dialyzer reprocessing: a comparison of 3 re-use methods and 3 membranes. Clin Nephrol 1989; 32:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/10\">",
"      Pascual M, Steiger G, Estreicher J, et al. Metabolism of complement factor D in renal failure. Kidney Int 1988; 34:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/11\">",
"      Pascual M, Catana E, White T, et al. Inhibition of complement alternative pathway in mice with Fab antibody to recombinant adipsin/factor D. Eur J Immunol 1993; 23:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/12\">",
"      Pascual M, Schifferli JA. Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int 1993; 43:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/13\">",
"      Pascual M, Schifferli JA, Pannatier JG, Wauters JP. Removal of complement factor D by adsorption on polymethylmethacrylate dialysis membranes. Nephrol Dial Transplant 1993; 8:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/14\">",
"      Deppisch R, Schmitt V, Bommer J, et al. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 1990; 37:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/15\">",
"      Deppisch R, Ritz E, H&auml;nsch GM, et al. Bioincompatibility--perspectives in 1993. Kidney Int Suppl 1994; 44:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/16\">",
"      Thomaneck U, Vienken J, Waldschl&auml;ger U, et al. Detection of charges and their distribution on dialysis membranes with cationic/anionic dyes using confocal laser scanning microscopy. Int J Artif Organs 1991; 14:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/17\">",
"      Schulman G, Hakim R, Arias R, et al. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol 1993; 3:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/18\">",
"      Krieter DH, Grude M, Lemke HD, et al. Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin. Kidney Int 1998; 53:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/19\">",
"      Wu CC, Chen JS, Wu WM, et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005; 20:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/20\">",
"      Arnaout, MA, Hakim, RM, Todd, RF, et al. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 1985; 312:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/21\">",
"      Strasser T, Schiffl H. Generation of leukotriene B4 by hemodialyzer membranes: a novel index of biocompatibility. Klin Wochenschr 1991; 69:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/22\">",
"      Dinarello CA. Cytokines: agents provocateurs in hemodialysis? Kidney Int 1992; 41:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/23\">",
"      Cheung AK. Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990; 1:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/24\">",
"      Schindler R, Linnenweber S, Schulze M, et al. Gene expression of interleukin-1 beta during hemodialysis. Kidney Int 1993; 43:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/25\">",
"      Canivet E, Lavaud S, Wong T, et al. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/26\">",
"      Himmelfarb J, Lazarus JM, Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991; 17:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/27\">",
"      Zaoui P, Green W, Hakim RM. Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 1991; 39:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/28\">",
"      Zaoui P, Hakim RM. Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane. Kidney Int 1993; 43:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/29\">",
"      Bariety J, Hinglais N, Bhakdi S, et al. Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex. Clin Exp Immunol 1989; 75:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/30\">",
"      Zalman LS, Wood LM, M&uuml;ller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A 1986; 83:6975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/31\">",
"      Himmelfarb, J, Lazarus, J., Hakim, RM. Increased expression of glycoprotein GP IIb/IIIa detected by flow cytometry on platelets during hemodialysis (abstract). Kidney Int 1987; 31:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/32\">",
"      Hornych A, R&eacute;my P, Luong N, et al. Biocompatibility of haemodialysis membranes: haemodialysis-related leukotriene B4 and C4 generation. France. Nephron 1996; 74:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9911/abstract/33\">",
"      Kiaii M, Djurdjev O, Farah M, et al. Use of electron-beam sterilized hemodialysis membranes and risk of thrombocytopenia. JAMA 2011; 306:1679.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1868 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9911=[""].join("\n");
var outline_f9_43_9911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1377501050\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPOSITION OF DIALYSIS MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BLOOD-MEMBRANE INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complement activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Importance of factor D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Importance of terminal complement complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Contact pathway activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coagulation pathway activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Activation of cellular components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H275385986\">",
"      Thrombocytopenia and electron-beam sterilized membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1377501050\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17537100\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=related_link\">",
"      Clinical consequences of hemodialysis membrane biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7096?source=related_link\">",
"      Reuse of dialyzers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_43_9912="Prevention and treatment of viral gastroenteritis in children";
var content_f9_43_9912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of viral gastroenteritis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9912/contributors\">",
"     David O Matson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9912/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9912/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9912/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/43/9912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenteritis ranks with respiratory tract infection as the most common infectious disease syndrome of humans. Approximately 5 billion episodes of diarrhea occur worldwide annually, accounting for 15 to 30 percent of all deaths in some countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial and parasitic gastrointestinal (GI) infections have decreased in frequency as a result of improvements in public health infrastructure from the treatment, piping, and proper delivery of drinking water and disposal of sewage; however, viral gastroenteritis has not declined in a comparable fashion. Viral gastroenteritis usually is treated with supportive measures, also in contrast to bacterial or parasitic infections.",
"   </p>",
"   <p>",
"    The prevention and treatment of viral gastroenteritis in children will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of this infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures can limit the number of episodes of viral gastroenteritis in the community, the home, and institutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic infections probably play an important role in the spread of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Virus excretion at levels below detection by conventional assays is well established for enteric viruses. In addition, virus excretion can begin before symptoms occur and persist after symptoms resolve. This combination of factors often obscures the source of exposure in individual cases or outbreaks, and preventive measures to reduce contact with infected persons are at best partially effective.",
"   </p>",
"   <p>",
"    The most successful preventive measures for child care situations and hospitals include education of caregivers about appropriate hygienic measures, cohorting of children, and isolation of ill children. No safe time for discontinuation of cohorting or isolation after cessation of symptoms in hospitalized children has been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Handwashing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Handwashing with soap by parent and child, especially after diaper changes, may decrease the spread of the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. A large study in Pakistan, where most pediatric diarrhea is of bacterial or parasitic cause, evaluated the effect of an intensive handwashing program on the incidence of diarrhea of all causes in children younger than 15 years, and especially in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/3\">",
"     3",
"    </a>",
"    ]. The study took place in low-income neighborhoods in which diarrhea is the leading cause of death in children. The design included field workers visiting the intervention households weekly for one year and providing the households with plain soap or antibacterial soap containing triclocarban; households in 11 neighborhoods without the intervention served as controls.",
"   </p>",
"   <p>",
"    Children in the plain soap households had a significant 53 percent reduction in the incidence of diarrhea (1.9 versus 4.1 per 100 person-weeks at risk), and infants in these households had 39 percent fewer days of diarrhea. The benefits were independent of nutritional status and were similar with antibacterial soap. The latter finding was not surprising, since triclocarban is a bacteriostatic agent that inhibits the growth of some gram-positive bacteria but is not effective against viruses, gram-negative bacteria, or parasites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Diaper changing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaper changing areas should be separate from food preparation areas. Diapers should be disposed of directly in the changing area and put in occlusive bags before moving outside the home. A wipe-down fluid for the changing area should be used; a reasonable choice is diluted household bleach or 70 percent alcohol (for rotaviruses), prepared in a spray bottle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Water purification",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developing countries, disinfection of water obtained from unsafe water sources is an important means of prevention of gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/6\">",
"     6",
"    </a>",
"    ]. Methods of disinfection include boiling water for 10 minutes or addition of chlorine-containing tablets or solutions. Application of these interventions may be limited by cost or acceptability [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/7\">",
"     7",
"    </a>",
"    ]. Solar disinfection of water has been shown to decrease the bacterial count in water and to decrease diarrheal morbidity in Africa and India [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Solar disinfection can be performed in clear one-liter polyethylene terephthalate bottles that have the bottom one-half painted black. The bottles are filled with water and placed for at least 24 hours in a location that receives maximum direct sunlight [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral gastroenteritis results from mucosal exposure and infection. As for most viral illnesses, the most effective preventive measure would be vaccination.",
"   </p>",
"   <p>",
"    Challenges in developing vaccines to prevent viral gastroenteritis include the antigenic and genetic diversity of the etiologic viruses and the need to establish vaccine-induced mucosal immunity, which is partially efficacious against rechallenge. This was illustrated in a natural history study of 200 Mexican infants who were monitored from birth to two years of age with weekly home visits and stool collections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/12\">",
"     12",
"    </a>",
"    ]. Diarrheal episodes and the risk of acquiring new rotavirus infections decreased with successive rotavirus infections. The efficacy of natural, acquired immunity to rotavirus illness after one and two infections was 77 and 83 percent, respectively, and to serious rotavirus illness after one and two infections was 87 and 100 percent.",
"   </p>",
"   <p>",
"    Effective vaccines have been developed for rotavirus. Calicivirus vaccines are the only other candidate vaccine for the prevention of viral gastroenteritis in clinical studies. Rotavirus vaccines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=see_link\">",
"     \"Rotavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating treatment by telephone or in person, the clinician should review the factors that place a child with gastroenteritis at increased risk for hospitalization or death [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;18 months",
"     </li>",
"     <li>",
"      Poor socioeconomic level",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Immunodeficiency",
"     </li>",
"     <li>",
"      Underlying disease",
"     </li>",
"     <li>",
"      Poor capability of the parents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concern is underscored when the affected child has more than one of these risk factors. Clinically significant dehydration can occur within six hours of the onset of illness, especially during primary rotavirus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Telephone assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician's knowledge of the patient's family is crucial in assessing the validity of information reported by telephone. Specific historical factors that can be assessed over the telephone include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of illness",
"     </li>",
"     <li>",
"      Presence of blood or mucus in the stool",
"     </li>",
"     <li>",
"      Intake of fluids",
"     </li>",
"     <li>",
"      Activity of the child",
"     </li>",
"     <li>",
"      Number of diarrhea and vomiting episodes",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Moisture on the mucous membranes",
"     </li>",
"     <li>",
"      Urine frequency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The context of the call, such as season, patient age, and knowledge of recent travel, influences the interpretation of reported historical factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish acute, self-limited gastroenteritis episodes from more serious disorders by history and physical examination. Important historical factors for acute gastroenteritis, in addition to those listed under telephone assessment, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous episodes of gastroenteritis or dehydration",
"     </li>",
"     <li>",
"      Other infections",
"     </li>",
"     <li>",
"      Underlying diseases",
"     </li>",
"     <li>",
"      Ill contacts",
"     </li>",
"     <li>",
"      Exposures outside the home such as child care attendance, travel, water source, and foods",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician can assess level of consciousness, vital signs, signs of dehydration, activity, the abdomen, localizing pain, and meningeal signs via the physical examination. It is important to rule out other diseases, such as acute appendicitis, intussusception, bowel obstruction of other kinds, diabetic ketoacidosis, and bacterial sepsis or meningitis, all of which can be confused with acute gastroenteritis in the first day or two of symptoms. The evaluation of children with diarrhea is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     When to refer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to refer the patient to the emergency department or for hospitalization will be guided by the practitioner's experience with the treatment of severe dehydration and metabolic imbalance. There are no absolute indications for referral. Consultation may be warranted for any child with viral gastroenteritis who has multisystem compromise, does not respond to therapy as expected, has multiple episodes of illness, has an underlying immunodeficiency, or has an underlying disease complicating the treatment or course of the illness (",
"    <a class=\"graphic graphic_table graphicRef66399 \" href=\"UTD.htm?21/34/22059\">",
"     table 1",
"    </a>",
"    ). Situations in which referral may be warranted include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged (more than seven days) diarrhea with no response to usual treatment",
"     </li>",
"     <li>",
"      Severe dehydration associated with cardiovascular instability",
"     </li>",
"     <li>",
"      Hypernatremic dehydration requiring a longer period of rehydration",
"     </li>",
"     <li>",
"      Those potentially associated with severe complications, such as seizures, hypotonia, hematemesis or hematochezia, and anuria &gt;12 hours&rsquo; duration",
"     </li>",
"     <li>",
"      An immunocompromised host",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUPPORTIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral gastroenteritis is a frequent, but potentially severe, condition in children. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Fluid repletion and replacement of ongoing fluid losses are the goals of therapy. Change in body weight is an objective measure of response to therapy. The assessment and treatment of hypovolemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fluid repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of acute gastroenteritis is made, initial therapy is directed toward correcting fluid deficit and electrolyte imbalance. Fluid repletion guidelines for children with gastroenteritis by the American Academy of Pediatrics (AAP), Centers for Disease Control (CDC), and the World Health Organization are based upon the degree of hypovolemia. Severe hypovolemia requires rapid isotonic fluid resuscitation, whereas oral rehydration is the preferred therapy for mild to moderate hypovolemia. The clinical assessment, treatment of hypovolemia, and oral rehydration therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Refeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC and European Society for Paediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Paediatric Infectious Diseases recommend resumption of feeding (an age-appropriate diet) as soon as rehydration is complete; among children with diarrhea, a relatively unrestricted diet reduces stool output and the duration of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Breast-feeding during oral rehydration appears to reduce the number, volume, and duration of diarrheal stools [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/16\">",
"     16",
"    </a>",
"    ]. Full-strength cow's milk and other nonhuman milks usually can be tolerated without problems [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/17\">",
"     17",
"    </a>",
"    ]. Dilution and substitution of lactose-free formulas usually are unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Foods containing high levels of fats and simple sugars are less well tolerated than are those with complex carbohydrates, lean meats, yogurt, fruits, and vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. The BRAT (bananas, rice, applesauce, toast) diet has been commonly recommended, as has restriction to clear liquids (eg, juice); however, these diets are unnecessarily restrictive and provide suboptimal nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, viral gastroenteritis is an acute and self-limited disease that does not require pharmacologic therapy. Agents that are commercially available are discussed below; however, these agents are not recommended in the treatment of viral gastroenteritis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antimicrobial agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because viruses are the main cause of acute diarrhea, antibiotics should not be used unless diagnostic tests establish a treatable bacterial or parasitic agent as the cause of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14\">",
"     14",
"    </a>",
"    ]. The routine use of antimicrobial agents may lead to increased antimicrobial resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antidiarrheal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of antidiarrheal compounds are available. However, pharmacologic agents should not be used to treat acute diarrhea. There are no data to prove efficacy, and there is a potential for serious side effects, as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Antidiarrheal agents are classified based on their mechanism of action as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Antimotility drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opiate receptor agonists, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/31/8692?source=see_link\">",
"     loperamide",
"    </a>",
"    and diphenoxalate-atropine combinations reduce intestinal luminal motility. Such agonists have significant side effects, including lethargy, paralytic ileus, toxic megacolon, central nervous system depression, coma, and even death [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In addition, because they delay transit time, they have been shown to prolong the course of bacterial diarrheas, such as shigella and Escherichia coli 0157:H7 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Whether this also is true in viral gastroenteritis is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Antisecretory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antisecretory drugs include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/14/30948?source=see_link\">",
"     bismuth",
"    </a>",
"    subsalicylate and racecadotril (acetorphan). Bismuth subsalicylate requires frequent dosing with limited efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/26\">",
"     26",
"    </a>",
"    ] and has potential toxicity from salicylate absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/27\">",
"     27",
"    </a>",
"    ]. It should not be routinely used in the management of children with gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Racecadotril, an enkephalinase inhibitor with antisecretory actions, has shown promise as an adjunct to oral rehydration in controlled trials, demonstrating decreased stool output and duration of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14,28-31\">",
"     14,28-31",
"    </a>",
"    ], but the results are inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/32\">",
"     32",
"    </a>",
"    ]. Racecadotril is not approved by the FDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Adsorbents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adsorbents (eg, hydrated aluminomagnesium silicates such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/55/11122?source=see_link\">",
"     attapulgite",
"    </a>",
"    and smectite, and kaolin-pectin), have the potential to bind digestive mucus and toxins and reduce water loss [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/55/11122?source=see_link\">",
"     Attapulgite",
"    </a>",
"    is the most commonly used agent in this category. There is no evidence that it reduces the duration of diarrhea, stool frequency, or volume [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smectite is another agent is this category that is commonly used in several European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14\">",
"     14",
"    </a>",
"    ]. A systematic review of nine randomized controlled trials found that smectite reduced the duration of diarrhea by approximately one day [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the results must be interpreted with caution because most of the included trials had important limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence from high-quality trials that kaolin-pectin is effective in the treatment of acute gastroenteritis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    , are live microbes that have the potential to benefit the host by altering its intestinal flora. Systematic reviews of some probiotics have demonstrated a benefit in reducing stool output and the duration of diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antiemetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antiemetics in the treatment of acute gastroenteritis is controversial. A range of medications, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"     promethazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , has been used to control vomiting in children, with mixed success [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/36\">",
"     36",
"    </a>",
"    ]. These medications, like all phenothiazines, have the potential to cause extrapyramidal reactions, including dystonic reaction and oculogyric crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, promethazine is associated with an increased risk of respiratory depression. It should not be used in children younger than two years and should be used with caution in older children; concomitant administration of other drugs with respiratory depressant effects should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     Ondansetron",
"    </a>",
"    (Zofran), a 5-HT3 receptor antagonist, has been used extensively and successfully in the management of chemotherapy-induced vomiting in children and adults. Its use in gastroenteritis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link&amp;anchor=H19#H19\">",
"     \"Oral rehydration therapy\", section on 'Vomiting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute diarrhea can cause significant zinc loss in the stool. In experimental zinc deficiency, zinc supplementation improves transport of water and electrolytes across the intestinal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/39\">",
"     39",
"    </a>",
"    ]. In malnourished children with acute diarrhea, zinc supplementation decreases stool output and duration of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Zinc supplementation may be an effective and affordable aid in the management of acute diarrhea, particularly in malnourished children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/14,42\">",
"     14,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FAILURE TO RESPOND",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative diagnosis should be considered in patients who do not respond to appropriate fluid administration and measures designed to correct metabolic abnormalities. Alternative diagnoses may include myocardial dysfunction, hemolytic-uremic syndrome, bacterial sepsis, inborn errors of metabolism, and multisystem failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of diarrhea in children\", section on 'Causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are related to shock from decreased total body water, hypoxemia, and tissue acidosis. Death usually occurs when severe dehydration is not addressed by prompt rehydration. Myelinolysis and cerebral edema may result from rapid drops in serum sodium or solute concentration with rehydration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients can develop unremitting or fatal symptoms. Factors important for clearing viral infection include an intact cellular immune system and the presence of specific neutralizing antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/43\">",
"     43",
"    </a>",
"    ]. In special situations, administration of immunoglobulins enterically as milk, colostrum, or specific globulin preparations may facilitate clearance of the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/44\">",
"     44",
"    </a>",
"    ]. The specific antiviral antibody content in such preparations required for clinical efficacy is unknown. The efficacy of lactobacillus and similar organisms is under evaluation in this clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9912/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=see_link\">",
"       \"Patient information: Viral gastroenteritis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       \"Patient information: Diarrhea in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       \"Patient information: Giving your child over-the-counter medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/13/27858?source=see_link\">",
"       \"Patient information: Rotavirus infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventive measures for viral gastroenteritis in children, other than rotavirus vaccination, rely upon hand hygiene, proper diaper disposal, other infection control measures, and cohorting of sick children if hospitalized or in another institution. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent referral for diagnostic evaluation and therapy may be warranted in patients with diarrhea lasting more than seven days, severe dehydration associated with cardiovascular instability, hypernatremia, complications beyond the expected fever, vomiting, and diarrhea suggesting extra-intestinal involvement or another etiology (eg, hemolytic uremia syndrome), and immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'When to refer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mainstay of supportive therapy is assessment of volume status and administration of oral rehydration solutions. The latter can be purchased commercially or prepared at home, taking care to use clean water. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fluid repletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The child must be evaluated to ensure the volume status is correcting properly. Intravenous fluids should be administered if dehydration is severe or if the patient is unable to take oral solutions. Weight should be monitored and electrolytes assessed for more severe dehydration. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fluid repletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Refeeding an age-appropriate diet can begin once fluid deficits are corrected. Breastfeeding can continue during diarrhea. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Refeeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral gastroenteritis is usually an acute and self-limited disease that",
"      <strong>",
"       does not",
"      </strong>",
"      require pharmacologic therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications, when they occur, relate to shock and multisystem failure. These tend to occur if rehydration is not begun promptly or is inadequate. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author would like to thank Pablo Avenda&ntilde;o, MD, and Miguel L O'Ryan, MD, for discussing this work.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/1\">",
"      Pickering LK, Bartlett AV 3rd, Reves RR, Morrow A. Asymptomatic excretion of rotavirus before and after rotavirus diarrhea in children in day care centers. J Pediatr 1988; 112:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/2\">",
"      Matson DO, O'Ryan ML, Herrera I, et al. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993; 167:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/3\">",
"      Luby SP, Agboatwalla M, Painter J, et al. Effect of intensive handwashing promotion on childhood diarrhea in high-risk communities in Pakistan: a randomized controlled trial. JAMA 2004; 291:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/4\">",
"      Curtis V, Cairncross S. Effect of washing hands with soap on diarrhoea risk in the community: a systematic review. Lancet Infect Dis 2003; 3:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/5\">",
"      Aiello AE, Coulborn RM, Perez V, Larson EL. Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. Am J Public Health 2008; 98:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/6\">",
"      Clasen T, Roberts I, Rabie T, et al. Interventions to improve water quality for preventing diarrhoea. Cochrane Database Syst Rev 2006; :CD004794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/7\">",
"      Gilman RH, Skillicorn P. Boiling of drinking-water: can a fuel-scarce community afford it? Bull World Health Organ 1985; 63:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/8\">",
"      Conroy RM, Meegan ME, Joyce T, et al. Solar disinfection of water reduces diarrhoeal disease: an update. Arch Dis Child 1999; 81:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/9\">",
"      Conroy RM, Elmore-Meegan M, Joyce T, et al. Solar disinfection of drinking water and diarrhoea in Maasai children: a controlled field trial. Lancet 1996; 348:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/10\">",
"      Cunliffe NA, Bresee JS, Hart CA. Rotavirus vaccines: development, current issues and future prospects. J Infect 2002; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/11\">",
"      Rose A, Roy S, Abraham V, et al. Solar disinfection of water for diarrhoeal prevention in southern India. Arch Dis Child 2006; 91:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/12\">",
"      Vel&aacute;zquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/13\">",
"      Ho MS, Glass RI, Pinsky PF, et al. Diarrheal deaths in American children. Are they preventable? JAMA 1988; 260:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/14\">",
"      Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr 2008; 46 Suppl 2:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/15\">",
"      King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/16\">",
"      Khin MU, Tin U. Effect on clinical outcome of breast feeding during acute diarrhoea. Br Med J (Clin Res Ed) 1985; 290:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/17\">",
"      Alarcon P, Montoya R, Perez F, et al. Clinical trial of home available, mixed diets versus a lactose-free, soy-protein formula for the dietary management of acute childhood diarrhea. J Pediatr Gastroenterol Nutr 1991; 12:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/18\">",
"      Brown KH, Peerson JM, Fontaine O. Use of nonhuman milks in the dietary management of young children with acute diarrhea: a meta-analysis of clinical trials. Pediatrics 1994; 93:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/19\">",
"      Brown KH, Perez F, Gasta&ntilde;aduy AS. Clinical trial of modified whole milk, lactose-hydrolyzed whole milk, or cereal-milk mixtures for the dietary management of acute childhood diarrhea. J Pediatr Gastroenterol Nutr 1991; 12:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/20\">",
"      Rabbani GH, Teka T, Zaman B, et al. Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children. Gastroenterology 2001; 121:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/21\">",
"      Brown JW. Toxic megacolon associated with loperamide therapy. JAMA 1979; 241:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/22\">",
"      Curtis JA, Goel KM. Lomotil poisoning in children. Arch Dis Child 1979; 54:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/23\">",
"      Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Med 2007; 4:e98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/24\">",
"      DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/25\">",
"      Pickering LK, Obrig TG, Stapleton FB. Hemolytic-uremic syndrome and enterohemorrhagic Escherichia coli. Pediatr Infect Dis J 1994; 13:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/26\">",
"      Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, et al. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N Engl J Med 1993; 328:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/27\">",
"      Pickering LK, Feldman S, Ericsson CD, Cleary TG. Absorption of salicylate and bismuth from a bismuth subsalicylate--containing compound (Pepto-Bismol). J Pediatr 1981; 99:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/28\">",
"      Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000; 343:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/29\">",
"      C&eacute;zard JP, Duhamel JF, Meyer M, et al. Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology 2001; 120:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/30\">",
"      Cojocaru B, Bocquet N, Timsit S, et al. [Effect of racecadotril in the management of acute diarrhea in infants and children]. Arch Pediatr 2002; 9:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/31\">",
"      Szajewska H, Ruszczy��ski M, Chmielewska A, Wieczorek J. Systematic review: racecadotril in the treatment of acute diarrhoea in children. Aliment Pharmacol Ther 2007; 26:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/32\">",
"      Santos M, Mara&ntilde;&oacute;n R, Miguez C, et al. Use of racecadotril as outpatient treatment for acute gastroenteritis: a prospective, randomized, parallel study. J Pediatr 2009; 155:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/33\">",
"      Mor&eacute; J, B&eacute;nazet F, Fioramonti J, Droy-Lefaix MT. Effects of treatment with smectite on gastric and intestinal glycoproteins in the rat: a histochemical study. Histochem J 1987; 19:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/34\">",
"      Brouillard MY, Rateau JG. [Adsorption potency of 2 clays, smectite and kaolin on bacterial enterotoxins. In vitro study in cell culture and in the intestine of newborn mice]. Gastroenterol Clin Biol 1989; 13:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/35\">",
"      Szajewska H, Dziechciarz P, Mrukowicz J. Meta-analysis: Smectite in the treatment of acute infectious diarrhoea in children. Aliment Pharmacol Ther 2006; 23:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/36\">",
"      DeCamp LR, Byerley JS, Doshi N, Steiner MJ. Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis. Arch Pediatr Adolesc Med 2008; 162:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/37\">",
"      Carey MJ, Aitken ME. Diverse effects of antiemetics in children. N Z Med J 1994; 107:452.",
"     </a>",
"    </li>",
"    <li>",
"     Phenergan&reg; (promethazine HCl) Tablets and suppositories. Package insert. Wyeth Pharmaceuticals Inc, Philadelphia.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/39\">",
"      Ghishan FK. Transport of electrolytes, water, and glucose in zinc deficiency. J Pediatr Gastroenterol Nutr 1984; 3:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/40\">",
"      Roy SK, Tomkins AM, Akramuzzaman SM, et al. Randomised controlled trial of zinc supplementation in malnourished Bangladeshi children with acute diarrhoea. Arch Dis Child 1997; 77:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/41\">",
"      Sazawal S, Black RE, Bhan MK, et al. Zinc supplementation in young children with acute diarrhea in India. N Engl J Med 1995; 333:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/42\">",
"      Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev 2012; 6:CD005436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/43\">",
"      Dharakul T, Rott L, Greenberg HB. Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes. J Virol 1990; 64:4375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9912/abstract/44\">",
"      Davidson GP, Whyte PB, Daniels E, et al. Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet 1989; 2:709.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5992 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9912=[""].join("\n");
var outline_f9_43_9912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Handwashing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Diaper changing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Water purification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Telephone assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      When to refer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUPPORTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fluid repletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Refeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antimicrobial agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antidiarrheal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Antimotility drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Antisecretory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Adsorbents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antiemetic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Zinc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FAILURE TO RESPOND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ACKNOWLEDGMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/34/22059\" title=\"table 1\">",
"      Diarrhea referral indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=related_link\">",
"      Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/13/27858?source=related_link\">",
"      Patient information: Rotavirus infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=related_link\">",
"      Rotavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_43_9913="Management of twin-twin transfusion syndrome";
var content_f9_43_9913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of twin-twin transfusion syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9913/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9913/contributors\">",
"     Kenneth J Moise Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9913/contributors\">",
"     Anthony Johnson, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9913/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9913/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9913/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9913/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/43/9913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions for management of twin-twin transfusion syndrome (TTTS) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Expectant management",
"     </li>",
"     <li>",
"      Amnioreduction",
"     </li>",
"     <li>",
"      Septostomy",
"     </li>",
"     <li>",
"      Selective feticide",
"     </li>",
"     <li>",
"      Fetoscopic laser ablation of vascular anastomoses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fetoscopic laser ablation is generally considered the definitive treatment for severe (Quintero stage II or above) TTTS between 16 and 26 weeks of gestation.",
"   </p>",
"   <p>",
"    This topic will review interventions for management of TTTS and outcome. The pathogenesis, clinical manifestations, and diagnosis of TTTS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=see_link\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXPECTANT MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8405339\">",
"    <span class=\"h1\">",
"     STAGE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five studies that evaluated the frequency of progression from Quintero stage I disease reported progression rates ranging from 10 to 46 percent with a collective average of 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. However, in over half of the cases, either an amnioreduction (95 percent) or laser ablation (5 percent) was performed. In a small retrospective study, intervention was associated with an improvement in long-term neurodevelopmental outcome (neurodevelopmental impairment with laser therapy",
"    <span class=\"nowrap\">",
"     0/16",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     7/18",
"    </span>",
"    with conservative management), but not overall survival (survival with laser therapy",
"    <span class=\"nowrap\">",
"     30/40",
"    </span>",
"    [75 percent] versus",
"    <span class=\"nowrap\">",
"     52/60",
"    </span>",
"    [87 percent] with conservative management) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no good prospective data on the frequency of progression or outcome of well-defined stage I disease in the absence of any intervention. A consensus conference was held by the North American Fetal Therapy Network to evaluate the available information regarding management of Quintero Stage I TTTS. The scientific panel, who were not actively involved in TTTS clinical care or research, concluded that there is &ldquo;normative equipoise to justify the performance of randomized clinical trials to identify the optimal treatment strategy for mild TTTS&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8405325\">",
"    <span class=\"h2\">",
"     Stage II or more",
"    </span>",
"    &nbsp;&mdash;&nbsp;The background incidence of loss in untreated pregnancies with severe (Quintero stage II or above) TTTS is difficult to ascertain. A MEDLINE review identified 28 studies involving a total of 68 pregnancies with untreated TTTS between 1966 and 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/7\">",
"     7",
"    </a>",
"    ]. Overall perinatal survival was 30 percent and survival by gestational age at diagnosis was: &lt;24 weeks (30 percent), &lt;26 weeks (33 percent), and &lt;28 weeks (27 percent). Nine of the 12 survivors with follow-up were neurologically normal. These data, as well as data described below on the efficacy of intervention, support intervention in severe or progressive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8405332\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute or chronic deterioration of one of the fetuses is the major indication for intervention by preterm delivery. As an example, the recipient twin may develop hydrops fetalis or the donor twin may exhibit progressive fetal growth restriction with nonreassuring antepartum fetal testing.",
"   </p>",
"   <p>",
"    In the absence of acute or chronic deterioration of one of the fetuses, the following interventions have been used to treat severe or progressive TTTS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106993435\">",
"    <span class=\"h1\">",
"     FETOSCOPIC LASER ABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;First introduced by De Lia in 1990, laser ablation of placental anastomoses has gained widespread acceptance as the definitive treatment for severe TTTS between 16 and 26 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/8\">",
"     8",
"    </a>",
"    ]. The value of this procedure was illustrated in a randomized clinical trial that evaluated outcomes after laser ablation versus amnioreduction in 142 women with second trimester severe TTTS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/9\">",
"     9",
"    </a>",
"    ]. As compared with the amnioreduction group, the laser group had a significantly higher likelihood of the survival of at least one twin to 28 days of age (76 versus 56 percent) and at six months of age, a significantly lower incidence of cystic periventricular leukomalacia (6 versus 14 percent), and survivors were significantly more likely to be free of neurologic complications at six months of age (52 versus 31 percent).",
"   </p>",
"   <p>",
"    Subsequently, a meta-analysis of comparative studies found that compared with fetuses undergoing serial amnioreduction, fetuses undergoing laser ablation were twice as likely to survive and had an 80 percent reduction in neurologic morbidity (overall survival OR 2.04, 95% CI 1.52-2.76; neonatal death: OR 0.24, 95% CI 0.15-0.40; neurologic morbidity OR 0.20, 95% CI 0.12-0.33) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, a meta-analysis of three randomized trials reported laser coagulation of anastomotic vessels resulted in fewer double deaths (RR 0.32-0.61, depending on Quintero stage, three trials), fewer perinatal deaths (26 versus 44 percent, RR 0.59; 95% CI 0.40-0.87, one trial) and fewer neonatal deaths (8 versus 26 percent, RR 0.29; 95% CI 0.14-0.61, one trial) than pregnancies treated with amnioreduction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laser ablation in the United States is usually undertaken for Quintero stage II to IV TTTS between 16 and 26 weeks of gestation. This is in part due to the current FDA investigational device exemption for fetoscopes that limits their use to treatment of TTTS between 16 and 26 weeks of gestation. In addition, laser ablation in the late second trimester is subject to several technical limitations: fetal vernix in the amniotic fluid reduces optimal visualization; placental vessels are larger in caliber and more difficult to successfully coagulate; and greater in utero distances may not be easily traversed by current fetoscopes.",
"   </p>",
"   <p>",
"    Some European and Canadian centers perform laser before 17 and after 26 weeks of gestation. Preliminary studies have suggested that procedures performed at these earlier and later gestational ages can result in outcomes comparable to those performed at 17 to 26 weeks and better than amnioreduction performed after 26 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although laser therapy is usually reserved for Quintero stage II to IV TTTS, many centers also offer laser therapy for severe cases of stage I TTTS (polyhydramnios associated with debilitating maternal symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/5,15\">",
"     5,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\", section on 'Clinical manifestations and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although laser therapy is not available at all tertiary obstetrical centers, 19 centers in the United States offer this treatment (see",
"    <a class=\"external\" href=\"file://www.fetalhope.org/\">",
"     www.fetalhope.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106993484\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preprocedural ultrasound should identify the placental umbilical cord insertion sites. Proximate umbilical cord insertions (&lt;1 cm apart) is a relative contraindication to treatment with laser photocoagulation, as the proximity of the cord insertions may preclude a successful intervention. Management options in these situations may include expectant observation, amnioreduction and, in advanced disease (stages III to IV), selective reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/16\">",
"     16",
"    </a>",
"    ]. The patient should then undergo extensive counseling regarding the risks of the procedure, as well as the complications, as noted below.",
"   </p>",
"   <p>",
"    The laser coagulation is performed as an outpatient procedure under local anesthesia with intravenous sedation. Some centers use regional anesthesia; general anesthesia with endotracheal intubation may be required in select cases when there is respiratory difficulty from extreme polyhydramnios.",
"   </p>",
"   <p>",
"    The fetoscope is inserted through the maternal abdomen and into the recipient twin&rsquo;s amniotic sac at the location that provides the best access to the placental equatorial plate between the two cord insertions. Either percutaneously or through a small mini-laparotomy, a 2 to 3 mm diameter fetoscope is introduced into the amniotic cavity of the recipient twin under ultrasound guidance. The location of the dividing twin membrane between the two amniotic cavities at the placental interface and the placental insertions of the umbilical cords are visualized. Laser energy (20 to 40 watts from a diode or YAG laser) is delivered to the vessels through a 400 to 600 micron quartz fiber that is introduced through an operating channel in the fetoscope. A second channel allows for continuous irrigation to promote visualization. Ablation of an AV anastomosis is shown in the video (",
"    <a class=\"graphic graphic_movie graphicRef64395 \" href=\"UTD.htm?20/29/20958\">",
"     movie 1",
"    </a>",
"    ) and in a series of photographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67539 \" href=\"UTD.htm?18/36/19023\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80616 \" href=\"UTD.htm?33/7/33918\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56339 \" href=\"UTD.htm?2/39/2687\">",
"     image 2",
"    </a>",
"    ). At the conclusion of photocoagulation of the placental vessels, the fetoscope is removed and an amnioreduction is performed until the amniotic fluid volume appears normal by ultrasound assessment.",
"   </p>",
"   <p>",
"    Originally, non-selective ablation of all surface vessels on the placenta that crossed the dividing membrane was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/17\">",
"     17",
"    </a>",
"    ]. Quintero subsequently proposed a technique (selective laser photocoagulation [SLPCV]) to precisely identify the placental vascular anastomoses that are to be coagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/18\">",
"     18",
"    </a>",
"    ]. Survival of at least one fetus was superior with selective than with nonselective ablation (83 versus 61 percent in the initial series of 92 patients with 18 treated nonselectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/18\">",
"     18",
"    </a>",
"    ]; 93 versus 50 percent in a follow-up series of 314 patients with 4 treated nonselectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/19\">",
"     19",
"    </a>",
"    ]). The improved outcome was mainly due to a lower rate of dual demise after selective ablation (5.6 percent versus 22 percent with nonselective ablation) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sequential selective laser photocoagulation (SQLPCV) is a further refinement of this technique. The anastomotic vessels are first mapped, then arteriovenous (AV), venoarterial (VA), and finally, arterioarterial (AA) anastomoses are coagulated in sequential order. The type of anastomosis can be determined based on several features as they are visualized through the fetoscope. AV or VA connections appear as a single vessel originating from the donor or recipient; this vessel disappears into the placental mass and a second vessel in immediate proximity of the disappearing vessel can be traced leading back to the co-twin. The arterial component of the anastomosis is dark in color (deoxygenated blood), while the venous component is bright red (oxygenated blood). AA anastomoses appear as tortuous vessels that connect the twin circulations on the surface of the placenta.",
"   </p>",
"   <p>",
"    Sequential selective ablation has been associated with a 40 to 50 percent reduction in risk of intrauterine demise of the donor or recipient twin compared with selective ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Sequential selective ablation has also been associated with an almost doubling of the rate of dual perinatal survival. These results should be interpreted cautiously because patients who received the standard procedure had technical difficulties that prevented them from receiving the full sequential selective treatment, potentially biasing the results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the placenta is anterior and centrally located, entry into the uterus from an extreme lateral approach can result in puncture of the placental edge or the dilated adnexal vascular complex. Various innovative approaches have been undertaken to address this problem. Originally, a maternal laparotomy with exteriorization of the uterus and puncture of the posterior wall was utilized. More recently, specialized fetoscopes (approved by the FDA) have been developed that allow better visualization of the anterior placenta. One fetoscope, a semi-rigid instrument with zero degree optics, can be introduced through a malleable operator sheath that can be curved to approximately 30 degrees. A second fetoscope, fitted with a 30 degree rod lens, is used in conjunction with a pulley apparatus to displace the laser fiber anteriorly. Finally, in rare cases where percutaneous access is compromised due to the adnexal vasculature, a laparoscopic-assisted approach can be utilized. This method directs the fetoscope through the posterior-lateral uterine wall under direct visualization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are minimal data on the learning curve for performing laser therapy. One study from a single center in England indicated that optimal perinatal outcomes were not achieved until 61 procedures had been performed and after 3.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106993491\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106993498\">",
"    <span class=\"h4\">",
"     PROM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative complications after laser therapy are common. The most common serious complication of fetoscopic intervention is PPROM. The rates of PPROM within one and three weeks post-procedure are 7 and 17 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/24\">",
"     24",
"    </a>",
"    ]. Other complications include amniotic fluid leakage into the maternal peritoneal cavity (7 percent), vaginal bleeding (4 percent), abruption (2 percent), and chorioamnionitis (2 percent). An amniotic band-like syndrome has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/25\">",
"     25",
"    </a>",
"    ]. These complication rates are comparable to those of amnioreduction, with the exception of PPROM, which occurs more often after laser therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106993505\">",
"    <span class=\"h4\">",
"     TAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-laser placental injection studies have demonstrated patent anastomoses or residual anastomoses (which can be &lt;1 mm in diameter) in as many as one-third of cases, which may lead to persistent TTTS (14 percent) or a milder variant of reversed TTTS (2 to 13 percent), known as TAPS (twin anemia polycythemia sequence) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In post-laser TAPS, small arteriovenous anastomoses between the recipient and donor allow slow passage of red cells in a reverse manner so that the recipient twin becomes anemic and the donor twin becomes plethoric [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/27\">",
"     27",
"    </a>",
"    ]. The risk is greater in cases where there were few anastomoses and no artery to artery communications preprocedure. In approximately 25 percent of cases, post-laser TAPS can also result in an anemic donor and a plethoric recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measures for reducing the risk of residual anastomoses include more careful scrutinization of the placental margins (where the majority of residual anastomoses have been found) and dichorionization of the placental surface by drawing a laser coagulation line across the entire placental vascular equator, edge to edge after ablation of the placental vascular anastomoses (\"Solomon technique\").",
"   </p>",
"   <p>",
"    TAPS can be detected by discordance of serial peak systolic Doppler measurements of the fetal middle cerebral artery (&gt;1.5 MoM in the anemic donor, &lt;0.8-1.0 MoM in the plethoric recipient twin). The following criteria have been proposed for neonatal TAPS from acute feto-feto transfusion at the time of delivery: presence of an intertwin hemoglobin difference &ge;8.0",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    in conjunction with an intertwin reticulocyte ratio of &gt;1.7 (reticulocyte count of the donor twin divided by the reticulocyte count of the recipient twin) and a placental injection examination showing very small arterio-venous anastomoses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TAPS after laser ablation has been treated with repeat laser, fetal intravascular and intraperitoneal transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/30\">",
"     30",
"    </a>",
"    ], selective feticide, expectant management, and delivery. The optimal treatment has yet to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/27,30,31\">",
"     27,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106993512\">",
"    <span class=\"h2\">",
"     Prognostic indicators",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series of 466 patients from eight North American treatment centers, stepwise logistic regression showed that reversed end diastolic velocity in the umbilical artery after laser ablation was predictive of fetal death in the donor twin (OR 4.0, 95% CI 1.54-10.2), while fetal death in the recipient twin after laser therapy was predicted by the presence of hydrops (OR 3.7, 95% CI 1.1 - 12.7) and a reversed &lsquo;a&rsquo; wave in the ductus venosus (OR 2.39, 95% CI 1.27-4.51) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106993519\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study from two fetal therapy referral centers using a similar protocol for 682 consecutive women undergoing selective or sequential laser photocoagulation reported perinatal survival of at least one twin ranged from 88 to 92 percent and dual twin survival ranged from 59 to 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of studies evaluating neurologic outcome in pregnancies complicated by TTTS and treated with laser therapy reported the following outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of neurologic morbidity at birth was 6.1 percent",
"      <span class=\"nowrap\">",
"       (55/895),",
"      </span>",
"      with no significant differences between donors and recipients.",
"     </li>",
"     <li>",
"      The incidence of any degree of neurologic impairment at follow-up at 6 to 48 months of age was 11.1 percent",
"      <span class=\"nowrap\">",
"       (140/1255),",
"      </span>",
"      with no significant differences between donors and recipients or pregnancies with one versus two survivors.",
"     </li>",
"     <li>",
"      Cerebral palsy accounted for 39.7 percent",
"      <span class=\"nowrap\">",
"       (60/151)",
"      </span>",
"      of long-term abnormal neurological outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These risks are not significantly different from the baseline risks in monochorionic twins without TTTS or dichorionic twins matched for gestational age at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Thus, it appears that almost all of the risk of neurologic impairment in survivors is due to prematurity and prematurity-related complications, rather than a direct result of TTTS or laser therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/33,36,37\">",
"     33,36,37",
"    </a>",
"    ]. In contrast to dichorionic twins, cerebral injury in TTTs has a higher incidence of antenatal occurrence, 17 versus 52 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other long-term, follow-up studies of TTTS treated with laser therapy have included investigations of the renal and cardiovascular systems. Only a single study evaluated the long-term renal effects of TTTS treated with laser. Eighteen surviving twin pairs were followed to a median age of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/38\">",
"     38",
"    </a>",
"    ]. Various serum and urinary markers of renal function, as well as creatinine clearance, were compared between donor and recipient twins. No significant differences were detected. This study suggests that chronic hypovolemia in the donor results in vascular remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/39\">",
"     39",
"    </a>",
"    ] that may be prevented by laser ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/40\">",
"     40",
"    </a>",
"    ]. Laser therapy can also improve flow through the pulmonary valve of the recipient twin. However, pulmonary valve pathology may persist and require postnatal intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/41\">",
"     41",
"    </a>",
"    ]. One series of 51 recipient survivors of laser therapy observed that 8 percent had pulmonary stenosis at the time of birth, a 200-fold increase over the rate in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/42\">",
"     42",
"    </a>",
"    ]. One half of the cases required valvular balloon dilation for treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106993546\">",
"    <span class=\"h2\">",
"     Follow-up and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on which to base specific recommendations for follow-up testing after laser therapy. A 2012 systematic review reported the incidence of recurrent TTTS ranged from 0 to 16 percent, and was often managed by a repeat laser procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TAPS has been reported up to six weeks after laser therapy, and is potentially treatable. We have adopted a policy of weekly ultrasound surveillance for the first six weeks after laser therapy that includes measurement of the peak middle cerebral artery systolic velocity to detect fetal anemia. Thereafter, ultrasounds are performed every two weeks.",
"   </p>",
"   <p>",
"    Normalization of the amniotic fluid volume occurs by week 5 in the donor amniotic cavity and by week 8 in the recipient amniotic cavity in more than 95 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal growth is monitored for signs of intrauterine growth restriction, especially in the donor twin. Antenatal glucocorticoids to enhance fetal lung maturity are given if fetal growth discordance is detected and preterm delivery is likely. However, growth restricted donor twins often exhibit catch-up growth after laser ablation. One study reported the proportion of donor twins with growth restriction fell from 65 to 29 percent after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By 30 weeks of gestation, we perform twice weekly antenatal testing with biophysical profile scoring.",
"   </p>",
"   <p>",
"    Delivery is indicated for fetal compromise or poor serial growth. With a normal progression of fetal growth and reassuring tests of fetal well-being, delivery should probably be undertaken after 32 weeks and by 37 weeks of gestation due to the risk of unexplained fetal demise in late gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AMNIOREDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial amniocentesis to remove excess amniotic fluid in the recipient twin's amniotic cavity results in higher survival rates than expectant management. Amnioreduction reduces uterine overdistention, which is a risk factor for preterm labor and preterm premature rupture of the membranes (PPROM). It also decreases pressure inside the amniotic cavity and thus appears to improve uteroplacental perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical threshold to begin serial amnioreductions is subjective. Potential indications include relieving maternal symptoms of respiratory difficulty and possibly decreasing the risk of preterm delivery in women with frequent contractions or decreased cervical length. It is probably most useful for prolonging pregnancy in patients with mild TTTS who have already reached 26 weeks of gestation since, in the United States, the Food and Drug Administration (FDA) has not approved use of fetoscopes for treatment of TTTS in the third trimester.",
"   </p>",
"   <p>",
"    However, weekly ultrasound surveillance is probably a safer alternative to amnioreduction in the early stages of TTTS, as complications from the procedure may preclude subsequent successful, definitive treatment by placental laser photocoagulation (see below). These complications include unintentional perforation of the intervening membrane, amnion-chorion separation, intraamniotic bleeding, and PPROM. &nbsp;Laser coagulation is contraindicated in the presence of PPROM. Amnion-chorion separation is a major risk factor for development of PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even without PPROM, iatrogenic membrane damage significantly increases the difficulty of introducing the fetoscope for laser coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/51\">",
"     51",
"    </a>",
"    ], while bloody amniotic fluid impedes visualization; amnioexchange may be necessary in such cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of amnioreduction techniques have been described; there are no randomized trials evaluating whether one is safer and more effective than another. There is no consensus regarding how much fluid to remove, how rapidly to remove the fluid, use of tocolytic medications, or use of antibiotics.",
"   </p>",
"   <p>",
"    We begin by anesthetizing the skin with a long-acting local anesthetic (eg, bupivicaine). Under ultrasound guidance, a long 18-gauge spinal needle is introduced into the amniotic cavity with polyhydramnios, avoiding the placental edge, if possible. The placenta will be markedly thinned on ultrasound imaging because of the excessive amniotic fluid.",
"   </p>",
"   <p>",
"    Placing the needle as close to the midline of the uterus as possible with a slight angulation toward the maternal xiphoid will reduce the risk of needle displacement as the uterine size diminishes with drainage of amniotic fluid. The technique we prefer is to connect the needle to one end of the specialized tubing included in a disposable thoracocentesis tray (male to male ends). The other end of the tubing is connected to a short 18-gauge needle that is spiked into a disposable vacuum bottle. This set-up maintains a closed system, avoids excessive needle manipulation, and allows the rate of flow to be controlled with the rollerball valve in the line.",
"   </p>",
"   <p>",
"    Some experts recommend removing no more than 5 liters of amniotic fluid over about an hour [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/52\">",
"     52",
"    </a>",
"    ]. Decompression of the uterus with rapid removal of a large volume of fluid may cause placental abruption or fetal bradycardia; therefore, we suggest removing smaller volumes of fluid in severe TTTS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Amnioreduction Registry reported outcomes from the largest series of TTTS patients undergoing amnioreduction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/53\">",
"     53",
"    </a>",
"    ]. A total of 223 twin pregnancies from 20 fetal medicine units were diagnosed with TTTS prior to 28 weeks of gestation and treated with 760 amnioreductions. The major findings from this series were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of the procedure included PPROM within 48 hours of the procedure (6 percent), spontaneous delivery (3 percent), fetal distress (2 percent), fetal death (2 percent), placental abruption (1.3 percent), and chorioamnionitis (1 percent).",
"     </li>",
"     <li>",
"      Both twins were live born in 55 percent of pregnancies, one twin was liveborn in 31 percent, and both twins were stillborn in the remaining 14 percent. During the first four weeks of neonatal life, an additional 30 percent of liveborn twins succumbed.",
"     </li>",
"     <li>",
"      24 percent of recipient twins and 25 percent of donor twins that survived to four weeks of age had evidence of intracranial abnormalities on neonatal cranial ultrasound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SEPTOSTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of intentional perforation of the inter-twin membrane is to equilibrate amniotic fluid volume and pressure between the two amniotic cavities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/54\">",
"     54",
"    </a>",
"    ]. However, computerized models have not found that restoring amniotic fluid in the donor sac enhances donor swallowing and intravascular volume, thereby reversing manifestations of TTTS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/55\">",
"     55",
"    </a>",
"    ]. As with amnioreduction, septostomy is probably most useful for prolonging pregnancy in patients who have already reached 26 weeks of gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septostomy is usually performed alone, but may be performed in conjunction with amnioreduction. When performed alone, under ultrasound guidance a long 22-gauge spinal needle is placed through the donor's sac and into the recipient's sac. A single puncture is all that is required. Multiple punctures can lead to significant disruption of the inter-twin membrane and entanglement of umbilical cords.",
"   </p>",
"   <p>",
"    If both septostomy and amnioreduction are being performed, an 18-gauge spinal needle is introduced into the recipient's sac to perform the amnioreduction. After the amnioreduction has been completed, a long 22-gauge spinal needle is inserted through the 18-gauge needle and used to puncture the inter-twin membrane.",
"   </p>",
"   <p>",
"    A repeat ultrasound examination is performed 24 hours after septostomy to confirm that the amniotic fluid volumes of the two sacs have equilibrated. The inter-twin membrane should be visualized easily and noted to move freely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized clinical trial in 73 women presenting with TTTS at less than 24 weeks of gestation compared amnioreduction with septostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/56\">",
"     56",
"    </a>",
"    ]. There were no significant differences between groups in the rate of survival of one twin or both twins. Long-term neurologic follow-up was not reported. The major benefit of septostomy was that fewer patients required more than one procedure (46 versus 69 percent, p = 0.04). Despite this potential benefit, many physicians choose amnioreduction over septostomy as their first line of intervention because septostomy requires more technical expertise than amnioreduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SELECTIVE FETICIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective feticide may be the best option when TTTS is complicated by a life-threatening anomaly in one of the fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/57\">",
"     57",
"    </a>",
"    ] or after failed laser ablation (eg, \"stuck\" donor twin overlying the site of the placental anastomoses or significant intraamniotic bleeding during the initial laser procedure that obscures fetoscopic visualization). Recurrent TTTS and twin anemia-polycythemia sequence (TAPS; see below) after laser therapy have also been treated with selective reduction. However, some experts have advocated this procedure in any pregnancy with advanced stage TTTS (severe cardiac failure in the recipient fetus or severe intrauterine growth restriction in the donor twin).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound-directed cord coagulation is usually performed with a disposable 3 mm bipolar cautery forceps. Laser can also be used to coagulate the cord under direct fetoscopic visualization; however, this procedure has failure rates as high as 5 percent compared with only rare failures when bipolar forceps are used. A specialized needle that uses radiofrequency energy to ablate the cord insertion (RFA) is another option. This ultrasound-directed thermal occlusion technique offers the advantage of a smaller puncture (14- to 17-gauge needle) with the potential for reduced maternal morbidity, but experience is too limited to determine success and complication rates.",
"   </p>",
"   <p>",
"    The fetus predicted to have the least chance for survival is usually selected for the reduction procedure. The available data do not show a difference in survival according to whether the donor or recipient twin was targeted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/58\">",
"     58",
"    </a>",
"    ]. If bipolar cautery is used, reduction of the recipient twin is technically easier since its cord is easily visualized floating amid the excess amniotic fluid. Oligohydramnios around the donor makes this twin a more difficult target, although the donor cord can be grasped through the inter-twin membrane after entry into the recipient's amniotic cavity. This results in a septostomy and the risk of subsequent cord entanglement. However, if the donor twin is the primary target, amnioinfusion can be performed to improve access for the bipolar forceps. Alternatively, RFA of the abdominal cord insertion can be undertaken, without the need for amnioinfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with selective feticide for TTTS is limited. One study including 15 cases of TTTS treated with bipolar coagulation of the umbilical cord reported an overall survival of 87 percent in the co-twin, but PPROM occurred in 20 percent of pregnancies within three weeks of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/60\">",
"     60",
"    </a>",
"    ]. Another study including 22 cases of TTTS treated with bipolar cautery reported an overall survival of 77 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/61\">",
"     61",
"    </a>",
"    ]. One infant had developmental delay at 16 months of age. In a third series of 24 cases of TTTS, the overall survival was 92 percent (one fetal death and three neonatal deaths) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/58\">",
"     58",
"    </a>",
"    ]. One infant exhibited mild motor delay at 18 months.",
"   </p>",
"   <p>",
"    The acute cessation of blood flow through the umbilical cord prevents a hypotensive episode in the surviving twin, which can lead to fetal anemia with subsequent death or neurologic insult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29601573\">",
"    <span class=\"h1\">",
"     CERCLAGE AND PROGESTERONE SUPPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of polyhydramnios and twins results in significant uterine overdistention, which is an established risk factor for preterm birth that is possibly mediated, in part, by cervical shortening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fifteen to 25 percent of patients with TTTS have a short (&le;25 mm) cervix. A multicenter retrospective cohort study did not find a significant prolongation in duration of pregnancy among TTTS patients with a short cervix who underwent cerclage before laser ablation, but the authors felt a prospective randomized trial was warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9913/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progesterone supplementation has not been studied in TTTS. Routine progesterone supplementation does not reduce the rate of preterm birth in multiple gestations, although there are some data suggesting it may be useful in twin pregnancies with a short cervix. The use of progesterone to reduce the risk of preterm birth is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link&amp;anchor=H31324701#H31324701\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Twin pregnancy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expectant management of twin-twin transfusion syndrome (TTTS) results in an overall fetal survival rate of only 30 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Expectant management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical threshold to begin serial amnioreductions is subjective. Serial amniocentesis to remove excess amniotic fluid in the recipient twin's amniotic cavity results in higher survival rates than expectant management, but not as high as laser photocoagulation. Disadvantages of amnioreduction are that multiple procedures are usually required and complications from the procedure may preclude subsequent treatment by laser photocoagulation of the vascular communications. No more than 5 liters of amniotic fluid should be removed at the time of amnioreduction, and we suggest removing lesser amounts in severe TTTS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Amnioreduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selective feticide may be the best option when TTTS is complicated by a life-threatening anomaly in one of the fetuses or after failed laser ablation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Selective feticide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with severe (Quintero stage II-IV) TTTS under 26 weeks of gestation, we suggest laser ablation of placental anastomoses rather than serial amnioreduction (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Laser ablation results in greater prolongation of gestational age, higher neonatal survival, and improved long-term neurologic outcome. (See",
"      <a class=\"local\" href=\"#H106993435\">",
"       'Fetoscopic laser ablation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with mild (Quintero stage I) TTTS under 26 weeks, we suggest expectant management rather than invasive therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We perform weekly ultrasound examinations to detect progression to more severe disease. Amnioreduction in these cases may decrease the chance for a later successful laser therapy. However, we consider laser therapy for patients with stage I disease and excessive maternal symptoms due to extreme polyhydramnios. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Amnioreduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with TTTS after 26 weeks of gestation, we suggest serial amnioreduction or septostomy rather than laser therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The upper gestational age limit is due to Food and Drug Administration restrictions on the use of current fetoscopes, as well as technical issues that make laser therapy difficult in the third trimester. (See",
"      <a class=\"local\" href=\"#H106993435\">",
"       'Fetoscopic laser ablation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the first six weeks after laser therapy, we suggest intensive fetal surveillance with weekly ultrasound examination to detect such complications as twin anemia-polycythemia sequence or growth restriction. Thereafter, ultrasounds can be performed every two weeks. We initiate antenatal testing by 30 weeks of gestation. Acute fetal compromise or poor serial growth will often be detected and is an indication for early delivery. (See",
"      <a class=\"local\" href=\"#H106993546\">",
"       'Follow-up and delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We deliver all patients with TTTS by 37 weeks of gestation due to the risk of unexplained fetal death late in pregnancy. (See",
"      <a class=\"local\" href=\"#H106993546\">",
"       'Follow-up and delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 11 percent of survivors of laser therapy have some degree of long-term neurodevelopment abnormality. Neurologic follow-up of apparently healthy neonates after laser therapy is warranted. (See",
"      <a class=\"local\" href=\"#H106993519\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/1\">",
"      Bebbington MW, Tiblad E, Huesler-Charles M, et al. Outcomes in a cohort of patients with Stage I twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 2010; 36:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/2\">",
"      Taylor MJ, Govender L, Jolly M, et al. Validation of the Quintero staging system for twin-twin transfusion syndrome. Obstet Gynecol 2002; 100:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/3\">",
"      Dickinson JE, Evans SF. The progression of disease stage in twin-twin transfusion syndrome. J Matern Fetal Neonatal Med 2004; 16:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/4\">",
"      O'Donoghue K, Cartwright E, Galea P, Fisk NM. Stage I twin-twin transfusion syndrome: rates of progression and regression in relation to outcome. Ultrasound Obstet Gynecol 2007; 30:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/5\">",
"      Wagner MM, Lopriore E, Klumper FJ, et al. Short- and long-term outcome in stage 1 twin-to-twin transfusion syndrome treated with laser surgery compared with conservative management. Am J Obstet Gynecol 2009; 201:286.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/6\">",
"      Stamilio DM, Fraser WD, Moore TR. Twin-twin transfusion syndrome: an ethics-based and evidence-based argument for clinical research. Am J Obstet Gynecol 2010; 203:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/7\">",
"      Berghella V, Kaufmann M. Natural history of twin-twin transfusion syndrome. J Reprod Med 2001; 46:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/8\">",
"      De Lia JE, Cruikshank DP, Keye WR Jr. Fetoscopic neodymium:YAG laser occlusion of placental vessels in severe twin-twin transfusion syndrome. Obstet Gynecol 1990; 75:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/9\">",
"      Senat MV, Deprest J, Boulvain M, et al. Endoscopic laser surgery versus serial amnioreduction for severe twin-to-twin transfusion syndrome. N Engl J Med 2004; 351:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/10\">",
"      Rossi AC, D'Addario V. Laser therapy and serial amnioreduction as treatment for twin-twin transfusion syndrome: a metaanalysis and review of literature. Am J Obstet Gynecol 2008; 198:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/11\">",
"      Roberts D, Gates S, Kilby M, Neilson JP. Interventions for twin-twin transfusion syndrome: a Cochrane review. Ultrasound Obstet Gynecol 2008; 31:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/12\">",
"      Middeldorp JM, Lopriore E, Sueters M, et al. Twin-to-twin transfusion syndrome after 26 weeks of gestation: is there a role for fetoscopic laser surgery? BJOG 2007; 114:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/13\">",
"      Baud D, Windrim R, Keunen J, et al. Fetoscopic laser therapy for twin-twin transfusion syndrome before 17 and after 26 weeks' gestation. Am J Obstet Gynecol 2013; 208:197.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/14\">",
"      Valsky DV, Eixarch E, Martinez-Crespo JM, et al. Fetoscopic laser surgery for twin-to-twin transfusion syndrome after 26 weeks of gestation. Fetal Diagn Ther 2012; 31:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/15\">",
"      Wilson RD, Johnson A, Ryan G. Current controversies in prenatal diagnosis 2: Should laser ablation of placental anastomoses be used in all cases of twin to twin transfusion? Prenat Diagn 2009; 29:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/16\">",
"      Gandhi M, Papanna R, Moise K, et al. Treatment of twin-twin transfusion syndrome with proximate umbilical cord insertions. J Ultrasound Med 2011; 30:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/17\">",
"      Ville Y, Hyett J, Hecher K, Nicolaides K. Preliminary experience with endoscopic laser surgery for severe twin-twin transfusion syndrome. N Engl J Med 1995; 332:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/18\">",
"      Quintero RA, Comas C, Bornick PW, et al. Selective versus non-selective laser photocoagulation of placental vessels in twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 2000; 16:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/19\">",
"      Crisan LS, Kontopoulos EV, Quintero RA. Appraisal of the selectivity index in a cohort of patients treated with laser surgery for twin-twin transfusion syndrome. Am J Obstet Gynecol 2010; 202:157.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/20\">",
"      Quintero RA, Ishii K, Chmait RH, et al. Sequential selective laser photocoagulation of communicating vessels in twin-twin transfusion syndrome. J Matern Fetal Neonatal Med 2007; 20:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/21\">",
"      Chmait RH, Kontopoulos EV, Korst LM, et al. Stage-based outcomes of 682 consecutive cases of twin-twin transfusion syndrome treated with laser surgery: the USFetus experience. Am J Obstet Gynecol 2011; 204:393.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/22\">",
"      Middeldorp JM, Lopriore E, Sueters M, et al. Laparoscopically guided uterine entry for fetoscopy in twin-to-twin transfusion syndrome with completely anterior placenta: a novel technique. Fetal Diagn Ther 2007; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/23\">",
"      Morris RK, Selman TJ, Harbidge A, et al. Fetoscopic laser coagulation for severe twin-to-twin transfusion syndrome: factors influencing perinatal outcome, learning curve of the procedure and lessons for new centres. BJOG 2010; 117:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/24\">",
"      Yamamoto M, El Murr L, Robyr R, et al. Incidence and impact of perioperative complications in 175 fetoscopy-guided laser coagulations of chorionic plate anastomoses in fetofetal transfusion syndrome before 26 weeks of gestation. Am J Obstet Gynecol 2005; 193:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/25\">",
"      Winer N, Salomon LJ, Essaoui M, et al. Pseudoamniotic band syndrome: a rare complication of monochorionic twins with fetofetal transfusion syndrome treated by laser coagulation. Am J Obstet Gynecol 2008; 198:393.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/26\">",
"      Lewi L, Jani J, Cannie M, et al. Intertwin anastomoses in monochorionic placentas after fetoscopic laser coagulation for twin-to-twin transfusion syndrome: is there more than meets the eye? Am J Obstet Gynecol 2006; 194:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/27\">",
"      Robyr R, Lewi L, Salomon LJ, et al. Prevalence and management of late fetal complications following successful selective laser coagulation of chorionic plate anastomoses in twin-to-twin transfusion syndrome. Am J Obstet Gynecol 2006; 194:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/28\">",
"      Lopriore E, Slaghekke F, Middeldorp JM, et al. Residual anastomoses in twin-to-twin transfusion syndrome treated with selective fetoscopic laser surgery: localization, size, and consequences. Am J Obstet Gynecol 2009; 201:66.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/29\">",
"      Slaghekke F, Kist WJ, Oepkes D, et al. Twin anemia-polycythemia sequence: diagnostic criteria, classification, perinatal management and outcome. Fetal Diagn Ther 2010; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/30\">",
"      Herway C, Johnson A, Moise K, Moise KJ Jr. Fetal intraperitoneal transfusion for iatrogenic twin anemia-polycythemia sequence after laser therapy. Ultrasound Obstet Gynecol 2009; 33:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/31\">",
"      Lopriore E, Hecher K, Vandenbussche FP, et al. Fetoscopic laser treatment of twin-to-twin transfusion syndrome followed by severe twin anemia-polycythemia sequence with spontaneous resolution. Am J Obstet Gynecol 2008; 198:e4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/32\">",
"      Skupski DW, Luks FI, Walker M, et al. Preoperative predictors of death in twin-to-twin transfusion syndrome treated with laser ablation of placental anastomoses. Am J Obstet Gynecol 2010; 203:388.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/33\">",
"      Rossi AC, Vanderbilt D, Chmait RH. Neurodevelopmental outcomes after laser therapy for twin-twin transfusion syndrome: a systematic review and meta-analysis. Obstet Gynecol 2011; 118:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/34\">",
"      Lenclen R, Ciarlo G, Paupe A, et al. Neurodevelopmental outcome at 2 years in children born preterm treated by amnioreduction or fetoscopic laser surgery for twin-to-twin transfusion syndrome: comparison with dichorionic twins. Am J Obstet Gynecol 2009; 201:291.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/35\">",
"      Ortibus E, Lopriore E, Deprest J, et al. The pregnancy and long-term neurodevelopmental outcome of monochorionic diamniotic twin gestations: a multicenter prospective cohort study from the first trimester onward. Am J Obstet Gynecol 2009; 200:494.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/36\">",
"      Spruijt M, Steggerda S, Rath M, et al. Cerebral injury in twin-twin transfusion syndrome treated with fetoscopic laser surgery. Obstet Gynecol 2012; 120:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/37\">",
"      Vanderbilt DL, Schrager SM, Llanes A, Chmailt RH. Prevalence and risk factors of cerebral lesions in neonates after laser surgery for twin-twin transfusion syndrome. Am J Obstet Gynecol 2012; 207:320.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/38\">",
"      Beck M, Gr&auml;f C, Ellenrieder B, et al. Long-term outcome of kidney function after twin-twin transfusion syndrome treated by intrauterine laser coagulation. Pediatr Nephrol 2005; 20:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/39\">",
"      Cheung YF, Taylor MJ, Fisk NM, et al. Fetal origins of reduced arterial distensibility in the donor twin in twin-twin transfusion syndrome. Lancet 2000; 355:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/40\">",
"      Gardiner HM, Taylor MJ, Karatza A, et al. Twin-twin transfusion syndrome: the influence of intrauterine laser photocoagulation on arterial distensibility in childhood. Circulation 2003; 107:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/41\">",
"      Moon-Grady AJ, Rand L, Lemley B, et al. Effect of selective fetoscopic laser photocoagulation therapy for twin-twin transfusion syndrome on pulmonary valve pathology in recipient twins. Ultrasound Obstet Gynecol 2011; 37:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/42\">",
"      Herberg U, Gross W, Bartmann P, et al. Long term cardiac follow up of severe twin to twin transfusion syndrome after intrauterine laser coagulation. Heart 2006; 92:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/43\">",
"      Walsh CA, McAuliffe FM. Recurrent twin-twin transfusion syndrome after selective fetoscopic laser photocoagulation: a systematic review of the literature. Ultrasound Obstet Gynecol 2012; 40:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/44\">",
"      Assaf SA, Korst LM, Chmait RH. Normalization of amniotic fluid levels after fetoscopic laser surgery for twin-twin transfusion syndrome. J Ultrasound Med 2010; 29:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/45\">",
"      Chmait RH, Korst LM, Bornick PW, et al. Fetal growth after laser therapy for twin-twin transfusion syndrome. Am J Obstet Gynecol 2008; 199:47.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/46\">",
"      Gajjar K, Gupta N, Spencer C. Increased perinatal mortality and morbidity in monochorionic versus dichorionic twin pregnancies: clinical implications of a large Dutch cohort study. BJOG 2008; 115:797; author reply 797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/47\">",
"      Stirnemann JJ, Quibel T, Essaoui M, et al. Timing of delivery following selective laser photocoagulation for twin-to-twin transfusion syndrome. Am J Obstet Gynecol 2012; 207:127.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/48\">",
"      Bower SJ, Flack NJ, Sepulveda W, et al. Uterine artery blood flow response to correction of amniotic fluid volume. Am J Obstet Gynecol 1995; 173:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/49\">",
"      Papanna R, Mann LK, Johnson A, et al. Chorioamnion separation as a risk for preterm premature rupture of membranes after laser therapy for twin-twin transfusion syndrome. Obstet Gynecol 2010; 115:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/50\">",
"      Egawa M, Hayashi S, Yang L et al. Chorioamniotic membrane separation after fetoscopic laser surgery for twin&ndash;twin transfusion syndrome. Prenat Diagn 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/51\">",
"      Quintero RA, Kontopoulos EV, Chmait R, et al. Management of twin-twin transfusion syndrome in pregnancies with iatrogenic detachment of membranes following therapeutic amniocentesis and the role of interim amniopatch. Ultrasound Obstet Gynecol 2005; 26:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/52\">",
"      Leung WC, Jouannic JM, Hyett J, et al. Procedure-related complications of rapid amniodrainage in the treatment of polyhydramnios. Ultrasound Obstet Gynecol 2004; 23:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/53\">",
"      Mari G, Roberts A, Detti L, et al. Perinatal morbidity and mortality rates in severe twin-twin transfusion syndrome: results of the International Amnioreduction Registry. Am J Obstet Gynecol 2001; 185:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/54\">",
"      Saade GR, Belfort MA, Berry DL, et al. Amniotic septostomy for the treatment of twin oligohydramnios-polyhydramnios sequence. Fetal Diagn Ther 1998; 13:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/55\">",
"      van den Wijngaard JP, Umur A, Ross MG, van Gemert MJ. Modelling the influence of amnionicity on the severity of twin-twin transfusion syndrome in monochorionic twin pregnancies. Phys Med Biol 2004; 49:N57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/56\">",
"      Moise KJ Jr, Dorman K, Lamvu G, et al. A randomized trial of amnioreduction versus septostomy in the treatment of twin-twin transfusion syndrome. Am J Obstet Gynecol 2005; 193:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/57\">",
"      Huber A, Diehl W, Bregenzer T, et al. Stage-related outcome in twin-twin transfusion syndrome treated by fetoscopic laser coagulation. Obstet Gynecol 2006; 108:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/58\">",
"      Lewi L, Gratacos E, Ortibus E, et al. Pregnancy and infant outcome of 80 consecutive cord coagulations in complicated monochorionic multiple pregnancies. Am J Obstet Gynecol 2006; 194:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/59\">",
"      Moise KJ Jr, Johnson A, Moise KY, Nickeleit V. Radiofrequency ablation for selective reduction in the complicated monochorionic gestation. Am J Obstet Gynecol 2008; 198:198.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/60\">",
"      Taylor MJ, Shalev E, Tanawattanacharoen S, et al. Ultrasound-guided umbilical cord occlusion using bipolar diathermy for Stage III/IV twin-twin transfusion syndrome. Prenat Diagn 2002; 22:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/61\">",
"      Robyr R, Yamamoto M, Ville Y. Selective feticide in complicated monochorionic twin pregnancies using ultrasound-guided bipolar cord coagulation. BJOG 2005; 112:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9913/abstract/62\">",
"      Papanna R, Habli M, Baschat AA, et al. Cerclage for cervical shortening at fetoscopic laser photocoagulation in twin-twin transfusion syndrome. Am J Obstet Gynecol 2012; 206:425.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6793 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9913=[""].join("\n");
var outline_f9_43_9913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXPECTANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8405339\">",
"      STAGE 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8405325\">",
"      Stage II or more",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8405332\">",
"      INDICATIONS FOR INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106993435\">",
"      FETOSCOPIC LASER ABLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106993484\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H106993491\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H106993498\">",
"      PROM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H106993505\">",
"      TAPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106993512\">",
"      Prognostic indicators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106993519\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106993546\">",
"      Follow-up and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AMNIOREDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SEPTOSTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SELECTIVE FETICIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29601573\">",
"      CERCLAGE AND PROGESTERONE SUPPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6793|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/36/19023\" title=\"diagnostic image 1\">",
"      Arteriovenous anastomosis preablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/39/2687\" title=\"diagnostic image 2\">",
"      Arteriovenous anastomosis postablation 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6793|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/7/33918\" title=\"picture 1\">",
"      Arteriovenous anastomosis postablation 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6793|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?20/29/20958\" title=\"movie 1\">",
"      Laser coagulation TTTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_43_9914="Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer";
var content_f9_43_9914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9914/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9914/contributors\">",
"     Elizabeth H Baldini, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9914/contributors\">",
"     Gregory P Kalemkerian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9914/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9914/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9914/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/43/9914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/43/9914/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/43/9914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of small cell lung cancer (SCLC) is one of rapid proliferation and early dissemination. This affects both the staging system and the therapeutic approach, which are different from those used for non-small cell lung cancer (NSCLC).",
"   </p>",
"   <p>",
"    Patients with SCLC are divided into those with limited versus extensive stage disease. Limited stage (LS) disease is defined as disease confined to one hemithorax, ie, disease that can be included in a \"tolerable\" radiation field. Approximately one-third of patients present with clinically staged \"limited disease\"; however, many of these patients have subclinical metastatic disease.",
"   </p>",
"   <p>",
"    Chemotherapy is the mainstay of treatment for patients with SCLC because of the high frequency of early dissemination. Considerable effort is being devoted to the development of more efficacious chemotherapy strategies to control systemic disease.",
"   </p>",
"   <p>",
"    In addition to chemotherapy, there is a significant role for radiation therapy (RT) in the treatment of LS-SCLC. Local tumor progression occurs in up to 80 percent of such patients treated with chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/1\">",
"     1",
"    </a>",
"    ]. The high local recurrence rate can be significantly reduced by the addition of thoracic RT, and survival is improved when thoracic RT is added to chemotherapy compared with chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will describe the roles of thoracic RT and systemic chemotherapy in patients with LS-SCLC, as well as their integration. Related topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The staging of SCLC, including the distinction between limited and extensive stage (ES) SCLC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"       \"Pathobiology and staging of small cell carcinoma of the lung\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of surgery in the exceptional case of patients who present with apparently localized SCLC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=see_link\">",
"       \"Role of surgery in multimodality therapy for small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of prophylactic cranial irradiation (PCI) to prevent intracranial relapse and improve survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=see_link\">",
"       \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of patients who present with extensive stage SCLC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147048869\">",
"    <span class=\"h1\">",
"     BENEFIT OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SCLC rarely survive more than a few months without treatment since SCLC is almost always disseminated even at presentation. However, SCLC is highly responsive to both RT and multiple chemotherapeutic drugs. The results with treatment vary significantly depending upon the extent of disease.",
"   </p>",
"   <p>",
"    For patients with LS-SCLC treated with contemporary chemoradiotherapy and prophylactic cranial irradiation, overall response rates of 80 to 90 percent, including 50 to 60 percent complete response rates are typically reported. Median survivals are around 17 months, and the five-year survival rate is 10-15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The impact of treatment on the natural history of SCLC and the differences in outcomes between LS-SCLC and ES-SCLC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H2#H2\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Benefit of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147047671\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key parameters that influence the effectiveness of RT are the dose of radiation, the treatment volume, and the fractionation schedule, as well as its integration with chemotherapy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Integration with chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Benefit of RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of thoracic RT to chemotherapy results in a small, statistically significant improvement in survival compared with the use of chemotherapy alone, although the combined modality approach is associated with an increase in toxicity.",
"   </p>",
"   <p>",
"    A meta-analysis of 13 randomized trials found that the use of combined chemotherapy and thoracic RT resulted in a statistically significant absolute survival benefit of 5.4 percent at three years, an effect that was greatest for patients less than 55 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/2\">",
"     2",
"    </a>",
"    ]. The chemotherapy regimens differed among the studies, as did the thoracic RT doses and delivery schedules.",
"   </p>",
"   <p>",
"    A second meta-analysis, which included 11 of these same trials, evaluated the effect of RT on local control [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/3\">",
"     3",
"    </a>",
"    ]. The addition of thoracic RT was associated with an absolute overall improvement in local control of 23 percent (two-year local control rate 47 versus 24 percent).",
"   </p>",
"   <p>",
"    The survival benefit associated with the use of thoracic RT outside of clinical trials was confirmed in a more recent review from the National Cancer Data Base [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/4\">",
"     4",
"    </a>",
"    ]. For patients with LS-SCLC, the five-year survival rate for the 6752 patients diagnosed in 2000 was significantly higher in patients treated with thoracic RT plus chemotherapy compared with chemotherapy alone (13.3 versus 5.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies of thoracic RT for SCLC provide evidence of a dose-response effect. Most thoracic RT regimens that employ conventional (once daily) fractionation use doses of approximately 60 to 70 Gy in 2.0 Gy fractions.",
"   </p>",
"   <p>",
"    In a retrospective analysis of SCLC patients treated with once daily fractionation, improved local control rates were observed as the total dose delivered increased from 30 Gy to 50 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/6\">",
"     6",
"    </a>",
"    ]. Reported 2.5 year local control rates were 16 percent for patients who received 30 Gy, compared with 63 percent for patients who received 50 Gy. A third study showed a local control rate of 96 percent for 26 patients with LS-SCLC who received 60 Gy thoracic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cancer and Leukemia Group B (CALGB) conducted a phase I study to determine the maximum tolerated dose (MTD) for once daily RT delivered in 2 Gy fractions and for twice daily RT delivered in 1.5 Gy fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/8\">",
"     8",
"    </a>",
"    ]. The MTD for once daily RT was not reached and was therefore considered to be &gt;70 Gy and the MTD for twice daily RT was 45 Gy. The follow-up phase II study demonstrated the safety of 70 Gy in 35 once daily fractions delivered over seven weeks concurrently with chemotherapy in patients with LS-SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite some uncertainty, the use of limited field thoracic RT is the current standard of care. Specifically, the treatment volume should include all gross disease present at the time of radiation planning (postchemotherapy volume), and all nodal regions involved at the time of initial diagnosis (prechemotherapy volume). PET scans should be obtained for staging if RT is planned for patients with suspected LS-SCLC.",
"   </p>",
"   <p>",
"    Treatment with these smaller fields is associated with a reduction in the severity of toxicity from combined modality therapy, and it does not appear to jeopardize local control rates. Such toxicity issues will have increasing importance as both radiation and chemotherapy doses are intensified and agents with potential lung toxicity are added to chemotherapy regimens.",
"   </p>",
"   <p>",
"    Historically, thoracic RT treatment volumes included all gross disease present at the time of initial diagnosis (pre-chemotherapy volume) as well as prophylactic inclusion of adjacent uninvolved nodal regions. Several lines of evidence support the use of more limited thoracic RT fields to include only the post-chemotherapy tumor volume and prechemotherapy nodal volume:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Southwest Oncology Group (SWOG) performed a randomized trial, in which 191 patients with LS-SCLC who had a partial response or stable disease following induction chemotherapy were randomly assigned to thoracic RT fields that included either the prechemotherapy or the postchemotherapy tumor volumes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/10\">",
"       10",
"      </a>",
"      ]. This study did not show a significant difference in patterns of failure or median survival between the two regimens. There was no apparent difference in severe drug-related toxicity or severe radiation pneumonitis between the thoracic RT groups. However, the frequency of severe complications related to myelosuppression was higher for patients treated with wide field thoracic RT (17 of 93 [18 percent], versus 8 of 98 [8 percent] with reduced field thoracic RT).",
"     </li>",
"     <li>",
"      A retrospective review of 59 patients with LS-SCLC treated at the Mayo Clinic also failed to show a significant difference in the rates of local recurrence, progression-free survival or overall survival for patients treated with thoracic RT fields which covered the prechemotherapy versus postchemotherapy tumor volumes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/11\">",
"       11",
"      </a>",
"      ]. In this series, all local failures occurred within the thoracic RT fields. There were no failures at the margin of a field, which would have implied that the treated volume was too small.",
"     </li>",
"     <li>",
"      The North Central Cancer Treatment Group (NCCTG) conducted a randomized study comparing daily thoracic RT to twice daily thoracic RT (with a treatment break) and all patients were treated to fields including postchemotherapy volumes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/12\">",
"       12",
"      </a>",
"      ]. They reported that less than 7 percent of local recurrences included a component of disease outside of the treatment field, further supporting the use of involved field thoracic RT.",
"     </li>",
"     <li>",
"      A phase II trial from the Netherlands treated 27 patients with ls-SCLC with 45 Gy of twice daily thoracic RT and concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/13\">",
"       13",
"      </a>",
"      ]. The RT volume was confined to the primary tumor and lymph nodes involved on the initial pretreatment CT scan. Three patients developed an isolated nodal failure (crude rate 11 percent) and all of these were in the ipsilateral supraclavicular region. The same group performed a subsequent study that was similar to the above approach except that the nodal tumor volume included in the RT field was based on a prechemotherapy PET scan. With this approach, there were only 2 of 60 isolated nodal failures (crude rate of 3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/14\">",
"       14",
"      </a>",
"      ]. Interestingly, the PET scans showed nodal involvement not appreciated on CT scans in 15 percent of cases. Further study is warranted, but these data suggest the importance of using PET staging for patients with suspected LS-SCLC if elective nodal irradiation is omitted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fractionation schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard radiation fractionation schedules employ single daily treatments of 1.8 to 2.0 Gy, five times per week, over a continuous course for about six weeks. An alternative approach is to use an accelerated hyperfractionation schedule, in which a course of radiation is given over a shorter total treatment time (acceleration) and with a greater number of treatment fractions (hyperfractionation).",
"   </p>",
"   <p>",
"    The use of hyperfractionation regimens is considerably more complex, increases the patient's daily treatment time, and is associated with more acute toxicity. Comparisons of these twice daily regimens to high-dose once daily regimens have not yet been reported, but the trials with the best five-year survival rates have all used hyperfractionated thoracic RT early in the treatment course along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (EP) chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Although the ultimate role for such alternative fractionation schedules has not been fully clarified, hyperfractionation (45 Gy given in twice daily fractions over three weeks) is clearly a standard treatment option for LS-SCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Accelerated hyperfractionation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated hyperfractionated RT reduces the opportunity for tumor cell regeneration during treatment by shortening the overall treatment time. However, acute toxicities are greater to normal tissues. Late toxicities should be similar, given that late effects of radiation are more dependent on dose per fraction and total dose than overall treatment time.",
"   </p>",
"   <p>",
"    Uncontrolled trials comparing once daily to twice daily fractionation have produced conflicting results. Two separate studies reported 57 and 65 percent two-year survival rates, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], while a third, which used hyperfractionated thoracic RT delivered late in the treatment course, reported only 19 percent two-year survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials comparing once and twice daily thoracic RT have been performed, but the results do not resolve the issue of which approach is superior:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Eastern Cooperative Oncology Group randomly assigned 417 patients with LS-SCLC to 45 Gy of concurrent thoracic RT, either as once-daily treatments for five weeks or twice-daily treatments over three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/15\">",
"       15",
"      </a>",
"      ]. In both groups, radiation was begun concurrently with cycle one of four planned 21-day cycles of EP. After a median follow-up of nearly eight years, survival was significantly longer in the group treated with twice-daily thoracic RT (five year survival rate, 26 versus 16 percent with once-daily treatment). However, severe esophagitis, such that patients could not swallow solids or required opiates or feeding tube placement, was significantly more common in the twice-daily thoracic RT group (27 versus 11 percent). Severe hematologic and pulmonary toxicities, which were reported in prior trials of hyperfractionation, did not differ significantly in this study [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/15,18-22\">",
"       15,18-22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This study showed that 45 Gy given twice daily was more efficacious than 45 Gy given once daily. However, 45 Gy twice daily results in a substantially higher biologically equivalent dose (BED) than 45 Gy delivered once daily. &nbsp;This study did not answer the question of the efficacy of 45 Gy twice daily compared to once daily treatment to a higher dose (60 to 70 Gy), which would have provided a more comparable BED. Nonetheless, these results with hyperfractionated treatment are some of the best reported and they have established 45 Gy given twice daily over three weeks as a standard regimen for the treatment of LS-SCLC.",
"     </li>",
"     <li>",
"      In a second trial by the NCCTG, 262 patients with LS-SCLC were randomly assigned to once daily (50.4 Gy in 28 fractions) or twice daily (48 Gy in 32 fractions, with a two week break after 24 Gy) thoracic RT beginning with cycle four of a planned six courses of EP [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/12\">",
"       12",
"      </a>",
"      ]. Both local control and overall survival (two-year survival rates 45 versus 47 percent) were similar in both study arms. However, the relevance of this study is limited by the fact that the hyperfractionated treatment was started late in the chemotherapy course and was interrupted by a two week break, both of which may have adversely affected the efficacy of this regimen.",
"      <br/>",
"      <br/>",
"      Although severe treatment-related esophagitis was twice as frequent in the hyperfractionated group of the NCCTG trial, a later quality of life analysis using Q-TWiST (Quality Time Without Symptoms or Toxicity) methodology demonstrated that the differences in the incidence and severity of toxicity between the two arms were inconsequential [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Split course treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperfractionated thoracic RT has also been delivered as a split course treatment with alternating regimens of chemotherapy and thoracic RT. In a pilot study by the Eastern Cooperative Oncology Group (ECOG), thoracic RT consisting of 1.5 Gy given twice daily over five continuous days was delivered after the first, second, and third cycles of EP chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/21\">",
"     21",
"    </a>",
"    ]. The two-year progression-free survival for this series was 47 percent. The Groupe Lyonnais d'Oncologique Thoracique reported the results of a similar hyperfractionated thoracic RT schedule alternating with chemotherapy in the treatment of 76 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/22\">",
"     22",
"    </a>",
"    ]. The median survival for this group was 14 months, and the one year disease-free survival was 42 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147048243\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current standard of care for patients with LS-SCLC consists of four cycles of combination chemotherapy (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [EP]) along with concurrent thoracic radiotherapy during the early part of the chemotherapy treatment. Prophylactic cranial irradiation (PCI) is generally recommended for patients with a complete response or significant tumor regression at the completion of chemotherapy.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    can be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    with statistically similar outcomes, EP is preferred in patients with LS-SCLC due to the paucity of directly comparative data in this setting. However, carboplatin can be substituted if cisplatin is contraindicated for reasons such as pre-existing neuropathy, hearing loss, renal insufficiency, or congestive heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147048250\">",
"    <span class=\"h2\">",
"     Etoposide plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (EP) is the standard regimen for chemotherapy in patients with LS-SCLC along with early, concurrent thoracic radiotherapy (",
"    <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Initial studies of combined-modality therapy in patients with LS-SCLC used chemotherapy regimens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (CAV), followed sequentially by thoracic RT. Subsequent studies used EP in a similar sequential approach and demonstrated favorable response and survival rates with relatively tolerable toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These regimens were compared in a trial in which patients with either LS- or ES-SCLC were randomly assigned to CAV, EP, or CAV alternating with EP [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/25\">",
"     25",
"    </a>",
"    ]. The 146 patients with LS-SCLC received thoracic RT to 40-50 Gy after 4 cycles of chemotherapy. For patients with LS-SCLC, response rates to initial chemotherapy were significantly higher with EP (77 percent) and",
"    <span class=\"nowrap\">",
"     CAV/EP",
"    </span>",
"    (88 percent) compared with CAV (51 percent); overall survival was similar in all three treatment arms (EP 11.7 mo.;",
"    <span class=\"nowrap\">",
"     CAV/EP",
"    </span>",
"    11.8 mo.; CAV 12.4 mo.). Based on these early studies, many oncologists adopted EP as the standard-of-care since it resulted in less myelotoxicity and was easier to combine with thoracic RT in patients with LS-SCLC due to a lower risk of mucosal and pulmonary toxicity.",
"   </p>",
"   <p>",
"    More recently, EP was compared to another alkylator-based regimen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (CEV), in 214 patients with LS-SCLC; thoracic RT (42 Gy) was given between the third and fourth cycles of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/26\">",
"     26",
"    </a>",
"    ]. Overall survival was significantly better in patients assigned to EP, with a median survival of 14.5 mo. vs. 9.7 mo. and 2-year survival rates of 25 versus 8 percent in the EP and CEV arms, respectively. There was no difference between arms in the number of patients who received definitive thoracic radiotherapy, PCI or second-line chemotherapy for relapse. These results in favor of EP are consistent with the findings of two meta-analyses that demonstrated a modest survival advantage in studies evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    -based or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based therapy in patients with both LS- and ES-SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Overall, these studies should confirm EP as the preferred regimen for the treatment of patients with LS-SCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147049799\">",
"    <span class=\"h2\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variations on the EP regimen have included the substitution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , the substitution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and the use of other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    in addition to EP. None of these has an established role in the treatment of LS-SCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147049875\">",
"    <span class=\"h3\">",
"     Carboplatin versus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is frequently substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    to reduce the risk of non-hematologic toxicities, such as nausea, vomiting, neuropathy, and nephropathy. However, due to the potential curability of LS-SCLC and the relatively small number of LS-SCLC patients evaluated thus far, cisplatin remains the standard agent with carboplatin restricted to patients with contraindications to or poor tolerance of cisplatin.",
"   </p>",
"   <p>",
"    A meta-analysis that included 663 patients in four trials compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    regimens in SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/29\">",
"     29",
"    </a>",
"    ]. A subset analysis based upon the two randomized trials conducted in patients with LS-SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] reported similar efficacy with cisplatin and carboplatin. Similarly there was no significant difference in the more extensive subset of patients with LS-SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/29\">",
"     29",
"    </a>",
"    ]. &nbsp;These data suggest that, if necessary, carboplatin can be safely substituted for cisplatin without compromising therapeutic efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147048257\">",
"    <span class=\"h3\">",
"     Irinotecan-containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    has been extensively studied as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    in patients with ES-SCLC. Although an initial phase III trial yielded promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/32\">",
"     32",
"    </a>",
"    ], these were not confirmed in two subsequent trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with LS-SCLC, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (IP) regimen has been evaluated in early phase trials as sequential, induction or consolidation therapy. The data with IP in patients with LS-SCLC is too premature to recommend its use outside of a clinical trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sequential IP followed by thoracic RT to 50 Gy was studied in a phase II trial of 40 patients with LS-SCLC, resulting in overall and complete response rates of 83 and 30 percent, respectively, but the two-year survival rate was a disappointing 18 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Induction IP alone followed by concurrent platinum plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      with thoracic RT has been evaluated. In the CALGB 30206 study, 75 patients with LS-SCLC were treated with two cycles of IP followed by three cycles of concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus etoposide and RT (70 Gy). The complete response rate to induction IP followed by concurrent chemoradiotherapy was 37 percent. The median survival and two-year survival rate were 18 months and 31 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/36\">",
"       36",
"      </a>",
"      ]. The investigators concluded that there was insufficient evidence for further investigation of this approach.",
"     </li>",
"     <li>",
"      Consolidation therapy was evaluated in two phase II Japanese studies [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. In these studies, 90 patients were treated with one cycle of concurrent EP and RT (45 Gy, using BID dosing) followed by three cycles of IP [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Complete response rates in these two trials were 37 and 41 percent, respectively, with two year overall survivals rates of 41 and 49 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147048264\">",
"    <span class=\"h3\">",
"     Paclitaxel-containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of a third drug to a standard platinum plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    regimen has been extensively evaluated in an effort to improve the overall outcome of patients with SCLC. The most extensively studied third agent has been",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , which has significant single-agent activity against SCLC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H17#H17\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Paclitaxel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    containing regimens have been studied in sequential approaches prior to thoracic RT, given concurrently with RT, and in more complex regimens. The use of three drug regimens incorporating paclitaxel remains experimental.",
"   </p>",
"   <p>",
"    In the largest trial incorporating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    into the treatment of LS-SCLC, sequential paclitaxel,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (TEC) followed by thoracic RT was compared with carboplatin, etoposide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (CEV) in 608 patients, 50 percent of whom had LS-disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/39\">",
"     39",
"    </a>",
"    ]. All patients initially received six cycles of chemotherapy, which was followed by thoracic RT (50 to 56 Gy) in patients with LS-SCLC. Overall, efficacy was similar in both arms with less hematologic toxicity in those treated with TEC. For the subset of patients with LS-SCLC, overall response rate (77 versus 75 percent) and complete response rate (22 versus 23 percent) were similar. An initial study that directly compared the three drug combination paclitaxel plus EP (TEP) with EP alone suggested that the addition of paclitaxel improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/40\">",
"     40",
"    </a>",
"    ]. However, two larger phase II studies that evaluated TEP with concurrent thoracic RT in patients with LS-SCLC concluded that this approach did not demonstrate any improvement in efficacy over standard EP plus early, concurrent RT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In the RTOG 9609 study, 53 evaluable patients were treated with one cycle of TEP given concurrently with thoracic RT (45 Gy using BID dosing), followed by three cycles of TEP [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/41\">",
"       41",
"      </a>",
"      ]. The complete response rate was 75 percent with a two-year survival rate of 55 percent. Grade 3 to 4 esophagitis was observed in 36 percent of patients and the treatment-related mortality rate was 6 percent. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In the ECOG 2596 study, 61 patients were treated with two cycles of TEP, followed by two additional cycles of TEP given concurrently with thoracic RT (63 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/42\">",
"       42",
"      </a>",
"      ]. The complete response rate was 20 percent with a two-year survival rate 24 percent. Grade 3 to 4 esophagitis was seen in 32 percent of patients; febrile neutropenia occurred in 19 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The better outcomes observed in RTOG 9609 compared with ECOG 2596 may reflect a potential benefit of early, hyperfractionated RT, since the chemotherapy regimens and patient populations were similar in these studies.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (TEC) with concurrent thoracic RT has been evaluated in two phase II trials, which yielded favorable overall and complete response rates, but relatively unexceptional survivals and substantial toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147048278\">",
"    <span class=\"h3\">",
"     Novel agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many novel agents have been evaluated in patients with SCLC. Most of these agents have been tested in patients with extensive stage disease, although several have been incorporated into combined-modality regimens for LS-SCLC. Examples of agents that have been incorporated into trials of patients with LS-SCLC include tirapazamine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/29\">",
"     29",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/45\">",
"     45",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/46\">",
"     46",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/47\">",
"     47",
"    </a>",
"    ], matrix metalloproteinase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/48,49\">",
"     48,49",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/50\">",
"     50",
"    </a>",
"    ], and the",
"    <span class=\"nowrap\">",
"     Bec2/BCG",
"    </span>",
"    vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/51\">",
"     51",
"    </a>",
"    ]. None of these approaches has a role in limited stage disease outside a protocol setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8951?source=see_link\">",
"     \"Experimental approaches to treatment for small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, two trials (one in LS-SCLC, one in stage III NSCLC) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in combination with concurrent chemoradiotherapy were stopped early due to the excessive incidence of tracheoesophageal fistulae [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/47\">",
"     47",
"    </a>",
"    ]. Bevacizumab should not be used in combination with chemoradiotherapy in patients with lung cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INTEGRATION WITH CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of thoracic RT integrated with EP chemotherapy during cycle 1 or 2 is the current standard of care for patients with LS-SCLC. Although there are conflicting data regarding the optimal timing of thoracic RT relative to chemotherapy, the studies that employed standard EP chemotherapy delivered with minimal dose reduction all showed a clear benefit for early thoracic RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sequential, concurrent, and alternating approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequential, concurrent, and alternating approaches integrating chemotherapy and thoracic RT have all been studied. Sequential therapy refers to treatment with one modality at a time, while concurrent therapy indicates that chemotherapy and thoracic RT are delivered simultaneously. Alternating therapy refers to delivery of thoracic RT on days when chemotherapy is not given, in such a fashion that the timing of the next chemotherapy cycle is not altered. In this treatment scheme, thoracic RT is necessarily delivered as a split course.",
"   </p>",
"   <p>",
"    The concurrent and alternating approaches are intuitively appealing because they enable delivery of multiple chemotherapy cycles without interruption. Insofar as SCLC is a systemic disease, the optimal delivery of systemic treatment is crucial. However, concurrent or alternating regimens have been associated with more toxicity (myelosuppression, esophagitis, pneumonitis) when compared with sequential treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/3\">",
"     3",
"    </a>",
"    ]. This increased toxicity can be justified only if a beneficial impact on outcome is achieved.",
"   </p>",
"   <p>",
"    Of the randomized trials that indicate a significant survival benefit for combined modality therapy compared to chemotherapy alone for limited stage disease, three used concurrent or alternating radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], while another used sequential therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An early meta-analysis of 15 randomized trials evaluating the contribution of thoracic radiation therapy to outcomes in SCLC indirectly compared the method of treatment integration (sequential versus alternating or concurrent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/2\">",
"     2",
"    </a>",
"    ]. There was no statistically significant difference in outcome between the two approaches.",
"   </p>",
"   <p>",
"    At least two subsequent randomized trials directly addressed the issue of concurrent versus sequential or alternating chemotherapy and radiation in SCLC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial from the European Organization for Research and Treatment of Cancer (EORTC), 335 patients with LS-SCLC were randomly assigned to alternating or sequential schedules of chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) and RT. There was no survival benefit with alternating therapy (median survival 15 versus 14 months with sequential therapy) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Japanese Clinical Oncology Group Study 9104, 231 patients with LS-SCLC were randomly assigned to four cycles of EP every three or four weeks with either sequential or concurrent thoracic RT (45 Gy twice daily over three weeks in both groups) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/16\">",
"       16",
"      </a>",
"      ]. The concurrent group began RT on day 2 of the first chemotherapy cycle. There was a sizeable, absolute improvement in median and overall survival that favored concurrent RT, although the differences did not reach statistical significance (median survival 27 versus 20 months with sequential RT, p = 0.10). The survival rates at two, three, and five years also favored concurrent RT (54 versus 35, 30 versus 20, and 24 versus 18 percent, respectively). All intended chemotherapy was delivered to 86 percent of patients in the concurrent arm and 88 percent in the sequential arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data are strongly suggestive of a benefit with concurrent therapy. Severe esophagitis was infrequent although more common in the concurrently treated group (9 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/16\">",
"     16",
"    </a>",
"    ]. Rates of pulmonary toxicity, and treatment-related death rates were similar. Furthermore, although the actual dose intensities for both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    were 1.3-fold higher in the sequential arm (because treatment cycles were administered every three rather than four weeks), the actual dose intensity as a proportion of the planned dose intensity was over 90 percent in both groups.",
"   </p>",
"   <p>",
"    Overall, the data are strongly suggestive that concurrent treatment is more efficacious than sequential therapy. Furthermore, studies suggest that early integration of thoracic RT concurrently with chemotherapy as compared to delayed thoracic RT is associated with a significant survival benefit. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Early versus late thoracic RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Early versus late thoracic RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data regarding the benefit of early versus late timing of thoracic RT relative to the administration of chemotherapy. However, all the studies which employed standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy without significant dose reductions convincingly showed that early (starting with cycle 1 or 2 of chemotherapy) rather than late integration of thoracic RT is associated with a better outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of SCLC generally begins with chemotherapy for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There may be an advantage to early treatment of subclinical metastatic disease.",
"     </li>",
"     <li>",
"      Initial treatment with chemotherapy enables evaluation of the disease response to chemotherapy.",
"     </li>",
"     <li>",
"      Treatment can often be initiated faster with chemotherapy than with thoracic RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been eight randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/16,17,52,56-61\">",
"     16,17,52,56-61",
"    </a>",
"    ] and three meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/62-64\">",
"     62-64",
"    </a>",
"    ] that have attempted to address the timing of the delivery of thoracic RT relative to chemotherapy.",
"   </p>",
"   <p>",
"    The key evidence pertaining to this issue includes the following two well-designed and performed randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial from the National Cancer Institute of Canada (NCIC) enrolled 308 patients with LS-SCLC all of whom received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      (CAV) alternating with EP chemotherapy for a total of six cycles. Patients were randomly assigned to thoracic RT (40 Gy in 15 once daily fractions over three weeks) delivered during cycle 2 or cycle 6 concurrently with EP. Five-year survival rates showed a significant benefit for early compared to late thoracic RT (22 versus 13 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/58\">",
"       58",
"      </a>",
"      ]. Full doses of chemotherapy were received by 83 percent of patients in the early RT arm and 84 percent of patients in the late RT arm.",
"     </li>",
"     <li>",
"      In another trial, 107 patients with LS-SCLC were randomly assigned to thoracic RT with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"        carboplatin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"        etoposide",
"       </a>",
"       ,",
"      </span>",
"      EP, or to two cycles of EP followed by thoracic RT with",
"      <span class=\"nowrap\">",
"       carboplatin/etoposide",
"      </span>",
"      and then two additional cycles of EP [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/17\">",
"       17",
"      </a>",
"      ]. Thoracic RT consisted of 54 Gy given in 1.5 Gy fractions twice daily. Five-year overall survival favored the early treatment arm compared to the late arm (30 versus 15 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/17\">",
"       17",
"      </a>",
"      ]. There were no chemotherapy dose reductions in either arm. Of note, there was no difference between the two groups in the rate of distant metastases, but there was a significantly better local control rate for those assigned to the early treatment arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two meta-analyses have examined the optimal timing of thoracic RT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis reported in 2004, which included seven randomized trials published after 1985, showed a significant improvement in two-year overall survival for early versus late thoracic RT [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/64\">",
"       64",
"      </a>",
"      ]. Subset analysis showed that this benefit was more pronounced with the use of hyperfractionated RT and platinum-based chemotherapy. These results are consistent with the opinion that standard treatment for LS-SCLC should include the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -containing regimens and concurrent therapy with thoracic RT delivered early.",
"     </li>",
"     <li>",
"      A 2005 Cochrane meta-analysis that incorporated data from seven randomized trials was unable to determine the optimal strategy for integrating chemotherapy and thoracic RT in patients with LS-SCLC, although several of the studies included did not use EP chemotherapy delivered at full doses [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/62\">",
"       62",
"      </a>",
"      ]. However, an additional meta-analysis from the same group indicated that the most important factor associated with improved five-year survival was a short interval between the start of any treatment and the completion of thoracic RT (relative risk [RR] 0.62) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/63\">",
"       63",
"      </a>",
"      ]. This observation was attributed to the phenomenon of accelerated repopulation during treatment. The importance of a short time between start of treatment and completion of RT can also be inferred from a report that analyzed outcome for 215 patients treated with concurrent chemotherapy and thoracic RT during cycle 2 or 3 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/65\">",
"       65",
"      </a>",
"      ]. On multivariate analysis, RT treatment interruptions due to toxicity were the most important adverse prognostic factor for survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all three of the studies which demonstrated a marked survival advantage for early thoracic RT, patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy and both the early and late treatment arms had similar high rates of patients receiving full doses of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/16,17,58\">",
"     16,17,58",
"    </a>",
"    ]. In contrast, the randomized trials that did not demonstrate an advantage for early thoracic RT either did not use cisplatin-based chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a lower percentage of patients in the early thoracic RT arms received full dose chemotherapy compared to those in the late thoracic RT arms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/52,56,57,59,61\">",
"     52,56,57,59,61",
"    </a>",
"    ]. These deficits may suffice to explain the lack of an observed benefit for early thoracic radiation therapy in those studies. The importance of receiving all planned chemotherapy was further supported in another meta-analysis of eight trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/43/9914/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are conflicting data regarding the optimal timing of thoracic RT relative to chemotherapy, the studies which employed standard EP chemotherapy delivered with minimal dose reduction all showed a clear benefit for early thoracic RT. Thus, delivery of thoracic RT integrated early (in cycle 1 or 2) with chemotherapy is the current standard of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"       \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"       \"Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with limited stage small cell lung cancer , we recommend combination chemotherapy with a platinum-based regimen, in conjunction with concurrent thoracic radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H2#H2\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Benefit of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest accelerated hyperfractionation (45 Gy given in twice daily fractions over three weeks) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If this is not feasible, a once daily schedule (total dose of approximately 60 to 70 Gy in fractions of 2.0 Gy) is an appropriate alternative. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Fractionation schedule'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of limited thoracic RT fields which include postchemotherapy gross disease and all lymph node regions involved at the time of diagnosis (prechemotherapy nodal volumes), rather than larger fields including the pretreatment tumor volume",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elective nodal sites (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Baseline PET scans at diagnosis should be obtained for radiation planning whenever possible. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that thoracic RT be given concurrently with chemotherapy, rather than sequentially after the completion of chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Integration with chemotherapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We recommend that thoracic RT be administered with the first or second cycle of chemotherapy rather than with later cycles of chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Early versus late thoracic RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemotherapy: We recommend the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The use of this combination is compatible with concurrent RT. Although other regimens may provide similar outcomes, there are insufficient data given the potential curability of these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H9#H9\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Cisplatin plus etoposide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Optimal results with combined modality therapy require completion of treatment to the prescribed full chemotherapy and thoracic RT doses without treatment interruption. Thus, patients must receive appropriate supportive care including analgesics and intravenous hydration when necessary in order to avoid breaks in treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/1\">",
"      Cohen MH, Ihde DC, Bunn PA Jr, et al. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 1979; 63:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/2\">",
"      Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/3\">",
"      Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/4\">",
"      Gaspar LE, Gay EG, Crawford J, et al. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer 2005; 6:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/5\">",
"      J&auml;nne PA, Freidlin B, Saxman S, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002; 95:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/6\">",
"      Choi NC, Carey RW. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update. Int J Radiat Oncol Biol Phys 1989; 17:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/7\">",
"      Papac RJ, Son Y, Bien R, et al. Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy. Int J Radiat Oncol Biol Phys 1987; 13:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/8\">",
"      Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998; 16:3528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/9\">",
"      Bogart JA, Herndon JE 2nd, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004; 59:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/10\">",
"      Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol 1987; 5:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/11\">",
"      Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994; 12:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/12\">",
"      Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999; 17:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/13\">",
"      De Ruysscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol 2006; 80:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/14\">",
"      van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010; 77:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/15\">",
"      Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/16\">",
"      Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20:3054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/17\">",
"      Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/18\">",
"      Turrisi, AT, Glover, DJ, Mason, BA. A preliminary report: Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 1988; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/19\">",
"      Johnson, BE, Salem, C, Nesbitt, J, et al. Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin. Lung Cancer 1993; 9:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/20\">",
"      Armstrong JG, Rosenstein MM, Kris MG, et al. Twice daily thoracic irradiation for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 1991; 21:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/21\">",
"      Johnson DH, Turrisi AT, Chang AY, et al. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/22\">",
"      Mornex F, Trillet V, Chauvin F, et al. Hyperfractionated radiotherapy alternating with multidrug chemotherapy in the treatment of limited small cell lung cancer (SCLC). Groupe Lyonnais d'Oncologie Thoracique. Int J Radiat Oncol Biol Phys 1990; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/23\">",
"      Sloan JA, Bonner JA, Hillman SL, et al. A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1). Int J Radiat Oncol Biol Phys 2002; 52:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/24\">",
"      Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985; 3:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/25\">",
"      Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/26\">",
"      Sundstr&oslash;m S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20:4665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/27\">",
"      Pujol JL, Carestia L, Daur&egrave;s JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/28\">",
"      Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/29\">",
"      Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; 30:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/30\">",
"      Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/31\">",
"      Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax 2009; 64:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/32\">",
"      Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/33\">",
"      Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/34\">",
"      Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/35\">",
"      Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998; 16:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/36\">",
"      Kelley MJ, Bogart JA, Hodgson LD, et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. J Thorac Oncol 2013; 8:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/37\">",
"      Kubota K, Nishiwaki Y, Sugiura T, et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 2005; 11:5534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/38\">",
"      Saito H, Takada Y, Ichinose Y, et al. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 2006; 24:5247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/39\">",
"      Reck M, von Pawel J, Macha HN, et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 2003; 95:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/40\">",
"      Levitan N, Dowlati A, Shina D, et al. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 2000; 18:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/41\">",
"      Ettinger DS, Berkey BA, Abrams RA, et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 2005; 23:4991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/42\">",
"      Horn L, Bernardo P, Sandler A, et al. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol 2009; 4:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/43\">",
"      Hainsworth JD, Gray JR, Stroup SL, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997; 15:3464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/44\">",
"      Baas P, Belderbos JS, Senan S, et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer 2006; 94:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/45\">",
"      Le QT, Moon J, Redman M, et al. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol 2009; 27:3014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/46\">",
"      Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009; 101:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/47\">",
"      Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/48\">",
"      Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/49\">",
"      Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20:4434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/50\">",
"      Rigas JR, Denham CA, Rinaldi DA, et al. Randomized, placebo-controlled trials of the matrix metalloproteinase inhibitor BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc ASCO 2003; 22:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/51\">",
"      McClay EF, Bogart J, Herndon JE 2nd, et al. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol 2005; 28:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/52\">",
"      Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/53\">",
"      Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann Intern Med 1987; 106:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/54\">",
"      Perez CA, Einhorn L, Oldham RK, et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 1984; 2:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/55\">",
"      Rosenthal, S, Tattersall, MH, Fox, RM, et al. Adjuvant thoracic radiotherapy in small cell lung cancer: ten year follow-up of a randomized study. Lung Cancer 1991; 7:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/56\">",
"      Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol 1997; 15:2840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/57\">",
"      Perry MC, Herndon JE 3rd, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998; 16:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/58\">",
"      Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/59\">",
"      Spiro SG, James LE, Rudd RM, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 2006; 24:3823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/60\">",
"      Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2001; 12:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/61\">",
"      Work E, Nielsen OS, Bentzen SM, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 1997; 15:3030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/62\">",
"      Pijls-Johannesma MC, De Ruysscher D, Lambin P, et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005; :CD004700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/63\">",
"      De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/64\">",
"      Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22:4837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/43/9914/abstract/65\">",
"      Videtic GM, Fung K, Tomiak AT, et al. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer 2001; 33:249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4634 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9914=[""].join("\n");
var outline_f9_43_9914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147048869\">",
"      BENEFIT OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147047671\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Benefit of RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Accelerated hyperfractionation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Split course treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147048243\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1147048250\">",
"      Etoposide plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1147049799\">",
"      Other regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1147049875\">",
"      - Carboplatin versus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1147048257\">",
"      - Irinotecan-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1147048264\">",
"      - Paclitaxel-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1147048278\">",
"      - Novel agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INTEGRATION WITH CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sequential, concurrent, and alternating approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Early versus late thoracic RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4634|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/23/43389\" title=\"table 1\">",
"      Cisplatin 80 plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8951?source=related_link\">",
"      Experimental approaches to treatment for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=related_link\">",
"      Role of surgery in multimodality therapy for small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_43_9915="Periop chronic pain medications";
var content_f9_43_9915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Perioperative management of chronic pain medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Name or class of drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical considerations",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recommended strategy for surgery with brief NPO state",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recommended strategy for surgery with prolonged NPO state",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Opioids",
"      </td>",
"      <td>",
"       Abrupt withdrawal can cause yawning, abdominal cramps, nausea, vomiting, diarrhea, insomnia, anxiety and salivation.",
"      </td>",
"      <td>",
"       Continue therapy up to and including day of surgery.",
"      </td>",
"      <td>",
"       Continue therapy up to and including day of surgery. Rectal, transmucosal, transdermal and parenteral preparations available.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tramadol",
"      </td>",
"      <td>",
"       Seizures, drug interactions.",
"      </td>",
"      <td>",
"       Substitute another analgesic.",
"      </td>",
"      <td>",
"       Substitute another analgesic until oral intake.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9915=[""].join("\n");
var outline_f9_43_9915=null;
var title_f9_43_9916="Values history";
var content_f9_43_9916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The values history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Section 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Written legal documents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Living will",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Durable power of",
"attorney",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Organ donations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"1\">",
"        Wishes concerning specific medical",
"procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Organ donation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Kidney dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Cardiopulmonary resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Respirators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Artificial nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Artificial hydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        General comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Section 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall attitude toward health",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Perception of the role of physician",
"and other health caregivers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Thoughts about independence and",
"control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Personal relationships",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall attitude toward life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Attitude toward illness, dying and death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Religious background and beliefs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Living environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Attitude concerning finances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wishes concerning funeral",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lambert, P, Gibson, J, Nathanson, P, Law, Medicine and Health Care 1990; 18:202.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9916=[""].join("\n");
var outline_f9_43_9916=null;
var title_f9_43_9917="Clinical manifestations of acute HIV";
var content_f9_43_9917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of acute HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Features",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Overall",
"        <br/>",
"        (n = 378)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Male",
"        <br/>",
"        (n = 355)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Female",
"        <br/>",
"        (n = 23)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sexual*",
"        <br/>",
"        (n = 324)",
"       </td>",
"       <td class=\"subtitle1\">",
"        IVDU",
"        <sup>",
"         &bull;",
"        </sup>",
"        <br/>",
"        (n = 34)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        74",
"       </td>",
"       <td class=\"centered\">",
"        83",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue",
"       </td>",
"       <td class=\"centered\">",
"        68",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        78",
"       </td>",
"       <td class=\"centered\">",
"        71",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myalgia",
"       </td>",
"       <td class=\"centered\">",
"        49",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        26",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"       <td class=\"centered\">",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin rash",
"       </td>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        51",
"       </td>",
"       <td class=\"centered\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"       <td class=\"centered\">",
"        45",
"       </td>",
"       <td class=\"centered\">",
"        45",
"       </td>",
"       <td class=\"centered\">",
"        44",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharyngitis",
"       </td>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        43",
"       </td>",
"       <td class=\"centered\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical adenopathy",
"       </td>",
"       <td class=\"centered\">",
"        39",
"       </td>",
"       <td class=\"centered\">",
"        39",
"       </td>",
"       <td class=\"centered\">",
"        39",
"       </td>",
"       <td class=\"centered\">",
"        41",
"       </td>",
"       <td class=\"centered\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthralgia",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        26",
"       </td>",
"       <td class=\"centered\">",
"        28",
"       </td>",
"       <td class=\"centered\">",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Night sweats",
"       </td>",
"       <td class=\"centered\">",
"        28",
"       </td>",
"       <td class=\"centered\">",
"        28",
"       </td>",
"       <td class=\"centered\">",
"        22",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"       <td class=\"centered\">",
"        27",
"       </td>",
"       <td class=\"centered\">",
"        27",
"       </td>",
"       <td class=\"centered\">",
"        21",
"       </td>",
"       <td class=\"centered\">",
"        28",
"       </td>",
"       <td class=\"centered\">",
"        23",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table lists the most frequent clinical findings reported among patients with acute HIV infection from five prospective cohorts.",
"    <div class=\"footnotes\">",
"     * Homosexual or heterosexual route of transmission.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     IVDU, intravenous drug use as route of transmission.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008; 3:10. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9917=[""].join("\n");
var outline_f9_43_9917=null;
var title_f9_43_9918="ACOVE quality indicators";
var content_f9_43_9918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Quality indicators for appropriate medication use in vulnerable elders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indicator title",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rationale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication list",
"       </td>",
"       <td>",
"        An up-to-date medication list that includes over-the-counter medications should be accessible to all healthcare providers in the medical record.",
"       </td>",
"       <td>",
"        Enables identification of potential drug-related causes of new symptoms, eliminates inappropriate duplications, allows review for drug-drug interactions, and allows streamlining of regimen to improve adherence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Annual drug regimen review",
"       </td>",
"       <td>",
"        All vulnerable elders should have an annual drug regimen review.",
"       </td>",
"       <td>",
"        Allows an opportunity for discontinuing unnecessary medications, or addition of necessary drugs that are not currently prescribed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug indication",
"       </td>",
"       <td>",
"        All drugs prescribed for vulnerable elders should have a clearly defined indication.",
"       </td>",
"       <td>",
"        Allows discontinuing medications that may have been prescribed for unclear or transient indications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient education",
"       </td>",
"       <td>",
"        All vulnerable elders (or caregivers) should receive appropriate education about the use of any prescribed drug.",
"       </td>",
"       <td>",
"        Education may improve adherence and clinical outcomes; also can alert patients or caregivers to potential adverse effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Response to therapy",
"       </td>",
"       <td>",
"        Response to therapy should be documented for all ongoing medical conditions.",
"       </td>",
"       <td>",
"        Documenting response will help clarify whether a drug is meeting the therapeutic goal for which it was prescribed and provides a basis for continuation, modification, or discontinuation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Education for warfarin therapy",
"       </td>",
"       <td>",
"        Patients newly prescribed warfarin should receive education about diet, drug interactions, and risk of bleeding, or should be referred to an anticoagulation clinic.",
"       </td>",
"       <td>",
"        Awareness of drugs and dietary substances that interact with warfarin can decrease the risk of bleeding complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitoring warfarin therapy",
"       </td>",
"       <td>",
"        When warfarin is prescribed, international normalized ratio (INR) should be determined within four days of initiation of therapy and at least every six weeks therafter.*",
"       </td>",
"       <td>",
"        Older adults are at high risk for drug toxicity, and close monitoring can help maintain the INR within the therapeutic range.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitoring angiotensin converting enzyme (ACE) inhibitor therapy",
"       </td>",
"       <td>",
"        When ACE inhibitor therapy is prescribed, a serum creatinine and potassium should be monitored within two weeks after initiation of therapy and at least yearly thereafter.",
"       </td>",
"       <td>",
"        Older adults are at increased risk of renal insufficiency and hyperkalemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitoring loop diuretic therapy",
"       </td>",
"       <td>",
"        When loop diuretic therapy is prescribed, electrolytes should be checked within two weeks after initiation and at least annually.",
"       </td>",
"       <td>",
"        Risk of hypokalemia due to diuretic therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid propoxyphene",
"       </td>",
"       <td>",
"        Do not prescribe propoxyphene as an analgesic agent.",
"       </td>",
"       <td>",
"        Propoxyphene is inferior to, or at best equivalent to, acetaminophen or other analgesics with better safety profiles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid chronic or high-dose benzodiazepine use",
"       </td>",
"       <td>",
"        If a benzodiazepine is taken for more than one month, there should be documentation of discussion of risks and attempt to taper or discontinue.",
"       </td>",
"       <td>",
"        Benzodiazepines increase the risk of falls, hip fracture, and confusion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid drugs with strong anticholinergic properties",
"       </td>",
"       <td>",
"        Do not prescribe drug therapies with a strong anticholinergic effect if alternative therapies are available.",
"       </td>",
"       <td>",
"        These therapies are associated with adverse events such as confusion, urinary retention, constipation, visual disturbance, and hypotension.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid barbiturates",
"       </td>",
"       <td>",
"        If an older adult does require the therapy for control of seizures, do not use barbiturates.",
"       </td>",
"       <td>",
"        These therapies are potent central nervous system depressants, have a low therapeutic index, are highly addictive, cause drug interactions, and are associated with an increased risk for falls and hip fracture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid meperidine as an opioid analgesic",
"       </td>",
"       <td>",
"        When analgesia is required, avoid use of meperidine.",
"       </td>",
"       <td>",
"        This therapy is associated with an increased risk for delirium and may be associated with the development of seizures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid chronic use of ketorolac",
"       </td>",
"       <td>",
"        Ketorolac should not be prescribed for more than five days.",
"       </td>",
"       <td>",
"        This therapy is associated with a high risk of GI side effects, including bleeding, and other analgesics are safer in older patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid skeletal muscle relaxants",
"       </td>",
"       <td>",
"        Skeletal muscle relaxants (cyclobenzaprine, methocarbamol, carisoprodol, chlorzoxazone, orphenadrine, tizanidine, metaxalone) should not be prescribed for more than one week.",
"       </td>",
"       <td>",
"        These medications can cause anticholinergic adverse effects, sedation, confusion, and data of efficacy are limited.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid ticlopidine",
"       </td>",
"       <td>",
"        Clopidogrel should be prescribed rather than ticlopidine for patients who require antiplatelet therapy (eg, recent stroke, myocardial infarction, acute coronary syndrome, percutaneous angioplasty).",
"       </td>",
"       <td>",
"        Ticlopidine may be less effective than clopidogrel and is associated with a higher risk of hematological disorders than clopidogrel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat iron deficiency anemia with low-dose oral iron therapy",
"       </td>",
"       <td>",
"        Vulnerable elders with iron deficiency anemia should take no more than one low-dose oral iron tablet daily.",
"       </td>",
"       <td>",
"        Low-dose therapy is equally effective with fewer adverse effects than high-dose oral iron therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotic medication response",
"       </td>",
"       <td>",
"        An assessment of response should be documented within one month for older adults started on an antipsychotic drug.",
"       </td>",
"       <td>",
"        The use of antipsychotic drugs increases mortality in older adults, and behavioral modification is an effective alternative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetaminophen",
"       </td>",
"       <td>",
"        Older adults prescribed high-dose (&ge;3 g per day) acetaminophen, or those with liver disease taking acetaminophen chronically, should be advised of the risk of liver toxicity.",
"       </td>",
"       <td>",
"        The risk of liver toxicity is greater with use of acetaminophen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAIDs and aspirin",
"       </td>",
"       <td>",
"        <p>",
"         The risk of GI bleeding should be discussed and documented.",
"        </p>",
"        Individuals at increased risk for GI bleeding (aged &gt;75 years, peptic ulcer disease, history of GI bleeding, warfarin use, chronic glucocorticoid use) should be treated concomitantly with misoprostol or a proton pump inhibitor when treated with a nonselective NSAID.",
"       </td>",
"       <td>",
"        Risks of GI bleeding are increased in older adults taking NSAIDs or daily aspirin.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These monitoring frequencies represent minimal indications; many experts would advise daily monitoring initially and monitoring every four weeks once a stable and at-goal therapeutic INR has been achieved.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Amer Geriatr Soc 2007; 55:S373.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9918=[""].join("\n");
var outline_f9_43_9918=null;
var title_f9_43_9919="Candida esophagitis CPC Endosc";
var content_f9_43_9919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic evaluation of the esophagus revealed an erythematous mucosa covered with white plaque like lesions through the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_43_9919=[""].join("\n");
var outline_f9_43_9919=null;
